HANDBOOK OF CLINICAL NEUROLOGY Series Editors
MICHAEL J. AMINOFF, FRANC¸OIS BOLLER, AND DICK F. SWAAB VOLUME 99
EDINBURGH LONDON NEW YORK OXFORD PHILADELPHIA ST LOUIS SYDNEY TORONTO 2011
ELSEVIER B.V. Radarweg 29, 1043 NX, Amsterdam, The Netherlands # 2011, Elsevier B.V. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Permissions may be sought directly from Elsevier’s Rights Department: phone: (þ1) 215 239 3804 (US) or (þ44) 1865 843830 (UK); fax: (þ44) 1865 853333; e-mail:
[email protected]. You may also complete your request on-line via the Elsevier website at http://www.elsevier.com/permissions. ISBN: 9780444520074 British Library Cataloguing in Publication Data A catalogue record for this book is available from the British Library Library of Congress Cataloging in Publication Data A catalog record for this book is available from the Library of Congress Notice Knowledge and best practice in this field are constantly changing. As new research and experience broaden our knowledge, changes in practice, treatment and drug therapy may become necessary or appropriate. Readers are advised to check the most current information provided (i) on procedures featured or (ii) by the manufacturer of each product to be administered, to verify the recommended dose or formula, the method and duration of administration, and contraindications. It is the responsibility of the practitioner, relying on their own experience and knowledge of the patient, to make diagnoses, to determine dosages and the best treatment for each individual patient, and to take all appropriate safety precautions. To the fullest extent of the law, neither the Publisher nor the Editors assumes any liability for any injury and/or damage to persons or property arising out or related to any use of the material contained in this book. Neither the Publisher nor the Editors assume any responsibility for any loss or injury and/or damage to persons or property arising out of or related to any use of the material contained in this book. It is the responsibility of the treating practitioner, relying on independent expertise and knowledge of the patient, to determine the best treatment and method of application for the patient. The Publisher
Printed in China
Commissioning Editor: Timothy Horne/Michael Houston Development Editor: Michael Parkinson Project Manager: Janaki Srinivasan Kumar Designer: Kirsteen Wright
The Publisher's policy is to use paper manufactured from sustainable forests
Handbook of Clinical Neurology 3rd Series Available titles Vol. 79, The human hypothalamus: basic and clinical aspects, Part I, D.F. Swaab ISBN 0444513574 Vol. 80, The human hypothalamus: basic and clinical aspects, Part II, D.F. Swaab ISBN 0444514902 Vol. 81, Pain, F. Cervero and T.S. Jensen, eds. ISBN 0444519017 Vol. 82, Motor neurone disorders and related diseases, A.A. Eisen and P.J. Shaw, eds. ISBN 0444518940 Vol. 83, Parkinson’s disease and related disorders, Part I, W.C. Koller and E. Melamed, eds. ISBN 9780444519009 Vol. 84, Parkinson’s disease and related disorders, Part II, W.C. Koller and E. Melamed, eds. ISBN 9780444528933 Vol. 85, HIV/AIDS and the nervous system, P. Portegies and J. Berger, eds. ISBN 9780444520104 Vol. 86, Myopathies, F.L. Mastaglia and D. Hilton Jones, eds. ISBN 9780444518966 Vol. 87, Malformations of the nervous system, H.B. Sarnat and P. Curatolo, eds. ISBN 9780444518965 Vol. 88, Neuropsychology and behavioural neurology, G. Goldenberg and B.C. Miller, eds. ISBN 9780444518972 Vol. 89, Dementias, C. Duyckaerts and I. Litvan, eds. ISBN 9780444518989 Vol. 90, Disorders of Consciousness, G.B. Young and E.F.M. Wijdicks, eds. ISBN 9780444518958 Vol. 91, Neuromuscular Junction Disorders, A.G. Engel, ed. ISBN 9780444520081 Vol. 92, Stroke – Part I: Basic and epidemiological aspects, M. Fisher, ed. ISBN 9780444520036 Vol. 93, Stroke – Part II: Clinical manifestations and pathogenesis, M. Fisher, ed. ISBN 9780444520043 Vol. 94, Stroke – Part III: Investigations and management, M. Fisher, ed. ISBN 9780444520050 Vol. 95, History of Neurology, S. Finger, F. Boller and K.L. Tyler, eds. ISBN 9780444520081 Vol. 96, Bacterial Infections of the Central Nervous System, K.L. Roos and A.R. Tunkel, eds. ISBN 9780444520159 Vol. 97, Headache, G. Nappi and M.A. Moskowitz, eds. ISBN 9780444521392 Vol. 98, Sleep Disorders Part I, P. Montagna and S. Chokroverty, eds. ISBN 9780444520067
Foreword
We spend about one-third of our life either sleeping or attempting to do so. Sleep is not only comforting, but is also essential for our normal cognitive functioning and for our survival. Yet sleep can be disturbed or abnormal in up to one-quarter of the US population. The field of sleep medicine has developed dramatically in the past few years. To reflect these advances, we are proud to introduce the present two volumes, which are a novelty in several respects. It is the first time that two Handbook volumes have been dedicated entirely to sleep and its disorders. Readers will find in these two volumes considerable emphasis on recent developments in the field. There is a new focus on diagnostic techniques, particularly imaging. Fresh attention is given to genetics and clinical aspects of sleep. Finally, there is extensive coverage of management and of new therapeutic strategies for sleep disorders. The volumes were edited by Pasquale Montagna and Sudhansu Chokroverty. As series editors, we reviewed all the chapters and made suggestions for improvement, but we are delighted that the volume editors and chapter authors produced such scholarly and comprehensive accounts of different aspects of sleep and its disorders. Hence we hope that these volumes will appeal to clinicians and neuroscientists alike. Significant new advances, particularly in terms of diagnosis and therapy, lead to new insights that demand a critical appraisal. Our goal is to provide basic researchers with the foundations for new approaches to the study of these disorders, and clinicians with a state-of-the-art reference that summarizes the clinical features and management of the many neurological manifestations of sleep disorders. In addition to the print form, the Handbook series is now available electronically on Elsevier’s Science Direct site. This should make it even more accessible to readers and should facilitate searches for specific information. We are grateful to the two volume editors and to the numerous authors who contributed their time and expertise to summarize developments in their field and helped put together these outstanding volumes. As always, we are grateful to the team at Elsevier and in particular to Mr. Michael Parkinson, Ms. Caroline Cockrell, and Mr. Timothy Horne for their unfailing and expert assistance in the development and production of these volumes. Michael J. Aminoff Franc¸ois Boller Dick F. Swaab
Preface
Sleep has been mentioned in art, literature, religion, and philosophy since antiquity, but a long period of ignorance and a lack of interest paralyzed the scientific community until recently. There has been an explosion of information about sleep medicine and sleep research in the past three decades, making it difficult to keep abreast of progress. There is therefore a need for a comprehensive book on sleep medicine and sleep science. Sleep researchers have made remarkable progress in the last century in unraveling the mysteries of sleep, including its molecular neurobiology and functional neuroanatomy. The 1930s to 1950s was an active period for sleep research, and, since the late 1990s, there has been a resurgence of interest in the neurobiology of sleep. The twenty-first century is witnessing the continuation of such progress. Advances have occurred in basic science, clinical aspects, laboratory techniques, and therapy. Advances in basic science include new understanding of the neurobiology of sleep–wakefulness, including new models of rapid eye movement (REM) sleep mechanisms; controversy about sleep states, stages, and memory consolidations; advances in the understanding of sleep–wake-dependent genes, gene products, and the circadian clock, and the role of sleep duration in mortality and morbidity; and fascinating noninvasive neuroimaging studies (particularly positron emission tomographic and single photon emission computed tomographic scans) visualizing marked changes in function in cortical and subcortical neuronal networks in different sleep states. Advances in clinical science include new understanding of the neurobiology of narcolepsy-cataplexy, restless legs syndrome, REM behavior disorders, and fatal familial insomnia. Further clinical advances have been made in our understanding of sleep apnea and heart failure, and nocturnal paroxysmal dystonia (now known as nocturnal frontal lobe epilepsy), and in describing new parasomnias and acquiring new knowledge about the genetics of sleep disorders. These clinical advances required revision of the International Classification of Sleep Disorders in 2005. New laboratory techniques (e.g., actigraphy, cyclic alternating pattern recognition and scoring in the electroencephalogram, peripheral arterial tonometry, and pulse transit time), in addition to the gold-standard techniques of polysomnography, with advances in ambulatory recordings, multiple sleep latency, and maintenance of wakefulness tests, expanded the horizon of the field of sleep medicine. Publication of the American Academy of Sleep Medicine (AASM) Manual for Scoring of Sleep and Associated Events in 2007 was a step towards standardization of the techniques. Finally, significant advances have been made in therapy, with the addition of new drugs for treating narcolepsycataplexy, insomnia, and restless legs syndrome. Considerable improvement has been made in treating central and upper-airway obstructive sleep apnea syndrome with the addition of bi-level positive airway pressure, flexible positive airway pressure, autotitrating continuous positive airway pressure, assisted servo-ventilation, and intermittent positive pressure ventilation for treating sleep-disordered breathing in neuromuscular disorders. Application of appropriately timed bright light therapy for circadian rhythm sleep disorders is also a significant therapeutic contribution of modern sleep science. It is therefore an opportune moment to produce a comprehensive volume on sleep disorders, addressing all these recent advances in basic, technical, clinical, and therapeutic issues. When we first drafted a preliminary list of topics, it immediately became obvious that a single volume, as originally conceived, would not be enough to cover the topic in the Handbook of Clinical Neurology (HCN) series. This series is widely regarded as the ultimate reference work of clinical neurology and it is found in every medical library. However, the previous two series of the HCN were organized by disease, and neither in the first nor second series was any volume specifically dedicated to sleep disorders. This absence was probably due to inadequate knowledge and awareness about sleep disorders within the context of classic neurological diseases at that time.
x
PREFACE
Despite all the progress, two vexing questions remain: What is sleep and why do we sleep? What happens if we are sleep-deprived? In animal experiments Rechtschaffen’s rats on carousel (“disk over water”), deprived of REM and non-REM sleep, lost weight despite eating excessively and died. REM-deprived rats survived longer than nonREM-deprived rats. In later experiments by other investigators using different sleep deprivation techniques, rats did not show a similar syndrome. Furthermore, adult and newborn dolphins survive with no ill effects after long periods (weeks) without sustained sleep. Awareness of the importance of sleep leads to an acceptance of sleep medicine as an independent specialty. There are new guidelines for practicing sleep medicine developed by the AASM and European Sleep Research Society. Other countries are also in the process of developing guidelines independently or in collaboration with the World Association of Sleep Medicine and other national and international organizations. In these two volumes devoted to sleep disorders, nationally and internationally known scholars, researchers, clinicians, and educators address various aspects of sleep disorders medicine to keep sleep clinicians and researchers, and all those interested in sleep, abreast of recent developments. We, the editors, owe these authors an enormous amount of gratitude for their excellent contributions, which we hope will make these two volumes authoritative reference books. They will be useful to those practicing neurology and internal medicine, especially those in pulmonary, cardiovascular, gastrointestinal, renal and endocrine specialties, and to family physicians, psychiatrists, otolaryngologists, pediatricians, dentists, psychologists, and to neurosurgeons and neuroscientists, as well as technologists, nurses, respiratory therapists, and other paraprofessionals with an interest and curiosity about the mysteries of sleep. Pasquale Montagna Sudhansu Chokroverty
Acknowledgments
We thank all of the authors for their scholarly contributions and patience in waiting to see these two volumes finally in production after a long and protracted period (beyond our control). We also thank all the authors, editors, and publishers who have granted us permission to reproduce illustrations that were published in other books and journals. We must thank Mike Parkinson, development editor for the Handbook of Clinical Neurology, for his dedication and professionalism, and the editorial and production staff at Elsevier B.V. Dr. Montagna would like to express his gratitude and love to his family and in particular to his wife, Flavia Valentini, for her continued support throughout the long time it took to edit the books, and especially for her unfailing assistance in a time of severe personal adversities. Dr. Chokroverty wishes to thank Annabella Drennan, the editorial assistant to the journal Sleep Medicine, for assisting in proofreading and corrections of many of the chapters, and, his wife, Manisha Chokroverty, MD, for her love, patience, tolerance, and continued support throughout the long period of editing and proofreading during the production of these volumes.
List of contributors
K. Adachi Faculte´ de Me´decine Dentaire, Universite´ de Montre´al, Hoˆpital Sacre´ Cur de Montre´al, Montreal, and Faculty of Dentistry, University of Toronto, Toronto, Canada
Michel A. Cramer Bornemann Minnesota Regional Sleep Disorders Center, Hennepin County Medical Center and Department of Neurology, University of Minnesota Medical School, Minneapolis, MN, USA
Richard P. Allen Department of Neurology, Johns Hopkins University, Baltimore, MD, USA
Christopher J. Earley Department of Neurology, Johns Hopkins University, Baltimore, MD, USA
R. Robert Auger Mayo Center for Sleep Medicine, Department of Psychiatry and Psychology, Mayo Clinic College of Medicine, Rochester, MN, USA
Stephen Feren Sleep Medicine and Research Center, St. John’s Mercy Medical Center and St. Luke’s Hospital, Chesterfield, MO, USA
Claudio L. Bassetti Department of Neurology, University Hospital Zurich, Zurich, Switzerland
Luigi Ferini-Strambi Sleep Disorders Center, Universita` Vita-Salute San Raffaele, Milan, Italy
Ruth M. Benca University of Wisconsin, Madison, WI, USA
Jean-Franc¸ois Gagnon Centre d’e´tude du sommeil et des rythmes biologiques, Hoˆpital du Sacre´-Coeur de Montre´al, and Department of Psychiatry, Universite´ de Montre´al, Montreal, Canada
Michel Billiard Department of Neurology, Gui de Chauliac Hospital, Montpellier, France Bradley F. Boeve Mayo Center for Sleep Medicine, Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN, USA
Peter J. Hauri Mayo Clinic, Department of Psychiatry and Psychology and Mayo Medical School, Rochester, MN, USA Wayne Hening (deceased) Department of Neurology, UMDNJ-RW Johnson Medical School, New Brunswick, NJ, USA
S. Chokroverty New Jersey Neuroscience Institute, JFK Medical Center, Seton Hall University, Edison, NJ, USA
Dirk M. Hermann Department of Neurology, University Hospital Essen, Essen, Germany
Cynthia L. Comella Department of Neurological Sciences, Section of Movement Disorders, Rush University Medical Center, Chicago, IL, USA
N. Huynh Faculte´ de Me´decine Dentaire, Universite´ de Montre´al, and Hoˆpital Sacre´ Cur de Montre´al, Montreal, Canada
xiv
LIST OF CONTRIBUTORS
Mayumi Kimura Max Planck Institute of Psychiatry, Munich, Germany Clete A. Kushida Stanford University Center of Excellence for Sleep Disorders, Stanford, CA, USA G.J. Lavigne Faculte´ de me´decine dentaire, Universite´ de Montre´al, Hoˆpital Sacre´ Cur de Montre´al, Montreal, and Faculty of Dentistry, University of Toronto, Toronto, Canada Mujahid Mahmood Kaiser Permanente South San Francisco Medical Center, South San Francisco, CA, USA Mark W. Mahowald Minnesota Regional Sleep Disorders Center, Hennepin County Medical Center, and Department of Neurology, University of Minnesota Medical School, Minneapolis, MN, USA Emmanuel Mignot Stanford University School of Medicine and Center for Narcolepsy, Stanford Sleep Research Center, Palo Alto, CA, USA Pasquale Montagna Department of Neurological Sciences, University of Bologna Medical School, Bologna, Italy Jacques Montplaisir Centre d’e´tude du sommeil et des rythmes biologiques, Hoˆpital du Sacre´-Coeur de Montre´al, Universite´ de Montre´al, Montreal, Canada Charles M. Morin Centre de recherche, Universite´ Laval, Quebec, Canada Adrian R. Morrison Laboratory for Study of the Brain in Sleep, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA Seiji Nishino Sleep and Circadian Neurobiology Laboratory and Center For Narcolepsy, Stanford University, and Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, CA, USA
K. Okura Faculte´ de me´decine dentaire, Universite´ de Montre´al, and Hoˆpital Sacre´ Cur de Montre´al, Montreal, Canada, and Institute of Health Bioscience, University of Tokushima Graduate School, Tokushima, Japan Liborio Parrino Sleep Disorders Center, Department of Neuroscience, University of Parma, Parma, Italy Teresa Paiva EEG/Sleep Laboratory, Centro Estudos Egas Moniz/ IMM, Medical Faculty of Lisbon, Hospital Santa Maria, Lisbon, Portugal Mathieu Pilon Centre d’e´tude du sommeil, Hoˆpital du Sacre´-Cur de Montre´al, Montreal, Canada Ronald B. Postuma Centre d’e´tude du sommeil et des rythmes biologiques, Hoˆpital du Sacre´-Coeur de Montre´al and Department of Neurology, Montreal General Hospital, Montreal, Canada F. Provini Department of Neurological Sciences, University of Bologna Medical School, Bologna, Italy Kathryn J. Reid Department of Neurology, Northwestern University Medical School, Chicago, IL, USA Carlos H. Schenk Minnesota Regional Sleep Disorders Center, Hennepin County Medical Center and Department of Psychiatry, University of Minnesota Medical School, Minneapolis, MN, USA Paula K. Schweitzer Department of Psychology, St. Louis University, St. Louis, MO, USA Luigi Ferini-Strambi Sleep Disorders Center, Universita` Vita-Salute San Raffaele, Milan, Italy Mario Giovanni Terzano Sleep Disorders Center, Department of Neuroscience, University of Parma, Parma, Italy
LIST OF CONTRIBUTORS
xv
Fred W. Turek Department of Neurobiology & Physiology, Center for Sleep and Circadian Biology, Northwestern University, Evanston, IL, USA
St. Louis, and Department of Psychiatry, St. Louis University Health Sciences Center, St. Louis, MO, USA
Me´lanie Vendette Centre d’e´tude du sommeil et des rythmes biologiques, Hoˆpital du Sacre´-Coeur de Montre´al, and Department of Psychology, Universite´ de Montre´al, Montreal, Canada
Juliane Winkelmann Department of Neurology, Institute of Human Genetics, Klinikum rechts der Isar, Technische Universita¨t Mu¨nchen and Helmholtz Zentrum Mu¨nchen, German Research Center for Environmental Health, Munich, Germany
R. Vetrugno Department of Neurological Sciences, University of Bologna Medical School, Bologna, Italy
D. Yao Faculty of Dentistry, University of Toronto, Toronto, Canada
Martha Hotz Vitaterna Department of Neurobiology & Physiology, Center for Sleep and Circadian Biology, Northwestern University, Evanston, IL, USA
Antonio Zadra Department of Psychology, Universite´ de Montre´al, Montreal, Canada
Aleksandar Videnovic Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
Phyllis C. Zee Department of Neurology, Northwestern University Medical School, Chicago, IL, USA
James K. Walsh Sleep Medicine and Research Center, St. John’s Mercy Medical Center and St. Luke’s Hospital, Chesterfield, Department of Psychology, St. Louis University,
Marco Zucconi Sleep Disorders Center, Department of Clinical Neurosciences, H San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy
Handbook of Clinical Neurology, Vol. 99 (3rd series) Sleep Disorders, Part 2 P. Montagna and S. Chokroverty, Editors # 2011 Elsevier B.V. All rights reserved
Chapter 42
Classification of sleep disorders PETER J. HAURI * Mayo Clinic, Rochester, Minnesota, USA
THE DEVELOPMENT OF A NEW SLEEP DISORDERS CLASSIFICATION This chapter introduces the Second Edition of the International Classification of Sleep Disorders (ICSD-2), which was published in the summer of 2005 (American Academy of Sleep Medicine, 2005). This revision of ICSD was commissioned and supervised by the Board of the American Academy of Sleep Medicine, but it was an international group of sleep specialists who developed it. I was privileged to be appointed as chairman of this Committee to develop ICSD-2. The committee first struggled to find a common organizing principle along which to sort the many different sleep disorders. We were unable to find one. In part this was because our knowledge about the different sleep disorders varies widely; for some, such as sleep apnea and narcolepsy, we know quite a bit and may be close to understanding the basic pathophysiological mechanisms of the disorder. For other sleep disorders we are still in the discovery phase and know very little about them, except for some of their symptoms. ICSD-2 therefore abandoned the hope for a common framework along which to classify all sleep disorders. Rather, we decided to group these disorders into eight categories that, at present, seemed to make the most pragmatic sense. Some of these eight categories are based on a common complaint such as insomnia or hypersomnia. Others are grouped around the organ system from which the problems arise, such as the sleep-related breathing disorders and the sleep-related movement disorders. Still others are grouped around a presumed common etiology, such as the problems with the biological clock that are thought to underlie circadian rhythm disorders. Hopefully, in the future, a more overarching framework will emerge for classifying the sleep disorders, but we are not there yet.
ICSD-2 distinguishes the following eight categories of sleep disorders, each of which will be discussed in more detail later in this chapter: 1. 2. 3.
4. 5. 6. 7. 8.
Insomnias Sleep-related breathing disorders Hypersomnias of central origin not due to a circadian rhythm sleep disorder, sleep-related breathing disorder, or other cause of disturbed sleep Circadian rhythm sleep disorders Parasomnias Sleep-related movement disorders Isolated symptoms, apparently normal variants, and unresolved issues Other sleep disorders.
Many sleep disorders are multifactorial. In accordance with the rules developed by the World Health Organization (WHO) for the International Classification of Diseases (ICD), these different factors are classified separately. For example, if a case of insomnia is related to anxiety, and to a restless legs syndrome, and to bad sleep habits, these three individual elements would be coded separately. Thus, the above case would carry three diagnoses.
HISTORY OF THE SLEEP DISORDERS CLASSIFICATION SYSTEM The WHO, based in Geneva, Switzerland, maintains a list of all known human diseases. This International Classification of Diseases was published in its 10th revision (ICD-10) in 1992. ICSD-10 contains two sections especially reserved for sleep disorders. The US Public Health Service maintains a standing committee that adapts the WHO’s ICD to the needs and practices of the USA. The one that is currently still used in the USA is ICD-9-CM (International
*Correspondence to: Peter J. Hauri, Ph.D., Mayo Clinic, 422 Seventh Ave, SW, Rochester, MN 55902, USA. Tel: (507) 282-0059, Fax: (507) 266-7772, E-mail:
[email protected]
670
P.J. HAURI
Classification of Diseases, ninth revision, Clinical Modifications). It is this committee that has authorized the five-digit code numbers that are listed for each of the individual sleep disorders discussed below. In the 1970s, our knowledge about sleep disorders exploded. There was the discovery that sleep apnea was a common disorder, the new understanding that insomnia had many more etiologies than had been anticipated, the finding that periodic limb movements during sleep could significantly disturb sleep, etc. ICD had not foreseen this vast increase in our knowledge of sleep disorders. True, from very early versions onwards, ICD had listed some sleep disorders such as narcolepsy and the restless legs syndrome, but no room was reserved to place all the new sleep disorders that had emerged. Therefore, in the mid-1970s, Dr W. Dement appointed an ad hoc group of interested sleep specialists under the leadership of Dr H. Roffwarg to develop a Diagnostic Classification of Sleep and Arousal Disorders (DCSAD), which was published in the journal Sleep in 1979 (Association of Sleep Disorders Centers, 1979). By the late 1980s, the field had developed beyond DCSAD. A revision and update was needed, carried out by a committee under the leadership of Dr M. Thorpe. This time the process was more formalized and international input was sought. This revision, called The International Classification of Sleep Disorders (ICSD-1), was published in 1990 and revised slightly in 1997 (American Sleep Disorders Association, 1997). There is no question that, in the long run, any classification of sleep disorders needs to be absorbed into the WHO’s International Classification of Diseases. Therefore, when developing ICSD-2, the current committee tried to move towards the goal of such a merger, mainly by adapting the thinking and structure of ICD whenever feasible. However, some significant obstacles for merger remain. Chief among them is the fact that ICD makes a fundamental distinction between the organic and the nonorganic disorders. For sleep disorders, this distinction is often very difficult to make, adds little to our understanding, and may even be counterproductive in our efforts to understand many of the sleep disorders.
THE CONTENT OF ICSD-2 ICSD-2 is published as a book containing about 300 tightly written pages. Obviously, only a minimal amount of that information can be included in a chapter such as this one. The following tries briefly to characterize each of the eight sleep disorders categories and each of the over 80 individual sleep disorders that are included in
ICSD-2. The goal of this chapter is to allow the reader some overview and appreciation of this nosology. No attempt is made in this chapter to provide enough information to make a diagnosis of each of the disorders.
Insomnia Insomnia is defined as a complaint of unsatisfactory sleep. The sleep difficulty may lie in problems with falling asleep, in frequent awakenings during sleep, in waking too early in the morning, or in poor quality, “nonrestorative” sleep. To be called insomnia, according to ICSD-2, there have to be daytime consequences of this poor sleep, such as fatigue, irritability, or cognitive problems (American Academy of Sleep Medicine, 2005). The following 11 subtypes of insomnia are recognized by ICSD-2. Adjustment insomnia (acute insomnia) (307.41). This involves a relatively short-term insomnia (< 3 months) that is caused by an identifiable stressor (Roehrs et al., 2000). Psychophysiological insomnia (307.42). This is characterized by heightened arousal and learned sleep-preventing associations such as trying too hard to fall asleep, or excessive worrying about sleep (Bonnet and Arand, 1995). Paradoxical insomnia (307.42). This used to be called “sleep state misperception syndrome”. However, there is more to paradoxical insomnia than just a marked mismatch between how the patients think they slept and what objective data document about their sleep. During sleep, patients with paradoxical insomnia show either a near-constant awareness of the environment or a near-continuous pattern of conscious thoughts (Edinger and Fins, 1995). Idiopathic insomnia (307.42). This is a form of chronic insomnia that started in infancy or childhood, has no identifiable precipitant, and is chronic and relentless, with no periods of sustained remission. An imbalance in the neurological/neurochemical sleep/ wake system has been postulated (Hauri and Olmstead, 1980). Insomnia due to mental disorder (327.02). This is diagnosed only in patients who have a diagnosed mental disorder. Also, this diagnosis is used only when the insomnia is an unusually predominant complaint of the underlying mental disorder or when insomnia warrants independent, clinical attention (Nofzinger et al., 1993).
CLASSIFICATION OF SLEEP DISORDERS Inadequate sleep hygiene (V69.4). This involves an insomnia that is caused by maladaptive habits that cause poor sleep, such as excessive daytime napping, alcohol or caffeine near bedtime, excessively stimulating activities close to bedtime, etc. (Morin et al., 1999). Behavioral insomnia of childhood (V69.5). This is diagnosed when maladaptive child-rearing techniques are at the base of the insomnia, such as a lack of limit-setting throughout the day, or inadvertently teaching the child to fall asleep only when being rocked (Gaylor et al., 2001). Insomnia due to drug or substance (292.85, or, if alcohol, 291.82). This indicates that the insomnia is based on the use of or withdrawal from prescription or recreational drugs, or it may be caused by food items or toxins such as carbon monoxide poisoning (Schweitzer, 2000). Insomnia due to medical condition (327.01). This is involved when a condition such as asthma is presumed to cause the insomnia (Gislasen and Almquist, 1987). Insomnia not due to substance or known physiological condition, unspecified (304.41). This category is used when a patient has insomnia that is not classifiable into any of the above insomnias, but seems to be related to psychological issues. The unusually cumbersome title for this insomnia has to do with the fact that terms such as “psychiatric” or “psychological” are hard to define nowadays, except by exclusion (nonphysiological, nonsubstance induced). Physiological (organic) insomnia, unspecified (327.00). This is the category to use when a patient has an insomnia that clearly does not fit into any of the above-named insomnias, or when there are not enough data to diagnose the patient into any of the above disorders.
Sleep-related breathing disorders Listed in this category are sleep problems that are characterized by disordered breathing during sleep. Other respiratory disorders that occur both during wakefulness and during sleep, such as asthma, are not classified as sleep disorders.
CENTRAL
SLEEP APNEA SYNDROMES
These are sleep disorders where respiratory drive is repetitively either diminished (central hypopnea) or absent (central apnea) during all or parts of sleep. It appears that the patient simply stops trying to breathe adequately. These syndromes are usually based on either cardiac or neurological dysfunctions.
671
Primary central sleep apnea (327.21). This involves the repeated stopping of respiratory effort during sleep. This leads to frequent awakenings (sleep fragmentation) and excessive daytime sleepiness (EDS). A high ventilatory response to carbon dioxide is often found in such patients (Xie et al., 1995). Central sleep apnea due to a Cheyne–Stokes breathing pattern (786.04). This breathing pattern shows repetitive crescendo–decrescendo breathing. Feedback in the respiratory system is slow. The tidal respiratory pattern gradually waxes and wanes. The repetitive hypoxic lows and the increased effort to restart breathing can disturb and fragment sleep (Xie et al., 2002). Central sleep apnea due to high-altitude periodic breathing (327.22). This is found in almost everyone when rapidly brought to altitudes, say over 4000 meters (Anholm et al., 1992). Central sleep apnea due to a medical condition not Cheyne Stokes (327.27). This is usually caused by a brainstem lesion, or by cardiac or renal disease. Central sleep apnea due to a drug or substance (327.29). This is usually related to taking long-acting drugs such as opioids for long periods. Such medications can also cause other sleep-related respiratory disorders such as obstructive hypoventilation or periodic breathing (Farney et al., 2003). Primary sleep apnea of infancy (770.81). This involves prolonged respiratory pauses that may be either central, obstructive, or mixed. This is usually a developmental problem, often caused by immaturity in the brainstem (Kahn et al., 2000).
OBSTRUCTIVE
SLEEP APNEA SYNDROMES
These disorders are based on an obstruction in the upper airway that develops during sleep, e.g. by the relaxing of the muscles that keep the airway open. The patient continues to try to breathe, but during all or parts of sleep the airflow is limited or inhibited by the obstruction, and gas exchange is absent or at least curtailed until the sleeper awakens. Obstructive sleep apnea, Adult (327.23). This is by far the most common problem seen in sleep disorders centers. It involves repetitively either complete collapse of the upper airway during sleep, or at least a narrowing. This results in either apnea or hypopnea, or it may simply require an increased effort to move
672
P.J. HAURI
air through the upper airway (upper airway resistance syndrome). In severe obstructive sleep apnea there may be as many as 500 or more respiratory-related arousals during a night. The usual consequence of such a massive disturbance of sleep is excessive daytime somnolence (Flemons, 2002). Obstructive sleep apnea, pediatric (327.23). This is essentially the same condition as adult obstructive sleep apnea, except for different criteria. While an occasional obstructive apnea is acceptable for an adult, even one obstructive apnea per hour may be pathological in a child (Marcus, 2000).
SLEEP-RELATED
HYPOVENTILATION/HYPOXEMIA
SYNDROMES
These disorders show a chronically reduced oxygen and carbon dioxide exchange during sleep. Typically, this causes sleep fragmentation and nonrestorative sleep. Sleep-related nonobstructive alveolar hypoventilation syndrome, idiopathic (327.25). Chronically decreased alveolar ventilation during sleep results in lower arterial oxygen saturation. When this occurs in patients with otherwise normal lung properties it is called idiopathic. The condition is usually based on blunted chemoresponsiveness (Plum and Leigh, 1981). Congenital central alveolar hypoventilation syndrome (327.24). This is present at birth and is lifelong. It involves a failure of the automatic central control of breathing. Sleep aggravates this syndrome, and many patients may need mechanical ventilation during sleep (American Thoracic Society, 1999).
SLEEP-RELATED
HYPOVENTILATION/HYPOXEMIA DUE
TO MEDICAL CONDITION
(327.26)
This occurs in such problems as lower airway obstructions, neuromuscular and chest wall disorders. (PerezPadilla et al., 1985).
SLEEP
APNEA/SLEEP-RELATED BREATHING DISORDER,
UNSPECIFIED
(327.20)
This is classified when the sleep-related breathing disorder cannot be classified into any of the above categories.
Hypersomnias of central origin not due to a circadian rhythm sleep disorder, sleep-related breathing disorder, or other cause of disturbed nocturnal sleep The tortured title of this category tries to indicate that many sleep disturbances that are dealt with in other
parts of ICSD-2 may also cause excessive daytime somnolence (EDS), but that the disorders discussed here are different. In them, EDS is a primary, not a secondary, symptom.
NARCOLEPSY This group of sleep disorders has been recognized for over 100 years. Characterizing features of narcolepsy are: (1) EDS, usually associated with markedly disrupted sleep; (2) daytime naps that are refreshing for a short time only; (3) an unusual tendency to transition rapidly from wakefulness to rapid eye movement (REM) sleep without intervening nonREM sleep. This fast transition into REM sleep gives rise to cataplexy, hypnagogic hallucinations, and sleep-onset paralysis, features that are characteristic of narcolepsy but not invariably present. Narcolepsy with cataplexy (347.01). This is the pure form of narcolepsy, involving almost daily excessive sleepiness, combined with a history of cataplexy (sudden, transient loss of muscle tone usually triggered by emotions). This form of narcolepsy is closely associated with sleep-onset REM periods, with a genetic abnormality, and 90% of these patients have abnormally low hypocretin levels (Overeem et al., 2001). Narcolepsy without cataplexy (347.00). This is a somewhat more heterogeneous, less clearcut group that may involve some patients whose cataplexy has not yet emerged and others who may have a milder or atypical form of the disease. In the majority of these patients, hypocretin levels are normal. Sleep-onset REM periods may or may not be present (Krahn et al., 2002). Narcolepsy due to a medical condition. This is secondary to medical conditions such as a hypothalamic tumor or a blow to the brainstem (Scammell et al., 2001). Distinguish narcolepsy with cataplexy (347.11) from narcolepsy without cataplexy (347.10). Narcolepsy, unspecified (347.11). This is the category to use if enough is known about a patient to diagnose narcolepsy, but not enough to classify them into one of the other narcolepsy categories.
HYPERSOMNIAS This group combines the various hypersomnias that are not dealt with elsewhere in ICSD-2. Recurrent hypersomnia (327.13). This consists of episodic hypersomnolence alternating with periods of normal sleep, such as is typical in menstrual-related hypersomnia or in the Kleine–Levin syndrome. This
CLASSIFICATION OF SLEEP DISORDERS
673
latter disorder involves episodes of 16–18 hours of sleep per day for a few days or weeks, alternating with long stretches of normal sleep (Dauvilliers et al., 2003).
it may have a periodicity that is significantly longer than 24 hours or it may be misaligned with local clock time, such as in jet lag.
Idiopathic hypersomnia with long sleep time (327.11). This is diagnosed when the patient typically sleeps longer than 10 hours per night but still is excessively sleepy during the day (Billiard and Dauvilliers, 2001).
Circadian rhythm sleep disorder, delayed sleep phase type (327.31). In this disorder, also called the “night owl syndrome”, the internal clock of the individual lags behind the local clock time. For example, when the clock on the wall indicates midnight, the internal clock may indicate only 9 pm, and the individual is biologically not yet ready to sleep. Then, when the clock on the wall indicates 8 am, the internal clock may show only 5 am, not yet time to get up. Now, if the biological clock were running in a time-free environment, the individual would go to bed and get up progressively later each day. However, in the real world, there are countervailing forces to free running, such as bright light during the day, or social pressures requesting a steady sleep time. The result is a delayed sleep phase syndrome – an uneasy balance is reached between internal and external clock: the individual goes to bed very late and gets up late, but still much earlier than is comfortable (Baker and Zee, 2000).
Idiopathic hypersomnia without long sleep time (327.12). This is diagnosed when the patient sleeps a normal 6–10 hours per night but is excessively sleepy during the day. Behaviorally induced insufficient sleep syndrome (307.44). Some patients are required by circumstances (e.g. jobs) to get by with less sleep than needed, others believe that sleep is an unnecessary waste of time, and many consistently obtain less sleep than they require, for social, cultural, financial, or other reasons. When they then show excessive somnolence during the day from lack of sleep, they often do not recognize what causes their EDS (Von Dongen et al., 2003). Hypersomnia due to a medical condition (327.14). This occurs when EDS is secondary to a disease such as Parkinson’s disease, a brain tumor, or an endocrine disorder.
Circadian rhythm sleep disorder, advanced sleep phase type (327.32). This is the opposite of the delayed sleep phase disorder: The patient has an internal clock that is ahead of local time. This results in the “early bird” behavior pattern (Jones et al., 1999).
Hypersomnia due to drug or substance (292.85, 291.82 if alcohol). This may be based on substance abuse (e.g. abuse of sedatives, withdrawal from excessive use of stimulants) or it may be related to the use of medically required drugs such as a high dose of sedative antiepileptic medication required for seizure control (Young-McCaughan and Miaskowski, 2001).
Circadian rhythm sleep disorder, irregular sleep– wake type (327.33). This disorder is characterized by a relative weakness or total lack of a circadian rhythm, with sleeping and waking being spread almost evenly over a 24-hour period. It appears as if the internal clock has stopped altogether (Pollack and Stokes, 1997).
Hypersomnia not due to substance or known physiological condition (327.15). Nonorganic hypersomnia, not otherwise specified, may be found in certain psychiatric diseases such as atypical depression, bipolar disorder, seasonal affective disorder, or conversion disorder (Overeem et al., 2002).
Circadian rhythm sleep disorder, free-running (non-entrained) type (327.34). This usually occurs when there are not enough stimuli to synchronize the internal clock to local time. It is like the delayed or the advanced sleep phase syndrome, except that the countervailing forces discussed under delayed sleep phase are absent. This problem is most often found in totally blind people (Sack et al., 1992).
Physiological (organic) hypersomnia, unspecified (327.10). Patients in this group satisfy the diagnosis of hypersomnia but do not fit any of the above types of hypersomnia.
Circadian rhythm sleep disorders Human functioning is regulated by an internal “clock” that is located in the suprachiasmatic nucleus. This clock dictates when we become sleepy and when we become alert. It may be malfunctioning. For example,
Circadian rhythm sleep disorder, jet lag type (327.35). This is a temporary complaint of insomnia or EDS after an individual has crossed many time zones and the body clock has not yet caught up to the new local time (Spitzer et al., 1999). Circadian rhythm sleep disorder, shift work type (327.36). Complaints of either insomnia or EDS occur in individuals who have difficulties adjusting to shift
674
P.J. HAURI
work. The problem is aggravated by the fact that during their time off work such individuals try to sleep on a “normal” day/night cycle, so that the clock can never adjust to any regular 24-hour periodicity (Akerstedt, 2003). Circadian rhythm sleep disorder due to a medical condition (327.37). This may occur in patients with dementia, Parkinson’s disease, hepatic encephalopathy, etc. (Bliwise et al., 1995). Circadian rhythm disturbance due to drug or substance (292.85) or, if alcohol induced (291.82). This occurs when substances such as some antidepressants affect the circadian rhythm. Circadian rhythm sleep disorder, other (327.39). Classified here are patients who have problems with the circadian rhythm but cannot be diagnosed into any of the above categories.
Parasomnias Parasomnias are undesirable events that accompany sleep. Often they seem to be purposeful and goal directed. They may result in injuries, disturb sleep (of the patient as well as of others), and they may cause untoward psychosocial developments.
DISORDERS
OF AROUSAL (FROM NONREM SLEEP)
Confusional arousals (327.41). Such patients are mentally or behaviorally more confused than others when awakening, usually from deep (slow-wave) sleep (Ohayon et al., 2000). Sleepwalking (307.67). This involves walking or other complex behaviors that are started when awakening, usually from slow-wave sleep. The person may be difficult to awaken, coordination is often impaired, and behavior is often inappropriate (Kavey et al., 1990). Sleep terrors (307.67). These involve sudden terrified arousals, usually with a piercing scream, usually from slow-wave sleep. There is evidence of intense autonomic activation and panic. The person is difficult to awaken and usually shows amnesia for the episode (Ohayon et al., 1999a).
PARASOMNIAS REM SLEEP
USUALLY ASSOCIATED WITH
REM sleep behavior disorder (327.42). During REM (dreaming) sleep, most of our voluntary muscles are paralyzed. This keeps us from acting out our dreams. When this paralysis is weak or fails altogether,
we start enacting parts of our dreams. Shouting, grabbing, punching, and leaping are often seen, but walking is rare. Injuries to self or bed partner are of concern (Olson et al., 2000). Recurrent isolated sleep paralysis (327.43). This involves the inability to speak or move, either when falling asleep or when waking up. Consciousness is preserved during the paralysis, which may last up to minutes (Ohayon et al., 1999b). Nightmare disorder (307.47). This consists of increasingly disturbing dream sequences that are highly emotional, involving fear, panic, and anger. However, in contrast to sleep terrors, autonomic arousal is minimal and patients often retain considerable recall of their dream (Levin and Fireman, 2002).
OTHER
PARASOMNIAS
Sleep-related dissociative disorders (300.15). These arise out of wakefulness during the sleep period. These events are similar to waking dissociative disorders, except that they are often associated with other parasomnias (Mahowald and Schenck, 2001). Sleep-related enuresis (788.36). While bedwetting in young children is expected, it becomes pathological if it occurs frequently after the age of about 5 years or so (Fritz and Rockney, 2004). Sleep-related groaning (catathrenia, 327.49). Chronic expiratory moaning and groaning during sleep usually occurs nightly and mainly during the later REM episodes of the night (Vetrugno et al., 2001b). Exploding head syndrome (327.49). This occurs at the transition between waking and sleeping. The person experiences either a sudden loud noise or a violent explosion in the head. Although very frightening, there is no pain, and, as far as known, the experience is benign (Pearce, 1989). Sleep-related hallucinations (368.16). These occur either when falling asleep or waking up. They are primarily visual and may be hard to distinguish from dreams (Silber et al., 2002), except that they occur when the patient is awake. Sleep-related eating disorder (327.49). In these patients there are recurrent episodes of involuntary eating and drinking during sleep. Some patients may be fully asleep during these episodes, others only partially so, or they may gradually awaken to full consciousness during the episode. Patients often consume
CLASSIFICATION OF SLEEP DISORDERS peculiar “foods” such as a peanut butter/cigarette sandwich. Many patients realize that they have had an eating episode only when they enter the kitchen in the morning, finding food items displaced or missing (Winkelman, 1998). Parasomnias due to drug or substance (292.85, if alcohol 291.82). There are many possibilities, such as a REM behavior disorder (RBD) triggered by antidepressants or sleep-related hallucinations triggered by b-adrenergic receptor blocking agents. Parasomnias due to a medical condition (327.44). These may involve such parasomnias as sleep-related visual hallucinations associated with Parkinson’s disease or RBD related to dementia. Parasomnia, other or unspecified (327.40). This is diagnosed when a given parasomnia cannot be classified into any of the above disorders.
Sleep-related movement disorders Except for restless legs, this category of sleep disorders involves relatively simple, stereotyped movements during sleep or on the threshold between sleeping and waking. These movements cause fragmented sleep, insomnia and/or EDS. Restless legs syndrome (333.94). In this disorder there are very strong urges to move the legs (occasionally arms as well), often accompanied by paresthesias such as a “creepy/crawly” feeling in the legs. Restless legs occur mainly when resting or lying down. There is a circadian rhythm to them (nights are worst) and there is temporary relief when the extremities are moved (Allen and Earley, 2001). Periodic limb movement sleep disorder (327.51). This involves episodes during sleep of highly stereotyped, periodic limb movements. Such movements can also occur in good sleepers. A sleep disorder is diagnosed only when these limb twitches cause arousals and lead to a complaint of either insomnia or EDS (Coleman, 1982). Sleep-related leg cramps (327.52). These may arise from either sleep or wakefulness during the night, may last up to a few painful minutes and then abate spontaneously (Saskin et al., 1988). Sleep-related bruxism (327.53). This indicates that the patient is grinding or clenching the teeth during sleep. Considerable tooth damage may occur and sleep may become disturbed (Kato et al., 2001).
675
Sleep-related rhythmic movement disorders (327.59). These may involve body rocking, head banging, head rolling, etc. during sleep. Quite normal in young children, the rhythmic movements may become a problem when they disturb sleep either in the patient or in a bed partner (Dyken et al., 1997). Sleep-related movement disorder due to a drug or substance (327.59). An example might be disturbed sleep secondary to tardive dyskinesia caused by dopamine receptor blocking agents. Sleep-related movement disorder due to a medical condition (327.59). This is diagnosed when such movements disturb sleep, an underlying condition such as Parkinson’s disease is suspected, but has not yet been properly identified as the reason for the sleep disturbance. Sleep-related movement disorder, unspecified (327.59). This is used when there is clearly a sleep disturbance caused by muscle movements that does not fit into any of the above disorders, or when not enough is known to assign it to any of the above categories.
Isolated symptoms, apparently normal variants, and unresolved issues Sleep clinicians frequently deal with issues that lie at the borderline between normal and abnormal sleep. Some may occur in many people without causing difficulties, but may become abnormal in excess or in highly sensitive sleepers. 1.
2.
3.
4. 5.
Long sleeper is a term reserved for adults who sleep more than 10 hours per night (or for children who sleep more than 2 hours longer than age-adjusted norms). When they do not get that amount of sleep, long sleepers show signs of sleep deprivation (Aeschbach et al., 1996). Short sleeper is an adult who regularly sleeps fewer than 5 hours per night, or a child who sleeps 3 hours less than age-appropriate norms, without showing daytime signs of sleep deprivation. Snoring is diagnosed when there is audible, often very loud, snoring without disruption of the snorer’s sleep. Sleep talking is usually disruptive to a bed partner, but not to the talker. Sleep starts (hypnic jerks) usually occur around sleep onset and may delay the beginning of sleep, especially when they occur frequently. A subjective feeling of falling, a sensory flash, or a dream fragment often accompanies them (Sander et al., 1998).
676 6.
7.
8.
9.
P.J. HAURI Benign sleep myoclonus of infancy involves repetitive large jerks that occur only during sleep, usually in children less than 6 months of age. Hypnagogic foot tremors and alternating leg muscle activation involves benign movements in the legs and feet during sleep. Propriospinal myoclonus at sleep onset consists of sudden muscular jerks occurring at sleep onset, mainly in the abdomen, trunk, or neck (Vetrugno et al., 2001a). Excessive fragmentary myoclonus involves small movements or fasciculations in fingers, toes, or corners of the mouth that may disturb the relaxing patient. (Vetrugno et al., 2002).
Other sleep disorders It seems likely that in the near future other sleep disorders will be found that do not fit into the framework of ICSD-2. The category of “other sleep disorders” is reserved for them. However, environmental sleep disorder is also classified here, mainly because it overlaps with so many other categories (insomnia, EDS, parasomnia). Environmental sleep disorder (307.48). This is diagnosed when the sleep disorder is caused by environmental factors such as noise, temperature, a bed partner, etc. It may manifest itself as insomnia, EDS, parasomnia or the patient may simply show daytime signs of sleep deprivation (Thiessen and Lapointe, 1983). Other or unspecified sleep disorder (327.8). This is diagnosed when there is a sleep disorder that does not fit into any of the other ICSD-2 diagnoses.
CONCLUDING REMARKS The above outline of the recognized sleep disorders gives a cursory glance at what is involved in the field of sleep disorders medicine. Clearly this field is multidisciplinary. Among others, knowledge of pulmonary medicine is needed to deal with the respiratory sleep disorders, knowledge from neurology to deal with the hypersomnias and some parasomnias, from psychiatry and psychology to deal with the insomnias. Obviously, the field of sleep medicine is still young and evolving. It will be different in a decade or so. For more information, the reader might contact the central office of the American Academy of Sleep Medicine, One Westbrook Corporate Center, Suite 920, Westchester, IL 60154, USA (Tel: 708 492-0930; www.aasmnet.org).
REFERENCES Aeschbach D, Cajochen C, Landolt H et al. (1996). Homeostatic sleep regulation in habitual short sleepers and long sleepers. Am J Physiol 270: R41–R53. Akerstedt T (2003). Shift work and disturbed sleep/wakefulness. Occup Med 53: 89–94. Allen R, Earley C (2001). Restless legs syndrome: a review of clinical and pathophysiologic features. J Clin Neurophysiol 18: 128–147. American Academy of Sleep Medicine (2005). International Classification of Sleep Disorders. 2nd edn. Diagnostic and Coding Manual. American Academy of Sleep Medicine, Westchester, IL. American Sleep Disorders Association (1997). International Classification of Sleep Disorders (Revised). Diagnostic and Coding Manual. American Sleep Disorders Association, Rochester, MN. American Thoracic Society C (1999). Idiopathic congenital central hypoventilation syndrome: diagnosis and management. Am J Respir Crit Care Med 160: 368–373. Anholm J, Powles A, Downey R et al. (1992). Operation Everest II: arterial oxygen saturation and sleep at extreme simulated altitude. Am Rev Respir Dis 145: 817–826. Association of Sleep Disorders Centers (1979). Diagnostic Classification of Sleep and Arousal Disorders. 1st edn. Prepared by the Sleep Disorders Classification Committee. Roffwarg HP, Chairman. Sleep 2: 1–127. Baker S, Zee P (2000). Circadian disorders of the sleep– wake cycle. In: MH Kryger, T Roth, WC Dement (Eds.), Principles and Practice of Sleep Medicine. 3rd edn. WB Saunders, Philadelphia, pp. 606–614. Billiard M, Dauvilliers Y (2001). Idiopathic hypersomnia. Sleep Med Rev 5: 351–360. Bliwise D, Watts R, Watts N et al. (1995). Disruptive nocturnal behavior in Parkinson’s disease and Alzheimer’s disease. J Geriatr Psychiatry Neurol 8: 107–110. Bonnet MH, Arand DL (1995). 24-Hour metabolic rate in insomniacs and matched normal sleepers. Sleep 18: 581–588. Coleman R (1982). Periodic movements in sleep (nocturnal myoclonus) and restless legs syndrome. In: C Guilleminault (Ed.), Sleeping and Waking Disorders: Indications and Techniques. Addison Wesley, Menlo Park, pp. 265–295. Dauvilliers Y, Baumann C, Carlander B et al. (2003). CSF hypocretin-1 levels in narcolepsy, Kleine–Levin syndrome, and other hypersomnias and neurological conditions. J Neurol Neurosurg Psychiatry 74: 1667–1673. Dyken M, Lin-Dyken D, Yamada T (1997). Diagnosing rhythmic movement disorder with video-polysomnography. Pediatr Neurol 16: 37–41. Edinger JD, Fins AL (1995). The distribution and clinical significance of sleep time misperceptions. Sleep 18: 232–239. Farney RJ, Walker JM, Cloward TV et al. (2003). Sleep-disordered breathing associated with long-term opioid therapy. Chest 123: 632–639. Flemons WW (2002). Clinical practice. Obstructive sleep apnea. N Engl J Med 347: 498–504.
CLASSIFICATION OF SLEEP DISORDERS Fritz G, Rockney R (2004). Summary of the practice parameter for the assessment and treatment of children and adolescents with enuresis. J Am Acad Child Adolesc Psychiatry 43: 123–125. Gaylor E, Goodlin-Jones B, Anders T (2001). Classification of young children’s sleep problems. J Am Acad Child Adolesc Psychiatry 40: 60–67. Gislason T, Almquist M (1987). Somatic disease and sleep complaints: an epidemiological study of 3201 Swedish Men. Acta Med Scand 22: 475–481. Hauri P, Olmstead E (1980). Childhood-onset insomnia. Sleep 3: 59–65. Jones C, Campbell S, Zone S et al. (1999). Familial advanced sleep-phase syndrome: a short-period circadian rhythm variant in humans. Nat Med 5: 1062–1065. Kahn A, Groswasser J, Franco P (2000). Breathing during sleep in infancy. In: G Loughlin, J Carroll, C Marcus (Eds.), Sleep and Breathing in Children, Vol. 147. Marcel Dekker, New York, pp. 405–422. Kato T, Thie N, Montplaisir J, Lavigne G (2001). Bruxism and orofacial movements during sleep. Dent Clin North Am 45: 657–684. Kavey NB, Whyte J, Resor SR, Gidro-Frank S (1990). Somnambulism in adults. Neurology 49: 749–752. Krahn LE, Pankratz VS, Oliver L et al. (2002). Hypocretin (orexin) levels in cerebrospinal fluid of patients with narcolepsy: relationship to cataplexy and HLA DQB1*0602 status. Sleep 25: 733–736. Levin R, Fireman G (2002). Nightmare prevalence, nightmare distress, and self-reported psychological disturbance. Sleep 25: 205–212. Mahowald M, Schenck C (2001). Nocturnal dissociation – Awake? Asleep? Both? Or Neither? Sleep Hypnosis 3: 129–130. Marcus CL (2000). Pathophysiology of childhood obstructive sleep apnea: current concepts. Respir Physiol 119: 143–154. Morin CM, Hauri PJ, Espie CA et al. (1999). Nonpharmacologic treatment of chronic insomnia. Sleep 22: 1134–1156. Nofzinger E, Buysse DJ, Reynolds CF 3rd et al. (1993). Sleep disorders related to another mental disorder (nonsubstance/primary): a DSM-IV literature review. J Clin Psychiatry 54: 244–255. Ohayon M, Guilleminault C, Priest R (1999a). Night terrors, sleepwalking, and confusional arousals in the general population: their frequency and relationship to other sleep and mental disorders. J Clin Psychiatry 60: 268–276. Ohayon M, Zulley J, Guilleminault C et al. (1999b). Prevalence and pathologic associations of sleep paralysis in the general population. Neurology 52: 1194–1200. Ohayon M, Priest R, Zulley J et al. (2000). The place of confusional arousals in sleep and mental disorders: findings in a general population sample of 13,057 subjects. J Nerv Ment Dis 188: 340–348. Olson E, Boeve B, Silber M (2000). Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. Brain 123: 331–339.
677
Overeem S, Mignot E, van Dijk JG et al. (2001). Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives. J Clin Neurophysiol 18: 78–105. Overeem S, van Hilten JJ, Ripley B et al. (2002). Normal hypocretin-1 levels in Parkinson’s disease patients with excessive daytime sleepiness. Neurology 58: 498–499. Pearce J (1989). Clinical features of the exploding head syndrome. J Neurol Neurosurg Psychiatry 52: 907–910. Perez-Padilla R, West P, Lertzman M et al. (1985). Breathing during sleep in patients with interstitial lung disease. Am Rev Respir Dis 132: 224–229. Plum F, Leigh R (1981). Abnormalities of central mechanisms. In: T Hornbein (Ed.), Regulation of Breathing. Part II. Lung Biology in Health and Disease, Vol. 17. Marcel Dekker, New York, pp. 989–1067. Pollack C, Stokes P (1997). Circadian rest–activity rhythms in demented and non-demented older community residents and their caregivers. J Am Geriatr Soc 6: 452. Roehrs T, Zorick F, Roth T (2000). Transient and short-term insomnias. In: Principles and Practice of Sleep Medicine, 3rd edn. WB Saunders, Philadelphia, pp. 624–632. Sack R, Lewy A, Blood M et al. (1992). Circadian rhythm abnormalities in totally blind people: incidence and clinical significance. J Clin Endocrinol Metabol 75: 127–134. Sander HW, Geisse H, Quinto C et al. (1998). Sensory sleep starts. J Neurol Neurosurg Psychiatry 64: 690. Saskin P, Whelton C, Moldofsky H et al. (1988). Sleep and nocturnal leg cramps. Sleep 11: 307–308. Scammell TE, Nishino S, Mignot E et al. (2001). Narcolepsy and low CSF orexin (hypocretin) concentration after a diencephalic stroke. Neurology 56: 1751–1753. Schweitzer P (2000). Drugs that disturb sleep and wakefulness. In: MH Kryger, T Roth, WC Dement (Eds.), Principles and Practice of Sleep Medicine. 3rd edn. WB Saunders, Philadelphia, pp. 1176–1196. Silber MH, Hansen M, Girish M (2002). Complex nocturnal visual hallucinations. Sleep 25: 484. Spitzer R, Terman M, Williams J et al. (1999). Jet lag: clinical features, validation of new syndrome-specific scale, and lack of response to melatonin in a randomized, double-blind trial. Am J Psychiatry 156: 1392–1396. Thiessen G, Lapointe A (1983). Effect of continuous traffic noise on percentage of deep sleep, waking, and sleep latency. Acoustic Soc Am 73: 225–229. Vetrugno R, Provini F, Meletti S et al. (2001a). Propriospinal myoclonus at the sleep–wake transition: a new type of parasomnia. Sleep 24: 835–843. Vetrugno R, Provini F, Plazzi G et al. (2001b). Catathrenia (nocturnal groaning): a new type of parasomnia. Neurology 56: 681–683. Vetrugno R, Plazzi G, Provini F et al. (2002). Excessive fragmentary hypnic myoclonus: clinical and neurophysiological findings. Sleep Med 3: 73–76. Von Dongen HP, Maislin G, Mullington JM et al. (2003). The cumulative cost of additional wakefulness: dose– response effects on neurobehavioral functions and sleep physiology from chronic sleep restriction and total sleep deprivation. Sleep 26: 117–126.
678
P.J. HAURI
Winkelman J (1998). Clinical and polysomnographic features of sleep-related eating disorder. J Clin Psychiatry 59: 14–19. Xie A, Ruthford R, Rankin F et al. (1995). Hypocapnia and increased ventilatory responsiveness in patients with idiopathic central sleep apnea. Am J Respir Crit Care Med 152: 1950–1955.
Xie A, Skatrud J, Puleao D et al. (2002). Apnea–hypopnea threshold for CO2 in patients with congestive heart failure. Am J Respir Crit Care Med 165: 1245–1250. Young-McCaughan S, Miaskowski C (2001). Measurement of opioid-induced sedation. Pain Manage Nurs 2: 132–149.
Handbook of Clinical Neurology, Vol. 99 (3rd series) Sleep Disorders, Part 2 P. Montagna and S. Chokroverty, Editors # 2011 Elsevier B.V. All rights reserved
Chapter 43
Genetics of sleep disorders JULIANE WINKELMANN 1 * AND MAYUMI KIMURA 2 Department of Neurology, Institute of Human Genetics, Klinikum rechts der Isar, Technische Universität München and Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany
1
2
Max Planck Institute of Psychiatry, Munich, Germany
INTRODUCTION In recent years, genetic approaches have became very popular in many fields of science. Finding causative genes specific for disorders and a variety of quantitative phenotypes is the hottest target in biomedical sciences, and such effort has also been made in the field of sleep research (Franken and Tafti, 2003; Lavie, 2005; Cirelli, 2009). One of the most successful findings in terms of sleep genetics so far is the discovery of the hypocretins/orexins, internal ligands of G-coupled orphan receptors in the hypothalamus. Hypocretins/orexins, when first discovered, were thought to function as appetite promoters (Sakurai et al., 1998), and it was then found that their impaired system initiates narcoleptic symptoms (Chemelli et al., 1999; Lin et al., 1999; Mieda and Yanagisawa, 2002; Sutcliffe and de Lecea, 2002; Sakurai, 2005; Nishino, 2007). However, as familial clustering had been observed in narcolepsy with a close association of human leukocyte antigens (e.g., HLA-DQB1 and HLA-DQA1), the discovery of gene products triggering or blocking narcolepsy was expected earlier (Peyron et al., 2000; Miyagawa et al., 2008). Thus, identifying a gene or its products responsible for sleep disorders will be difficult because of the complexity of these conditions. However, there is an increasing demand for the discovery of genetic factors in sleep pathology (Taheri and Mignot, 2002; Dauvilliers et al., 2005; Dauvilliers and Tafti, 2008; Kimura and Winkelmann, 2007). It is known that several sleep problems can be inherited. Further, twin studies have demonstrated that sleep components are influenced significantly by genetic background. Thus, sleep regulation or dysregulation must
be closely linked to genetic control. To prescreen a risk factor, find an adequate cure, or even classify the complexity of sleep phenotypes for further treatments, genetic information contributes to an in-depth understanding of the pathophysiology of major sleep disorders. Indeed, several mutations in particular genes are reported to be involved in certain sleep disorders. These “sleep-related” genes or mutations have mostly been demonstrated in animal models (Andretic et al., 2008), but, with the help of advanced molecular genetic approaches, sleep genetics will soon expand into a search among human models and lead to pharmacogenomic development for individualized sleep medicine. In this chapter, we first describe the genetic influence on normal sleep and its regulatory mechanism, and then discuss recent clinical discoveries regarding the role of genetic factors in selected sleep disorders.
A GENETIC INFLUENCE ON NORMAL SLEEP AND SLEEP^WAKE REGULATION Evidence for genes The various genetic aspects in normal sleep of healthy subjects are evident from earlier studies employing twin pairs (Linkowski, 1999). Under visual inspection, monozygotic (MZ) twins show a very similar hypnogram if they have not been exposed to similar environmental factors. The similarities of their sleep patterns are observed particularly in sleep latency, duration of sleep cycles, and appearance of rapid eye movement (REM) sleep (Webb and Campbell, 1983). The majority of twin studies have been based on questionnaire analyses, comparing sleep habits, subjective mood
*Correspondence to: Dr Juliane Winkelmann, Klinik fu¨r Neurologie und Institut fu¨r Humangenetik, Klinikum rechts der Isar, Technische Universita¨t Mu¨nchen (TUM), Ismaninger Strasse 22, 81675 Mu¨nchen, Germany. Tel: þ49-89-4140-4688, E-mail:
[email protected]
682
J. WINKELMANN AND M. KIMURA
after night sleep, etc., and most demonstrate higher concordance for sleep characteristics in MZ than in dizygotic (DZ) twins (Partinen et al., 1983; Heath et al., 1990). However, more advanced polygraphic analyses show a stronger impact of the influence on genes in sleep regulation of twins (van Beijsterveldt and van Baal, 2002). In a previous study, alpha rhythms during waking were reported to be similar only in MZ twin pairs (Davis and Davis, 1936; Lennox et al., 1945). Recently, quantitative EEG measures revealed that spectral power during nonREM sleep showed significantly higher concordance than in DZ twin pairs, especially in the range of alpha and sigma bands (Ambrosius et al., 2008; De Gennaro et al., 2008). Furthermore, even MZ twins who were discordant for schizophrenia demonstrated almost identical spectra profiles (Brunner et al., 2001) (Figure 43.1). Apart from the strong evidence of similarity between MZ twins, more general findings of similarities in siblings suggest broader genetic heredity in sleep architecture (de Castro, 2002). Genetic factors do affect sleep architecture. Whether sleep disorders can be transmitted within mV 10
5
2
0.1 50
0.1 10
5
2
0.1 50
0.1 10
5
2
0.1 50
0.1 10
5
2
0.1 50
0.1 10
5
2
0.1 50
0.1 10
5
2
REM
Sigma
Delta
0.1 1
A
4
8
0.1 12 16 19 Hz 1 4 Frequency
#4 #5
#1.5
#5
#4
#3
50
2
#1
#1 #2 #3
NonREM
#2
2
mV
families is a moot question. In the case of insomnia, familial occurrence is common (Bastien and Morin, 2000). Although not every sibling experiences insomniac symptoms, they show similar power spectral distribution in their EEGs (Brunner et al., 2001). Therefore, genetic vulnerability to insomnia would be hidden even in normal sleep cycles, and the signs for potential sleep problems could be assessed by polysomnography. According to our local survey, vulnerability has been found in healthy probands who have family members diagnosed with insomnia associated with anxiety or depression (Modell et al., 2002; Friess et al., 2008); affected and nonaffected family members all showed higher REM density. However, this is controversial because insomnia begins prior to the onset of affective disorders, which are also inheritable. We cannot really separate which genomic factor influences the most or primarily, but it is worth recalling that sleep is a complex of phenotypes. Many gene factors may be involved in sleep, and balancing or counterbalancing their functions maintains homeostasis of sleep–wake regulation. Thus, there must be many possible genetic avenues for sleep disturbances.
8
12 16 19Hz
11
B
1
3
5
7 11 1 Clock time
3
5
7
Fig. 43.1. Comparison of spectral profiles in nonREM and REM sleep (A) and temporal dynamics of delta and sigma EEG activity during nonREM sleep (B) in five monozygotic twin pairs who were discordant for schizophrenia (black line, affected twin; grey line, unaffected twin) (Brunner et al., 2001). (Reprinted with permission from Kimura and Winkelmann, 2007. # Birkhauser.)
GENETICS OF SLEEP DISORDERS
Genetic aspects of the human and animal EEG HUMANS EEG is the most useful and convenient tool available at present to examine genetic influences on individual differences in CNS functioning and human behaviors. EEG records reflect rhythmic electrical activity of the brain and provide a direct measure of the functional state of the brain and its different levels of arousal. EEGs are described by various parameters, such as amplitude (power in mV2) and rhythm (frequency in Hz). These EEG variants can reflect genetic traits. From the EEG recordings for three consecutive nights in 26 twin pairs living apart, Linkowski and associates (1989, 1991) found heritable signs in stages 2 and 4 of nonREM sleep, but not in REM sleep. In their study, variance in REM sleep appeared to be influenced substantially by environmental rather than genetic components. However, when heritability of EEGs was investigated in 213 twin pairs across four main frequency bands, van Beijsterveldt et al. (1996) reported that all delta, theta, alpha, and beta frequencies showed significantly high heritability. However, Vogel (1970) performed extensive earlier studies and, in the 1970s, had already proposed a hypothesis that the normal EEG rhythm is influenced by many genes. His group focused on the low-voltage EEG (lack of a waves) in 17 families with 191 individuals, and identified a linkage region for a putative gene underlying the normal human EEG variant to chromosome 20q (Steinlein et al., 1992). Their results indicate strong evidence for close linkage with the high polymorphic marker CMM6 (D20S19) and for genetic heterogeneity to the low-voltage EEG. Recently, Re´tey et al. (2005) demonstrated a functional polymorphism of the gene encoding adenosine deaminase on chromosome 20, revealing an association with interindividual variability in sleep architecture and the sleep EEG. Their healthy young subjects, who possess a G to A transition at nucleoside 22 (G/A genotype compared with G/G), were characterized by more slow-wave sleep (SWS) and of greater intensity, indicating a direct role for a single gene in homeostatic human sleep regulation. Furthermore, recently Viloa, Archer and their collaborators have reported the significance of a variablenumber tandem-repeat polymorphism in the PERIOD3 (PER3) gene on individual differences in sleep structure (Viola et al., 2007; Archer et al., 2008). This polymorphism was found earlier in association with diurnal preferences and delayed sleep phase syndrome (Ebisawa et al., 2001; Archer et al., 2003). The later studies have revealed that individuals with the longer PER35 allele than the others who are homozygous for
683
the PER34 allele show higher delta power during nonREM sleep, and also higher theta and alpha power during REM sleep and wakefulness. Taken together, PER3 polymorphism seems to affect susceptibility to sleep loss, resulting from its influences on sleep homeostasis. Regarding polymorphisms, it is known that a cause of fatal familial insomnia (FFI; see below for details) is a mutation at codon 178 of the prion protein gene, located on human chromosome 20, cosegregating with the methionine polymorphism at codon 129 (129M) of the mutated allele (Goldfarb et al., 1992; Montagna et al., 1998). These mutations are also found in another prion disease, Creutzfeldt–Jakob disease (CJD), in which a valine residue segregates at codon 129 (129V). Although the polymorphism at codon 129 is critical in distinguishing between FFI and CJD, the 129 polymorphism without the mutation at codon 178 occurs commonly in the general population, and does not result in prion disease. One study recently conducted EEG recordings and insomnia questionnaires in 884 middle-aged men and women to examine whether the 129V/M polymorphism influences sleep, with special emphasis on items related to insomnia complaints and any sleep disruption (Pedrazzoli et al., 2002). The results failed to clarify any differences in polysomnographic measures among three genotypes (129VV, 129MV, and 129MM), indicating that the prion 129 polymorphism does not really affect normal sleep. Other pathogenic mechanisms, implicating the normal allele of prion protein gene, need to be considered.
ANIMALS A role for the prion protein in sleep regulation has been also investigated in a genetically modified animal model, the prion protein null mouse (Tobler et al., 1996). Involvement of the prion protein in the neuropathogenesis of human and animal transmissible spongiform encephalopathies has been well documented (Prusiner, 1997); the normal function of this protein is still unknown. Compared with wild-types (129/Ola mice or 129/Sv and C57BL/6J mixture, Prn-pþ/þ), prion gene-disrupted homozygous mice (Prn-p0/0) display abnormalities in circadian activity rhythm and sleep structure; none of the mice differed particularly in their behavior or sleeping time. EEG studies have revealed that Prn-p0/0 mice exhibit a larger degree of sleep fragmentation and a larger response to sleep deprivation. The response to sleep deprivation is often indicated by the magnitude of EEG slow-wave activity (SWA, power density in the delta band) during and after sleep deprivation (Tobler and Borbe´ly, 1986; Dijk et al., 1987). SWA in Prn-p0/0 mice during recovery
J. WINKELMANN AND M. KIMURA 80
Wake (%)
60
40
20
A
0 50 40
SWS (%)
sleep is twice than that in Prn-pþ/þ mice after 6 hours of sleep deprivation. Data from the gene-knockout model suggest that the prion protein may participate in maintaining sleep continuity and regulating sleep intensity (Huber et al., 1999). More recently, a study by Dossena et al. (2008) confirmed its impact on sleep regulation, characterizing EEG abnormalities (e.g., sawtooth waves in the range of 3–4 Hz), and showed significantly reduced REM sleep in transgenic mice expressing the mouse homolog of the D178N/V129 mutation in the prion protein gene. In mouse strains, systematic and quantitative studies of sleep EEG can also distinguish a genetic background that influences particular rhythmic brain activity (Valatx et al., 1972; Friedmann, 1974), as described above in the determination of zygosity in twins. Franken and Tafti’s group screened many inbred mice and categorized them according to spectral dynamics of their EEG activity (Franken et al., 1998). First, time spent in each vigilance state was compared across six commonly used inbred strains (Figure 43.2). There were slight but significant differences in the amount of sleep and wakefulness, in which the relative amount of wakefulness appeared to be counterbalanced by that of SWS (¼ nonREM sleep). Among these six strains, AKR/J (AK) mice had most SWS (least wakefulness), whereas DBA/2J (D2) mice had least SWS (most wakefulness) per day. When spectral profiles were compared, delta power (c. 1.5–4.0 Hz) typical for SWS was highest in AK and lowest in D2 mice respectively, whereas the distribution of peak delta frequencies was similar among the six strains. However, the peak frequency for theta band (c. 5.5– 8.5 Hz) during paradoxical sleep (PS ¼ REM sleep) was distributed in a strain-dependent manner, which did not coincide proportionally with relative power or episode duration of PS (Figure 43.3). Therefore, it is plausible that the theta peak frequency (TPF) associated with PS varies with genotype. Based on these findings, Tafti and colleagues (2003) performed quantitative trait loci (QTL) analysis, crossing a slow-theta strain (BALB/cByJ, C) with a fast-theta strain (C57BL/6J, B6), and demonstrated a chromosomal region that segregates with TPF. Finally, a single autosomal recessive gene, which contributes to controlling theta oscillations during REM sleep, was identified as the acylcoenzyme-A dehydrogenase for short-chain fatty acids (encoded by Acads). Demonstrating this gene with reference to TPF suggests also that brain fatty acid metabolism is important for cognitive function, and sleep represents a condition favoring or requiring b-oxidation. Furthermore, with recombinant inbred mice, changes in the accumulation of EEG delta power can
30 20 10
B
0 10 8
PS (%)
684
6 4 2
C
0 AK
C
B6
BR
D2
129
Fig. 43.2. Comparison of time spent in each vigilance state across six inbred mouse strains: (A) Wake; (B) slow-wave sleep (SWS); (C) paradoxical sleep (PS). AK, AKR/J; C, BALB/cByJ; B6, C57BL/6J; BR, C57BR/6J; D2, DBA/2J; 129, 129/Ola mice. Hatched bars represent significant differences from other strains. (Redrawn from Franken et al., 1998. Reprinted with permission from Kimura and Winkelmann, 2007. # Birkhauser.)
be used to detect a trace of genetic factors. As described above, and in other chapters in this volume, delta power increases proportionally over the course of recovery sleep after a certain period of sleep loss (or prior wakefulness). Therefore, requirement of SWS is predictive through the magnitude of delta power that indicates SWS intensity, i.e., homeostatic drive for nonREM sleep. Using QTL analysis, Franken et al. (1999) examined 25 BXD (B6 D2 mice) recombinant inbred strains and looked for genomic regions that might affect the increase of delta power after 6 hours of sleep deprivation. One significant locus was identified on chromosome 13 that accounted for
GENETICS OF SLEEP DISORDERS 15
10
5 Relative frequency (%)
AK 0 C B6
BR 10 D2 5 129 0 3
5
9 7 11 Frequency (Hz)
13
Fig. 43.3. Distributions of peak frequency in paradoxical sleep of six inbred mouse strains. AK, AKR/J; C, BALB/ cByJ; B6, C57BL/6J; BR, C57BR/6J; D2, DBA/2J; 129, 129/Ola mice. Curves illustrate changes in maximum power spectra for each frequency bin. (Modified from Franken et al., 1998. Reprinted with permission from Kimura and Winkelmann, 2007. # Birkhauser.)
49% of the genetic variance in this trait. In contrast, the decrease in delta power afterwards did not vary with genotype. These results indicate that the homeostatic regulation of SWS need is under genetic control (Franken et al., 2001). In addition, QTL analysis has also demonstrated PS-related loci on chromosome 7 during the light period, chromosome 5 during the dark period, and chromosomes 2, 17, and 19 across the 24-hour period from CXB (C B6 recombinant mice) lines (Tafti et al., 1997). Differences in the level of delta power during nonREM sleep can also indicate a sign of gene mutation when compared with respective wild-types. For example, double knockout mice lacking both cryptochromes 1 and 2 (cry1,2/) show greater delta power during nonREM sleep across 24 hours (Wisor et al., 2002). The cryptochrome genes, as well as period genes (per), are mainly involved in circadian rhythm generation under the control of transcriptional factors such as CLOCK and BMAL1; therefore, genetic inactivation of cryptochromes results in circadian arrhythmicity (for details see Chapter 60). Although cryptochromes
685
are clock-related genes, the experimental data from cry1,2/ mice suggest their noncircadian role in the homeostatic regulation of sleep (Dudley et al., 2003; Franken et al., 2007). In this mutant mouse, per 1 and 2 genes are overexpressed reversely; therefore, it is not yet clear which genes or gene products are responsible for high nonREM sleep drive. However, their more recent study demonstrates increased gene expression of both per 1 and 2 in the mouse forebrain after 6 hours of sleep deprivation (Franken et al., 2007). Although upregulation of these genes does not show a linear parallel with the accumulation of process S (see below) among different strains, the results further support the hypothesis that clock-related genes participate in controlling sleep homeostasis. On the other hand, low nonREM sleep drive is seen in mouse mutants with T-type calcium channel deficiency (Lee et al., 2004; Cueni et al., 2008). In a model (a1G/), low-threshold spikes in the thalamocortical relay neurons are absent, suggesting that the a1G subunit of T-type calcium channels is critical for the genesis of sleep spindles and delta oscillations (Kim et al., 2001). In fact, Lee et al. (2004) reported lack of delta waves with much lower power density during nonREM sleep in a1G/ mice compared with wild-types, and sleep disturbances were significantly characterized by brief awakening interrupting nonREM but not REM stages. Similar sleep fragmentation was also observed in potassium channel-related mutant mice that do not have functional Kv3 potassium channels (double knockout of Kv3.1 and Kv3.3 encoding genes) (Espinosa et al., 2004). In this Kv3.1- and Kv3.3-deficient mouse model, significant sleep loss of nearly 40% was detected during the light period owing to a reduced mean duration of SWS episodes (Joho et al., 2006). Furthermore, the double mutant mice displayed dramatically reduced spectral power in the delta band and fewer sleep spindles (Espinosa et al., 2008), resembling the sleep phenotypes of the above-mentioned calcium channel-related mutants. According to these studies, genes related to influx–efflux ion channels in brain regions implicated in the modulation of the sleep–wake cycle appear to influence thalamocortical oscillations and contribute to the stabilization of nonREM sleep. Regarding REM sleep regulation, using a genemodified (transgenic) mouse model in which corticotropin-releasing hormone (CRH) was site-specifically overexpressed in the brain, we demonstrated that CNS-restricted CRH overexpression produces a strong drive towards REM sleep (Kimura et al., 2010). In this model, theta power during REM sleep is not particularly affected under baseline conditions. However, in response to sleep deprivation, even heterozygous
686 J. WINKELMANN AND M. KIMURA CRH-overexpressing mice that fail to show increased lead to the development of personalized sleep medibaseline REM sleep demonstrate more REM sleep cine. As QTL analysis reveals, a small difference in rebound than is seen in respective control and wildgenotypes may result in a large difference in phenotype animals. The results indicate that homeostatic contypes in terms of the characteristics of sleep patterns, trol in REM sleep can be detected in a particular model including EEG modulation. cDNA array studies will and only a single gene manipulation could possibly provide a novel direction for searching for a central contribute to changes in REM sleep. alteration that causes sleep disorders, and suggest a sleep cure on an individual basis. At present, gene hunting for human sleep disorders is not yet estabMicroarrays lished; however, the microarray technique has been During the past several years, microarray technology used to demonstrate gene traits in selectively bred anihas become a significant trend in the genetics of sleep mals for short or long sleepers (Xu et al., 2001). In the research and opens up an opportunity for new discovnear future, perhaps using this gene technology, differeries in this field. Most of the related studies so far have ences in sleep architecture seen in different ethnic been done under conditions of sleep deprivation, and groups may also be explained (Profant et al., 2002; then cDNA arrays are applied to find genes in the whole Stepnowsky et al., 2003). brain that are upregulated or downregulated, particuFAMILIAL SLEEP DISORDERS larly during the process of sleep loss (Tononi and Cirelli, 2001; O’Hara et al., 2007). In the past, “sleep-inducing Restless legs syndrome factors” were hypothesized to accumulate in the brain The restless legs syndrome (RLS) is probably one of during prolonged wakefulness, and some of the putathe prime examples of a sleep disorder demonstrating tive sleep-promoting substances were isolated from a strong genetic component. RLS is characterized by the brain of sleep-deprived animals. When “sleep presunpleasant sensation and an urge to move the lower sure” (power densities in delta waves ¼ process S) is limbs, occurring exclusively at rest in the evening or enhanced, the expression of related mRNAs either at night. Moving the affected extremity improves the increases or decreases. cDNA microarrays would be symptoms. The diagnosis is based on the clinical able to detect such an intensified transcription of particdescription of the symptoms by the patient and the ular genes in relation to sleep needs. Earlier studies in presence of four essential diagnostic criteria, including rats (Cirelli and Tononi, 2000) and fruit flies (Cirelli the core clinical features of the disease (Allen et al., et al., 2005; Zimmerman et al., 2006) showed that either 2003). It has been reported that 40–60% of patients 3, 6, or 8 hours of sleep deprivation increases the with RLS have a positive family history (Montplaisir expression of several genes that can be categorized as: et al., 1997; Winkelmann et al., 2000). Similar figures immediate early genes/transcription factors, energy with heritability estimates of 0.6 derived from twin balance-related genes, growth factors, heat shock prostudies further support the importance of a genetic teins (chaperons), neurotransmitter/hormone receptors, contribution to the disease (Ondo et al., 2000; Xiong kinases, etc. (Terao et al., 2003; Cirelli et al., 2004). et al., 2007). Comparing all clinical characteristics in Most of the properties and functions of these molefamilial and nonfamilial RLS, it has been consistently cules have not yet been clearly defined in association demonstrated that patients with a positive family hiswith sleep regulation. However, amongst these encodtory have an earlier age at onset of the disease coming genes, Homer1a is the most promising candidate pared with patients with a negative family history that reflects sleep need, depending on the duration of (Ondo and Jancovic, 1996; Montplaisir et al., 1997; sleep loss (Maret et al., 2007). The expression of Winkelmann et al., 2000). Several families with RLS Homer1a can be induced in the brain of D2, B6, and have been described, showing a large phenotypic variaAK mice by sleep deprivation in a dose-dependent bility. Within a single family there are family members manner. It has been hypothesized that sleep plays a with very severe symptoms and sleep disturbances key role in synaptic plasticity (Krueger and Oba´l, owing to the dysesthesias at night, as well as family 1993; Tononi and Cirelli, 2006). As the Homer1 gene members with only mild symptoms on a few occasions contributes to recovery from glutamate-induced neuroin their lives. nal hyperactivity, its involvement in sleep homeostasis Linkage studies are family based and analyze a posis quite reasonable, suggesting that sleep has a funcsible cosegregation with a genetic marker and a specific tion in protecting neurons from the consistent activaphenotype. A prerequisite is an accurate assumption tion imposed by wakefulness. of the underlying genetic model and knowledge about In any case, such transcriptome profilings have the the disease penetrance and phenocopy rate. Several loci potential to identify a gene or gene product that may
GENETICS OF SLEEP DISORDERS 687 for RLS have been published on chromosomes 12q the nitric oxide/arginine pathway in the pathogenesis (RLS1), 14q (RLS2), 9p (RLS3), 2q (RLS4), and 20p of RLS. (RLS5) (Winkelmann, 2008). In a French Canadian famCurrent technology has made large-scale, highily, linkage to chromosome 12q was identified based on density, genome-wide association studies a reality. a recessive mode of inheritance and was confirmed These studies combine the power of association studies in further five French Canadian families (Desautels with the systematic nature of a genome-wide search. et al., 2001). Possible phenocopies and nonpenetrants Three studies have taken advantage of this new methmade it difficult to detect a common segregating haploodology. In a study conducted in up to 2600 patients type in these families and it is not clear whether a with RLS and up to 5000 controls in the German, founder effect of the French Canadian population plays Canadian, and Czech populations, four genomic a role (Desautels et al., 2005). Based on an autosomal regions have been identified encoding the genes dominant mode of inheritance, a second locus was idenMEIS1, BTBD9, a region that encodes the genes tified on chromosome 14q13-21 (RLS2) in a northern MAP2K5 and LBXCOR1 (Winkelmann et al., 2007) Italian RLS family (Bonati et al., 2003), and confirmed and PRPRD (Schormair et al., 2008). The association in an independent family of French Canadian origin was identified within intronic variants, suggesting a (Levchenko et al., 2004). Investigating 15 extended functional role in the expression or alternative splicing American families including 134 RLS-affected indiviof the gene. Carriers of one risk allele had a 50% duals, a third RLS locus on chromosome 9p24-23 increased risk of developing RLS. In a similar study (RLS3) was identified using a model-free multipoint conducted in Icelandic and US populations, an associaanalysis with a multipoint nonparametric linkage score tion was found with the identical variant in BTBD9 of 3.22 (Chen et al., 2004). Although the statistical anal(Stefansson et al., 2007). The studies used different assessments of the phenotype. In the latter study, the ysis was criticized (Ray and Weeks, 2005), this locus association of BTBD9 was based on individuals with was confirmed within a RLS family (Liebetanz et al., periodic leg movements (PLM), suggesting that 2006; Lohmann-Hedrich et al., 2008) under the assumpBTBD9 is associated more with PLM than with RLS. tion of intrafamilial heterogeneity and stratification Furthermore, an analysis of parameters involved in according to an early age at onset phenotype (Liebetanz iron metabolism revealed that the risk allele was assoet al., 2006), and possibly further defined to the centrociated with a 13% decrease in the serum ferritin level meric part of chromosome 9p (Lohmann-Hedrich et al., (Stefansson et al., 2007). 2008). Defining the exact candidate region in RLS is A closer inspection of the known function of the difficult owing to intrafamilial, allelic, and nonallelic genes identified is surprising because some of them heterogeneity. This suggests locus heterogeneity and it are developmental factors and challenge our previous appears likely that several genes contain several dispathophysiological concept of RLS. MEIS1 is a memease-associated variants contributing different effects ber of a family of highly conserved TALE homeobox (Desautels et al., 2005). transcription factors. Heterodimers of MEIS1 with Association studies analyze the frequencies of PBX and HOX proteins augment the affinity and specalleles or genotypes at the site of interest and compare ificity of DNA binding by HOX proteins. HOX genes these in a case and control sample (although familyare organized in clusters and are expressed along the based designs can also be used). A higher frequency body axis in a manner corresponding to their position in cases is taken as evidence that the allele or genotype along the chromosome. Mutation in HOX genes results is associated with an increased risk for the disease. in morphological transformation of the segmental A systematic, hypothesis-free approach was perstructures in which a specific gene is normally formed in a case–control study of 918 independent expressed (Capecchi, 1997). MEIS1 is part of a trancases and controls of European ancestry. The RLS1 scriptional regulatory network that specifies spinal locus on chromosome 12q was analyzed and significant motor neuron pool identity and connectivity (Dasen association with the neuronal nitric oxide synthase et al., 2005), and therefore may have a function in (NOS1) identified. Different allele frequencies with the motor part of RLS or PLM. A study in Xenopus opposite directions were found after analyzing singleshowed that MEIS1 was also involved in neural crest associated single nucleotide polymorphisms (SNPs) development (Maeda et al., 2001). within the NOS1 gene (Winkelmann et al., 2008). This The third region encoded the MAP2K5 gene, a implies that the same allele is a risk allele in one but member of the mitogen-activated protein kinase fama protective allele in the other sample. Further studies ily, and the adjacent LBXCOR1 gene. LBXCOR1 is in independent populations are needed to replicate annotated downstream of MAP2K5 and acts as a and confirm this finding. The association of variants transcriptional corepressor of LBX1. This homeobox in NOS1 and RLS, however, suggests involvement of
688 J. WINKELMANN AND M. KIMURA gene plays a critical role in the development of sensory specific HLA haplotypes suggested an autoimmune pathways in the dorsal horn of the spinal cord, which process in the etiology. Therefore, DRB1 and DQB1 relays pain and touch (Gross et al., 2002). Based on genes have been sequenced in narcoleptic patients, but its function, it is more likely that LBX1 is involved in no mutation has been found (Tafti et al., 2005). Further RLS. Both genome-wide association studies showed alleles contributing to the risk are DQB1*0301 and association with BTBD9. Little is known about BTBD9 DQB1*0407, whereas the DQB1*0501 or DQB1*0601 other than that it belongs to the BTB (POZ) domainalleles are likely protective (Mignot et al., 2001). containing proteins, making assignment of a specific Families with narcolepsy–cataplexy over several function difficult at present (Stogios et al., 2005). generations show a variable phenotype and individuals Analysis of endophenotypes can give a better with and without cataplexy within a single family have understanding about the genes involved in association complicated the clinical classification within these with a specific symptom of RLS. It is very likely that studies. So far, only a few linkage studies of narcoinvestigations in a larger sample size will identify leptic families have been performed. In eight narcolepfurther variants associated with RLS. Analysis of tic families of Japanese origin, suggestive evidence pooled data will also provide the basis for a comfor linkage was found on chromosome 4p13-21q bined analysis of several thousand samples. This will (Nakayama et al., 2000). A second locus was identified allow researchers to identify further common variants on chromosome 21q in a French family, based on an contributing to the phenotype with even smaller autosomal dominant mode of inheritance (Dauvilliers effects. Finally, it is of course also possible that rare et al., 2004). Interestingly, the authors were able to variants with large effects on the phenotype will be show that the primary excessive daytime sleepiness in identified using the second-generation sequencing individuals of the narcolepsy family was a reliable mintechnology. imal clinical condition for the affected phenotype in multiplex families (Dauvilliers et al., 2004). Today, a causal relationship between narcolepsy and Narcolepsy hypocretin, a neuropeptide of the lateral hypothalaNarcolepsy is characterized by excessive daytime sleepmus, is well established. It has been shown repeatedly iness, cataplexy (sudden loss of muscle tone triggered that most narcoleptics have undetectable levels of by emotions), hypnagogic hallucinations, and sleep hypocretin in the CSF. Originally, a mutation in the paralysis (Taheri and Mignot, 2002). The disease is gene encoding the type 2 hypocretin/orexin receptor mainly sporadic, and pathophysiological studies point was found to be responsible for narcolepsy in canines, to an involvement of both environmental and genetic where the disease follows an autosomal recessive mode susceptibility factors interacting with one another. of inheritance (Lin et al., 1999). Further behavioral Familial cases of narcolepsy are rare and first-degree assessments of transgenic mice with a null mutation relatives have a risk of 2% to develop narcolepsy, of the prepro-hypocretin/orexin gene showed sympwhich is up to 10–40% times higher than the prevalence toms like behavioral arrests and EEG patterns similar (0.02–0.06%) in the general population of western to those in human narcolepsy (Chemelli et al., 1999). European countries and the USA (Mignot, 1998). Up However, no association of single nucleotide polyto one-third of monozygotic twins are concordant for morphisms (SNPs) in the prepro-hypocretin gene or narcolepsy, demonstrating that nongenetic factors in the hypocretin 1 and hypocretin 2 genes have been must also play a role in the etiology of the disorder identified in humans. So far, only a single patient (Taheri and Mignot, 2002). with a mutation in the prepro-hypocretin gene has Narcolepsy has a high association to a specific been identified (Peyron et al., 2000). This patient human leukocyte antigen (HLA) allele. Some 88–98% was DQBq*01602 negative, had undetectable levels of of patients with narcolepsy–cataplexy are positive for hypocretin 1 in the CSF, and showed the first sympthe HLA class II allele, DQB1*0602, most often in toms of cataplexy at the age of 6 months. combination with DR2 (Mignot et al., 2001). Even up Altogether these findings indicate that, although to 60% of patients with milder symptoms or without hypocretin deficiency constitutes the best biological catalepsy show this haplotype, in comparison to only marker of sporadic narcolepsy, the molecular cause 12–38% of the general population. However, patients remains elusive and mutations of the three hypocretiwith narcolepsy can also be negative for the nergic genes are exceptional in human narcolepsy DQB1*0602 allele, and familial cases cannot be (Tafti et al., 2005). Genome-wide association studies explained by a shared HLA haplotype (Dauvilliers identified polymorphisms in the T-cell receptor alpha et al., 2004), pointing to the involvement of further (TRA-a) locus. Thus, narcolepsy is the first documensusceptibility genes. The strong association with ted disease with a genetic involvement of the TRA-a
GENETICS OF SLEEP DISORDERS 689 locus, encoding the major receptor for HLA peptide A biometric genetic study based on data from presentation. It is still unclear how specific HLA alleles 68 MZ and 54 DZ twin pairs demonstrated that sleepconfer susceptibility to over 100 HLA-associated disordisordered breathing, even in old age, is determined, ders; thus, narcolepsy will provide new insights into in part, by genetic factors. Differences in age of presenhow HLA–TCR interactions contribute to organtation and anatomic risk factors for obstructive sleep specific autoimmune targeting and may serve as a apnea (OSA) in Caucasians and African Americans model for HLA-associated disorders (Hallmayer suggest possible racial differences in the genetic underet al., 2009). Furthermore, an association with a genetic pinnings of the disorder. Performing a segregation analvariant between CPT1B and CHKB was identified ysis, Buxbaum et al. (2002) assessed the transmission (Miyagawa et al., 2008). The involvement and function patterns in 177 Caucasian and 125 African American of the variant is still unknown. CPT1B regulates families for the AHI, adjusted for age, and for age b-oxidation, a pathway involved in regulating theta and body mass index (BMI). Analysis of the Caucasian frequency during REM sleep, and CHKB is an enzyme sample showed that the transmission pattern was consisinvolved in the metabolism of choline, a precursor tent with a major gene that was stronger with the of the REM- and wake-regulating neurotransmitter age-adjusted than with the age- and BMI-adjusted acetylcholine (Miyagawa et al., 2008). variable. In the African American families, adjusting for BMI gave strong evidence for the segregation of a codominant gene. These results provide support Sleep apnea syndrome for an underlying genetic basis for OSA in African Obstructive sleep apnea syndrome (OSAS) is a comAmericans independent of the contribution of BMI mon disorder affecting up to 2–4% of middle-aged (Buxbaum et al., 2002). adults (Young et al., 1993). It is characterized by recurTo identify susceptibility loci for OSA, Palmer and rent episodes of apnea (no airflow) and hypopnea (parcoworkers (2004) performed a genome-wide model tially obstructed airflow) that occur during sleep, and free linkage analysis on AHI and BMI in 59 African is followed by oxygen desaturation, sleep fragmentaAmerican OSA pedigrees. A region on chromosome tion, and symptoms of disruptive snoring, all leading 8q gave the only evidence for linkage to the AHI, to daytime sleepiness (Flemons et al., 1999). The diagwhereas the BMI was linked to multiple regions, most nosis is based on standard clinical criteria, and is gensignificantly to markers on chromosomes 4q and 8q, erally validated by an overnight sleep study with suggesting that there are both shared and unshared measurement of the apnea–hypopnea index (AHI), genetic factors underlying susceptibility to OSA and the number of apneas and hypopneas per hour of sleep obesity (Palmer et al, 2004). (Flemons et al., 1999). It is a complex phenotype and is Furthermore, at the central level there may also be associated with other conditions such as regional obean associated genetic factor. Congenital central hyposity, alteration of craniofacial morphology, and ventilation syndrome (CCHS; OMIM 209880) is a enlargement of critical upper airway soft tissue, as life-threatening disorder involving an impaired ventilawell as significant cardiovascular morbidity and daytory response to hypercarbia and hypoxemia. This phetime sleepiness. Moreover, OSAS is an independent notype is associated with lower-penetrance anomalies risk factor for hypertension, myocardial infarction, of the autonomic nervous system (ANS), including and insulin resistance. Hirschsprung disease and tumors such as ganglioneurA number of studies have shown that a familial omas and neuroblastomas. In mice, the development of aggregation of some associated conditions is involved ANS reflex circuits is dependent on the paired-like in the pathogenesis of sleep apnea. An extensive homeobox gene Phox2b. Amiel and colleagues (2003) family study was performed by Guillminault and identified the human ortholog PHOX2B as a candidate colleagues (1995), who investigated 157 patients with gene in CCHS heterozygous de novo mutations in 18 of OSAS using a detailed assessment of clinical symp29 CCHS patients. This indicates an essential role for toms, physical evaluation, cephalometric X-ray films, PHOX2B in the normal patterning of the autonomous and polysomnography. In addition, 531 living firstventilation system in humans (Amiel et al., 2003). degree relatives and 189 age-matched controls were Further investigation of candidate genes suggested investigated. Interestingly, this study demonstrated a polymorphism in angiotensin-converting enzyme in that none of the very obese patients had any familial association with hypertension in moderate OSAS aggregate of OSAS, whereas patients with specific (Zhang et al., 2000). A possible association of an allele craniofacial features, mostly involving maxilloin the apolipoprotein E e4 gene to OSAS was not mandibular growth, did have a familial aggregate found consistently in independent populations (Taheri (Guillminault et al., 1995). and Mignot, 2002).
690
J. WINKELMANN AND M. KIMURA
Circadian sleep disorders Advanced sleep phase syndrome (APS) is characterized by consistently advanced sleep onset and awakenings that are earlier than desired. It is a rare disorder and only a few families have been described. It is suggested that the phenotype is transmitted in a classic mendelian autosomal dominant mode of inheritance. A mutation responsible for the disorder was identified in the PER2 gene on chromosome 2q (Toh et al., 2001). However, further cases of familial APS are not caused by a mutation in the PER2 gene, suggesting genetic heterogeneity of the disorder. Delayed phase syndrome (DPS) is characterized by persistent delayed sleep– waking timing. Although DPS seems to be heterogeneous, an association with HLA-DR1 and a PER gene polymorphism has been suggested (Hohjoh et al., 1999; Satoh et al., 2003).
Kleine–Levin syndrome Kleine–Levin syndrome (KLS) is a very rare disorder with the cardinal clinical features of recurring spells of hypersomnia, cognitive and mood disturbances, accompanied by altered behavior such as hyperphagia, hypersexuality, and autonomic alterations (Katz and Ropper, 2002). The pathophysiological hypotheses suggest dysfunction of the hypothalamus. KLS is usually sporadic, but recently two siblings with the syndrome have been described (Katz and Ropper, 2002). An analysis of polymorphism in candidate genes in 30 unrelated patients with KLS showed that the human leukocyte antigen HLS-DQB1*0201 allele frequency is significantly increased in these patients. The authors therefore suggested a possibility of an autoimmune etiology for the disorder (Dauvilliers et al., 2002).
SUMMARY AND PERSPECTIVES The first sleep-related genes have been identified in monogenic disorders. Most of the sleep disorders in this review, however, have complex phenotypes. Using array technologies and performing genome-wide association studies and investigating thousands of patients and controls, we were able to identify common genetic susceptibility factors for sleep phenotypes. Genomewide sequencing with second-generation sequencers will allow us to detect further rare genetic variants with a large effect on the phenotype. Finally, to explore further the genetics of sleep disorders, epigenetic factors should be also considered that might explain the complexity of phenotypes.
REFERENCES Allen RP, Picchietti D, Hening WA et al. Restless Legs Syndrome Diagnosis and Epidemiology workshop at the National Institutes of Health; International Restless Legs Syndrome Study Group (2003). Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 4: 101–119. Ambrosius U, Lietzenmaier S, Wehrle R et al. (2008). Heritability of sleep electroencephalogram. Biol Psychiatry 64: 344–348. Amiel J, Laudier B, Attie-Bitach T et al. (2003). Polyalanine expansion and frameshift mutations of the paired-like homeobox gene PHOX2B in congenital central hypoventilation syndrome. Nat Genet 4: 459–461. Andretic R, Franken P, Tafti M (2008). Genetics of sleep. Annu Rev Genet 42: 361–388. Archer SN, Robilliard DL, Skene DJ et al. (2003). A length polymorphism in the circadian clock gene PER3 is linked to delayed sleep phase syndrome and extreme diurnal performance. Sleep 26: 413–415. Archer SN, Viola AU, Kyriakopoulou V et al. (2008). Interindividual differences in habitual sleep timing and entrained phase of endogenous circadian rhythms of BMAL1, PER2 and PER3 mRNA in human leukocytes. Sleep 31: 608–617. Bastien CH, Morin CM (2000). Familial incidence of insomnia. J Sleep Res 9: 49–54. Bonati MT, Ferini-Strambi L, Aridon P et al. (2003). Autosomal dominant restless legs syndrome maps on chromosome 14q. Brain 126: 1485–1492. Brunner H, Kathmann N, Engel RR et al. (2001). Sleep parameters in identical twins discordant for schizophrenia. Sleep 24 (Suppl): A392. Buxbaum SG, Elston RC, Tishler PV et al. (2002). Genetics of the apnea hypopnea index in Caucasians and African Americans: I. Segregation analysis. Genet Epidemiol 3: 243–253. Capecchi MR (1997). Hox genes and mammalian development. Cold Spring Harb Symp Quant Biol 62: 273–281. Chemelli RM, Willie JT, Sinton CM et al. (1999). Narcolepsy in orexin knock-out mice: molecular genetics of sleep regulation. Cell 98: 437–451. Chen S, Ondo WG, Rao S et al. (2004). Genomewide linkage scan identifies a novel susceptibility locus for restless legs syndrome on chromosome 9p. Am J Hum Genet 74: 876–885. Cirelli C (2009). The genetic and molecular regulation of sleep: from fruit flies to humans. Nature Rev Neurosci 10: 549–560. Cirelli C, Tononi G (2000). Gene expression in the brain across the sleep-waking cycle. Brain Res 885: 303–321. Cirelli C, Gutierrez C, Tononi G (2004). Extensive and divergent effects of sleep and wakefulness on brain gene expression. Neuron 41: 35–43. Cirelli C, LaVaute TM, Tononi G (2005). Sleep and wakefulness modulate gene expression in Drosophila. J Neurochem 94: 1411–1419.
GENETICS OF SLEEP DISORDERS Cueni L, Canepari M, Lujan R et al. (2008). T-type Ca2þ channels, SK2 channels and SERCAs gate sleep-related oscillations in thalamic dendrites. Nat Neurosci 11: 683–692. Dasen JS, Tice BC, Brenner-Morton S et al. (2005). A Hox regulatory network establishes motor neuron pool identity and target-muscle connectivity. Cell 123: 477–491. Dauvilliers Y, Tafti M (2008). The genetic basis of sleep disorders. Curr Pharm Des 14: 3386–3395. Dauvilliers Y, Blouim J-L, Neidhart E et al. (2004). A narcolepsy susceptibility locus maps to a 5Mb region of chromosome 21q. Ann Neurol 56: 382–388. Dauvilliers Y, Maret S, Tafti M (2005). Genetics of normal and pathological sleep in humans. Sleep Med Rev 9: 91–100. Dauvilliers Y, Mayer G, Lecendreux M et al. (2002). KleineLevin syndrome: an autoimmune hypothesis based on clinical and genetic analyses. Neurology 59: 1739–1745. Davis H, Davis P (1936). Action potentials of the brain in normal persons and in normal states of cerebral activity. Arch Neurol Psychiatry 36: 1214–1224. De Castro JM (2002). The influence of heredity on selfreported sleep patterns in free-living humans. Physiol Behav 76: 479–486. De Gennaro L, Marzano C, Fratello F et al. (2008). The electroencephalographic fingerprint of sleep is genetically determined: a twin study. Ann Neurol 64: 455–460. Desautels A, Turecki G, Montplaisir J et al. (2001). Identification of a major susceptibility locus for restless legs syndrome on chromosome 12q. Am J Hum Genet 69: 1266–1270. Desautels A, Turecki G, Montplaisir J et al. (2005). Restless legs syndrome: confirmation of linkage to chromosome 12q, genetic heterogeneity, and evidence of complexity. Arch Neurol 62: 591–596. Dijk DJ, Beersma DG, Daan S (1987). EEG power density during nap sleep: reflection of an hourglass measuring the duration of prior wakefulness. J Biol Rhythms 2: 207–219. Dossena S, Imeri L, Mangieri M et al. (2008). Mutant prion protein expression causes motor and memory deficits and abnormal sleep patterns in a transgenic mouse model. Neuron 60: 598–609. Dudley CA, Erbel-Sieler C, Estill SJ et al. (2003). Altered patterns of sleep and behavioral adaptability in NPAS2deficient mice. Science 301: 379–383. Ebisawa T, Uchiyama M, Kajimura N et al. (2001). Association of structural polymorphisms in the human period3 gene with delayed sleep phase syndrome. EMBO Rep 2: 342–346. Espinosa F, Marks GA, Heintz N et al. (2004). Increased motor drive and sleep loss in mice lacking Kv3-type potassium channels. Genes Brain Behav 3: 90–100. Espinosa F, Torres-Vega MA, Marks GA et al. (2008). Ablation of Kv3.1 and Kv3.3 potassium channels disrupts thalamocortical oscillations in vitro and in vivo. J Neurosci 28: 5570–5581. Flemons WW, Buysse D, Redline S et al. (1999). Sleeprelated breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. Report of an American Academy of Sleep Medicine Task Force. Sleep 22: 533–570.
691
Franken P, Tafti M (2003). Genetics of sleep and sleep disorders. Front Biosci 8: e381–e397. Franken P, Malafosse A, Tafti M (1998). Genetic variation in EEG activity during sleep in inbred mice. Am J Physiol 275: R1127–R1137. Franken P, Malafosse A, Tafti M (1999). Genetic determinants of sleep regulation in inbred mice. Sleep 22: 155–169. Franken P, Chollet D, Tafti M (2001). The homeostatic regulation of sleep need is under genetic control. J Neurosci 21: 2610–2621. Franken P, Thomason R, Heller HC et al. (2007). A noncircadian role for clock-genes in sleep homeostasis: a strain comparison. BMC Neurosci 8: 87. Friedmann JK (1974). A diallele analysis of the genetic underpinnings of mouse sleep. Physiol Behav 12: 169–175. Friess E, Modell S, Brunner H et al. (2008). The Munich vulnerability study on affective disorders: microstructure of sleep in high-risk subjects. Eur Arch Psychiatry Clin Neurosci 258: 285–291. Goldfarb LG, Petersen RB, Tabaton M et al. (1992). Fatal familial insomnia and familial Creutzfeldt–Jakob disease: disease phenotype determined by a DNA polymorphism. Science 258: 806–808. Gross MK, Dottori M, Goulding M (2002). Lbx1 specifies somatosensory association interneurons in the dorsal spinal cord. Neuron 34: 535–549. Guillminault C, Pertinen M, Hollman K et al. (1995). Familial aggregates in obstructive sleep apnea syndrome. Chest 107: 1545–1551. Hallmayer J, Faraco J, Lin L et al. (2009). Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet 41: 708–711. Heath AC, Kendler KS, Eaves LJ et al. (1990). Evidence for genetic influences on sleep disturbance and sleep pattern in twins. Sleep 13: 318–335. Hohjoh H, Takahashi Y, Hatta Y et al. (1999). Possible association of human leucocyte antigen DR1 with delayed sleep phase syndrome. Psychiatry Clin Neurosci 53: 527–529. Huber R, Deboer T, Tobler I (1999). Prion protein: a role in sleep regulation? J Sleep Res 8 (Suppl 1): 30–36. Joho RH, Marks GA, Espinosa F (2006). Kv3 potassium channels control the duration of different arousal states by distinct stochastic and clock-like mechanisms. Eur J Neurosci 23: 1567–1574. Katz J, Ropper AH (2002). Familial Kleine–Levin syndrome: two siblings with unusually long hypersomnic spells. Arch Neurol 59: 1959–1961. Kim D, Song I, Keum S et al. (2001). Lack of the burst firing of thalamocortical relay neurons and resistance to absence seizures in mice lacking a1G T-type Ca2þ channels. Neuron 31: 35–45. Kimura M, Winkelmann J (2007). Genetics of sleep and sleep disorders. Cell Mol Life Sci 64: 1216–1226. Kimura M, Mu¨ller-Preuss P, Lu A et al. (2010). Conditional corticotropin-releasing hormone overexpression in the mouse forebrain enhances rapid eye movement sleep. Mol Psychiatry 15: 154–165.
692
J. WINKELMANN AND M. KIMURA
Krueger JM, Oba´l F Jr (1993). A neuronal group theory of sleep function. J Sleep Res 2: 63–69. Lavie P (2005). Genetics wakes up for human sleep. Sleep Med Rev 9: 87–89. Lee J, Kim D, Shin H-S (2004). Lack of delta waves and sleep disturbances during non-rapid eye movement sleep in mice lacking a1G-subunit of T-type calcium channels. Proc Natl Acad Sci U S A 101: 18195–18199. Lennox W, Gibbs E, Gibbs F (1945). The brain-wave patterns and hereditary trait. J Hered 36: 233–243. Levchenko A, Montplaisir JY, Dube MP et al. (2004). The 14q restless legs syndrome locus in the French Canadian population. Ann Neurol 55: 887–891. Liebetanz K, Winkelmann J, Trenkwalder C et al. (2006). RLS3: fine-mapping of an autosomal dominant locus in a family with intrafamilial heterogeneity. Neurology 67: 320–321. Lin L, Faraco J, Li R et al. (1999). The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98: 365–376. Linkowski P (1999). EEG patterns in twins. J Sleep Res 8 (Suppl 1): 11–13. Linkowski P, Kerkhofs M, Hauspie R et al. (1989). EEG sleep patterns in man: a twin study. Electroencephalogr Clin Neurophysiol 73: 279–284. Linkowski P, Kerkhofs M, Hauspie R et al. (1991). Genetic determinations of EEG sleep: a study in twins living apart. Electroencephalogr Clin Neurophysiol 79: 114–118. Lohmann-Hedrich K, Neumann A, Kleensang A et al. (2008). Evidence for linkage of restless legs syndrome to chromosome 9p: are there two distinct loci? Neurology 70: 686–694. Maeda R, Mood K, Jones TL et al. (2001). Xmeis1, a protooncogene involved in specifying neural crest cell fate in Xenopus embryos. Oncogene 20: 1329–1342. Maret S, Dorsaz S, Gurcel L et al. (2007). Homer1a is a core brain molecular correlate of sleep loss. Proc Natl Acad Sci U S A 104: 20090–20095. Mieda M, Yanagisawa M (2002). Sleep, feeding, and neuropeptides; roles of orexins and orexin receptors. Curr Opin Neurobiol 12: 339–345. Mignot E (1998). Genetic and familial aspects of narcolepsy. Neurology 50: 16–22. Mignot E, Lin L, Rogers W et al. (2001). Complex HLA-DR and DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet 68: 686–969. Miyagawa T, Kawashima M, Nishida N et al. (2008). Variant between CPT1B and CHKB associated with susceptibility to narcolepsy. Nat Genet 40: 1324–1328. Modell S, Ising M, Holsboer F et al. (2002). The Munich vulnerability study on affective disorders: stability of polysomnographic findings over time. Biol Psychiatry 52: 430–437. Montagna P, Cortelli P, Avoni P et al. (1998). Clinical features of fatal familial insomnia: phenotypic variability in relation to a polymorphism at codon 129 of the prion protein. Brain Pathol 8: 515–520.
Montplaisir J, Boucher S, Priorier G et al. (1997). Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord 12: 61–65. Nakayama J, Miura M, Honda M et al. (2000). Linkage of human narcolepsy with HLA association to chromosome 4p13q21. Genomics 65: 84–86. Nishino S (2007). Clinical and neurobiological aspects of narcolepsy. Sleep Med 8: 373–399. O’Hara BF, Ding J, Bernat RL et al. (2007). Genomic and proteomic approaches towards an understanding of sleep. CNS Neurol Disord Drug Targets 6: 71–81. Ondo WG, Jankovic J (1996). Restless legs syndrome: clinicoetiologic correlates. Neurology 47: 1435–1441. Ondo WG, Vuong KV, Wang Q (2000). Restless legs syndrome in monozygotic twins: clinical correlates. Neurology 55: 1404–1406. Palmer LJ, Buxbaum SG, Larkin EK et al. (2004). Whole genome scan for obstructive sleep apnea and obesity in African-American families. Am J Respir Crit Care Med 169: 1314–1321. Partinen M, Kaprio J, Koskenvuo M et al. (1983). Genetic and environmental determination of human sleep. Sleep 6: 179–185. Pedrazzoli M, Ling L, Young TB et al. (2002). Effect of the prion 129 polymorphism on nocturnal sleep and insomnia complaints: a population-base study. J Sleep Res 11: 357–358. Peyron C, Faraco J, Rogers W et al. (2000). A mutation in early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 6: 991–997. Profant J, Ancoli-Israel S, Dimsdale JE (2002). Are there ethnic differences in sleep architecture? Am J Hum Biol 14: 321–326. Prusiner AB (1997). Prion diseases and the BSE crisis. Science 278: 245–251. Ray A, Weeks DE (2005). No convincing evidence of linkage for restless legs syndrome on chromosome 9p. Am J Hum Genet 76: 705–707. Re´tey JV, Adam M, Honegger E et al. (2005). A function genetic variation of adenosine deaminase affects the duration and intensity of deep sleep in humans. Proc Natl Acad Sci U S A 102: 15676–15681. Sakurai T (2005). Roles of orexin/hypocretin in regulation of sleep/wakefulness and energy homeostasis. Sleep Med Rev 9: 231–241. Sakurai T, Amemiya A, Ishii M et al. (1998). Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92: 573–585. Satoh K, Mishima K, Inoue Y et al. (2003). Two pedigrees of familial advanced sleep phase syndrome in Japan. Sleep 26: 416–417. Schormair B, Kemlink D, Roeske D et al. (2008). PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. Nat Genet 40: 946–948.
GENETICS OF SLEEP DISORDERS Stefansson H, Rye DB, Hicks A et al. (2007). Genetic risk factor for periodic limb movements in sleep. N Engl J Med 357: 639–647. Steinlein O, Anokhin A, Yping M et al. (1992). Localization of a gene for the human low-voltage EEG on 20q and genetic heterogeneity. Genomics 12: 69–73. Stepnowsky CJ, Moore PJ, Dimsdale JE (2003). Effect of ethnicity on sleep: complexities for epidemiologic research. Sleep 26: 329–332. Stogios PJ, Downs GS, Jauhal JJ et al. (2005). Sequence and structural analysis of BTB domain proteins. Genome Biol 6: R82. Sutcliffe JG, de Lecea L (2002). The hypocretins: setting the arousal threshold. Nature Rev Neurosci 3: 339–349. Tafti M, Franken P, Kitahama K et al. (1997). Localization of candidate genomic regions influencing paradoxical sleep in mice. Neuroreport 8: 3755–3758. Tafti M, Petit B, Chollet D et al. (2003). Deficiency in shortchain fatty acid beta-oxidation affects theta oscillations during sleep. Nat Genet 34: 320–325. Tafti M, Maret S, Dauvilliers Y (2005). Genes for normal sleep and sleep disorders. Ann Med 37: 580–589. Taheri S, Mignot E (2002). The genetics of sleep disorders. Lancet Neurol 1: 242–250. Terao A, Steininger TL, Hyder K et al. (2003). Differentially increase in the expression of heat shock protein family members during sleep deprivation and during sleep. Neuroscience 116: 187–200. Tobler I, Borbe´ly AA (1986). Sleep EEG in the rat as a function of prior waking. Electroencephalogr Clin Neurophysiol 64: 74–76. Tobler I, Gaus SE, Deboer T et al. (1996). Altered circadian activity rhythms and sleep in mice devoid of prion protein. Nature 380: 639–642. Toh KL, Jones CR, He Y et al. (2001). An hPer2 phosphorylation site mutation in familial advanced sleep phase syndrome. Science 291: 1040–1043. Tononi G, Cirelli C (2001). Modulation of brain gene expression during sleep and wakefulness: a review of recent findings. Neuropsychopharmacology 25: S28–S35. Tononi G, Cirelli C (2006). Sleep function and synaptic homeostasis. Sleep Med Rev 10: 49–62. Valatx JL, Bugat R, Jouvet M (1972). Genetic studies of sleep in mice. Nature 238: 226–227. Van Beijsterveldt CEM, van Baal GCM (2002). Twin and family studies of the human electroencephalogram: a review and a meta-analysis. Biol Psychiatry 61: 111–138.
693
Van Beijsterveldt CEM, Molenaar PCM, de Geus EJC et al. (1996). Heritability of human brain functioning as assessed by electroencephalography. Am J Hum Genet 58: 562–573. Viola AU, Archer SN, James LM et al. (2007). PER3 polymorphism predicts sleep structure and waking performance. Curr Biol 17: 613–618. Vogel F (1970). The genetic basis of the normal human electroencephalogram (EEG). Humangenetik 10: 91–114. Webb WB, Campbell SS (1983). Relationships in sleep characteristics of identical and fraternal twins. Arch Gen Psychiatry 40: 1093–1095. Winkelmann J (2008). Genetics of restless legs syndrome. Curr Neurol Neurosci Rep 8: 211–216. Winkelmann J, Wetter TC, Collado-Seidel V et al. (2000). Clinical characteristics and frequency of the hereditary restless legs syndrome in a population of 300 patients. Sleep 23: 597–602. Winkelmann J, Schormair B, Lichtner P et al. (2007). Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet 39: 1000–1006. Winkelmann J, Lichtner P, Schormair B et al. (2008). Variants in the neuronal nitric oxide synthase (nNOS, NOS1) gene are associated with restless legs syndrome. Mov Disord 23: 350–358. Wisor JP, O’Hara BF, Terao A et al. (2002). A role for cryptochromes in sleep regulation. BMC Neurosci 3: 20. Xiong L, Jang K, Montplaisir J et al. (2007). Canadian restless legs syndrome twin study. Neurology 68: 1631–1633. Xu Y, Ehringer M, Yang F et al. (2001). Comparison of global brain gene expression profiles between inbred long-sleep and inbred short-sleep mice by high-density gene array hybridization. Alcohol Clin Exp Res 25: 810–818. Young T, Palta M, Dempsey J et al. (1993). The occurrence of sleep disordered breathing in middle-aged adults. N Engl J Med 328: 1230–1235. Zhang J, Zhao B, Gesongluobu et al. (2000). Angiotensinconverting enzyme gene insertion/deletion (I/D) polymorphism in hypertensive patients with different degrees of obstructive sleep apnea. Hypertens Res 23: 407–411. Zimmerman JE, Rizzo W, Shockley KR et al. (2006). Multiple mechanisms limit the duration of wakefulness in Drosophila brain. Physiol Genomics 27: 337–350.
Handbook of Clinical Neurology, Vol. 99 (3rd series) Sleep Disorders, Part 2 P. Montagna and S. Chokroverty, Editors # 2011 Elsevier B.V. All rights reserved
Chapter 44
Neurological perspectives in insomnia and hyperarousal syndromes MARIO GIOVANNI TERZANO * AND LIBORIO PARRINO Sleep Disorders Center, Department of Neuroscience, University of Parma, Italy
INSOMNIA: SYMPTOM OR DISEASE? Soon I ceased to sleep altogether, an acute attack of insomnia set in, so terrible that it nearly made me go off my head. Insomnia does not kill its man unless he kills himself – sleeplessness is the most common cause of suicide. But it kills his joie de vivre, it saps his strength, it sucks the blood from his brain and from his heart like a vampire. It makes him remember during the night what he was meant to forget in blissful sleep. It makes him forget during the day what he was meant to remember. Memory is the first to go overboard, soon friendship, love, sense of duty, even pity itself are one after another washed away. Despondency alone sticks to the doomed ship to sheer it on the rocks to total destruction. Voltaire was right when he placed sleep on the same level of hope. . . Beware of a doctor who suffers from insomnia! My patients began to complain that I was rough and impatient with them, many of them left me. . . Only when they were about to die did I seem to wake up from my torpor, for I continued to take keen interest in Death long after I had lost all interest in Life. (Axel Munthe, The Story of San Michele)
Definition of insomnia According to the International Classification of Sleep Disorders (American Academy of Sleep Medicine, 2005) insomnia is defined as: 1. A complaint of difficulty initiating sleep, difficulty maintaining sleep, or waking up too early,
or sleep that is chronically nonrestorative or poor in quality. 2. Sleep difficulty occurs despite adequate opportunity and circumstances for sleep. 3. At least one of the following forms of daytime impairment related to the nighttime sleep difficulty is reported by the patient: ● Fatigue or malaise ● Attention, concentration, or memory impairment ● Social or vocational dysfunction, or poor school performance ● Mood disturbance or irritability ● Daytime sleepiness ● Motivation, energy, or initiative reduction ● Proneness for errors or accidents at work or while driving ● Tension, headaches, or gastrointestinal symptoms in response to sleep loss ● Concerns or worries about sleep. Diagnosis of insomnia is based on the identification of one or more symptoms which also include nonrestorative or poor quality of sleep. This implies that classification criteria have definitely accepted the pivotal issue that sleep can be unrefreshing independent of its duration. Another important consideration is that the sleep-related symptoms must be associated with a diurnal complaint. Among daytime dysfunction, sleepiness is not the most frequent impairment and may not be always reported by the insomniac patient. Other more common disturbances are psychosomatic manifestations or mood disorders. In particular, the complaint of fatigue is almost always associated with insomnia. However, if insomnia is associated with daytime complaints, is it still correct to define it as a
*Correspondence to: Professor Mario Giovanni Terzano, Centro di Medicina del Sonno, Clinica Neurologica, Universita` di Parma, Via Gramsci 14, 43100 Parma, Italy. E-mail:
[email protected]
698 M.G. TERZANO AND L. PARRINO symptom or would it more correctly be indicated as disorders that are, in fact, associated with an increased a syndrome with global implications throughout the risk of morbidity. 24-hour period? Some authors consider insomnia to Epidemiological studies of both clinical and general be a symptom with numerous possible causes. Others samples of population have demonstrated an associaconsider insomnia as a syndrome or a disease. This tion between insomnia and depression (Nowell et al., seems particularly appropriate for primary insomnia, 1997; Bixler et al., 2002), whereas cardiovascular illwhich is unrelated to any physical or mental comorbidnesses and chronic pain are the most frequent comorbid ity, but is characterized by a set of symptoms, a medical conditions in patients with insomnia (Hatoum defined disease course, and, in most cases, a predictet al., 1998; Terzano et al., 2004). Insomnia is also often able response to treatment. associated with an increased metabolic rate 24 hours per day, and increased heart rate, sympathetic tone, and plasma cortisol concentrations, indicating a heightened Diagnosis of insomnia activation of the nervous system or “hyperarousal” Insomnia is the most common sleep complaint in the (Bonnet and Arand, 1995; Vgontzas et al., 2001a; general population around the world (Soldatos et al., Nofzinger et al., 2004). A statement from the National 2005). Recent research has addressed a wide range Institutes of Health State of the Science Conference on of issues related to this condition, including epidemiManifestations and Management of Chronic Insomnia ology, consequences, pathophysiology, and treatment. in Adults (2005) proposed to use the term comorbid An updated review of epidemiological studies showed insomnia, suggesting the presence of one or more disthat the reported prevalence of insomnia in the general orders in addition to insomnia as a distinct disorder. population ranges from 6% to about 33%, depending This proposal indicates a revision of the cause–effect on the definition of insomnia (Ohayon, 2002). Studies relationship. For instance, despite the clinical evidence examining the clinical and physiological characteristics that emotional stress or depression precedes the onset of insomnia have used definitions ranging from the of insomnia and that insomnia is a risk factor for very broad (e.g., self-defined “good vs. poor sleepers”), depression, there is growing evidence that insomnia is to the very narrow (e.g., individuals with “sleep state not simply a byproduct of depression and the complex misperception”, which can be defined only with polyassociation of these two disorders needs independent somnography). The term insomnia symptom refers to research and clinical efforts. Clinicians have long the sleep-specific insomnia definition, i.e., difficulty recognized that insomnia is often maintained despite falling asleep, difficulty staying asleep, early awakenthe remission of the accompanying depression and ing, or unrefreshing nonrestorative sleep in an individmay require separate therapeutic interventions from ual who has adequate circumstances and opportunity depression. for sleep (American Psychiatric Association, 2000). The separation criteria between insomnia and other The following quantitative criteria have been suggested medical or psychiatric disorders have inspired the secto define insomnia symptoms: sleep-onset latency or ond edition of the International Classification of Sleep wakefulness after sleep onset of more than 30 minutes, Disorders (American Academy of Sleep Medicine, frequency of at least three times a week, and duration 2005), where specific insomnia diagnostic subtypes of at least 6 months. In contrast, the term insomnia are identified (Table 44.1) and where the term insomdisorder, or simply insomnia, denotes a broader clininia finally reappears after a 15-year blackout (in the cal condition with both sleep and waking symptoms International Classification of Sleep Disorders pub(Billiard and Bentley, 2004). lished in 1990, the term insomnia was omitted and secInsomnia symptoms, considered in isolation, confer ondarily incorporated in the definition of dyssomnia). limited morbidity and thus are of questionable cliniWhat remains to be clarified is the objective nature cal significance. Therefore, reliance solely on insomnia of poor sleep quality. While insomnia symptoms of symptoms for sample selection appears a suboptidifficulty initiating asleep, difficulty maintaining sleep, mal research practice. Arguably, a more defensible and early morning awakening correlate with practical research practice is that of defining insomnia as a dispolysomnographic (PSG) measures (sleep latency, order with impairment of sleep and waking functions. wake after sleep onset, and wake after final awakenTypically such definitions include complaints of insoming, respectively), conventional quantitative criteria nia symptoms coupled with waking symptoms such do not address unrefreshing or nonrestorative sleep as functional impairments, sleep-related distress, or (Guilleminault et al., 2006), one of the cardinal sympgeneral sleep dissatisfaction. Insomnia definitions that toms of insomnia. An individual under PSG monitoring combine sleep-specific complaints with daytime sympcan report a sleep period of several hours with a contoms appear to represent clinically significant insomnia comitant high sleep efficiency and still wake up feeling
NEUROLOGICAL PERSPECTIVES IN INSOMNIA AND HYPERAROUSAL SYNDROMES Table 44.1 Classification of adult insomnia Type of insomnia Primary insomnia Idiopathic
Psychophysiological
Paradoxical (sleep-state misperception)
Secondary insomnia Adjustment Inadequate sleep hygiene
Insomnia due to a psychiatric disorder Insomnia due to a medical condition
Insomnia due to a drug or substance
Description
Arising in infancy or childhood with a persistent, unremitting course Insomnia due to maladaptive conditioned response in which the patient learns to associate the bed environment with heightened arousal rather than sleep; onset often associated with an event causing acute insomnia, with the sleep disturbance persisting despite resolution of the precipitating factor Insomnia characterized by a marked mismatch between the patient’s description of sleep duration and objective polysomnographic findings Insomnia associated with active psychosocial stressors Insomnia associated with lifestyle habits that impair sleep Insomnia due to an active psychiatric disorder, such as anxiety or depression Insomnia due to a condition such as restless legs syndrome, chronic pain, nocturnal cough or dyspnea, or hot flashes Insomnia due to consumption or discontinuation of medication, drugs of abuse, alcohol, or caffeine
Modified from the International Classification of Sleep Disorders (American Academy of Sleep Medicine, 2005).
tired and sleepy throughout the day. The lack of objective criteria for the identification of normal sleepers vs. insomniac patients can also determine underestimation of treatment effects in clinical and research trials (Cortoos et al., 2006). Collectively, these observations suggest that a more accurate neurophysiological approach to insomnia is deemed necessary. This chapter reviews the mechanisms that regulate the sleep process and describes the quantitative criteria that support the restoring properties of sleep.
699
THE NEUROPHYSIOLOGICAL BASES OF INSOMNIA The sleeping process Sleep is a spontaneous active process, consisting of cyclic changes in many aspects of body chemistry and function, that must occur periodically to restore and maintain health. The control mechanisms of sleep are manifested at every level of biological organization, from genes and intracellular mechanisms to networks of cell populations and to all neuronal systems, including those that control movement, arousal, autonomic functions, behavior, and cognition. During sleep, the brain controls the sequence of a number of states that follow some general rules. We fall asleep in nonrapid eye movement (NREM) sleep, we reach slow-wave sleep (SWS) in approximately 20–25 minutes, we remain in this state for approximately 30–40 minutes, and then we shift within 10–15 minutes into an episode of rapid eye movement (REM) sleep. This process is regulated by an ultradian oscillator in the brainstem that controls the regular alternation of NREM and REM sleep. Once the first period of REM sleep has been completed, the cycle starts again, although it tends to change from cycle to cycle. As sleep goes on, the amount of SWS decreases, leaving progressive space for stage 2 and REM sleep, which become the dominant features of the second part of the night (Carskadon and Dement, 2000). The nocturnal sleep chronogram is depicted by the conventional histogram (Figure 44.1). The onset and offset of sleep are regulated by the circadian process (closely related to thermoregulation), whereas the intensity of SWS depends on the amount of previous wakefulness (homeostatic process). However, the skeleton of sleep (i.e., macrostructure) can be manipulated within certain limits. If we prolong the time of previous wakefulness, we will have an enhancement of SWS and a contraction of stages 2 and REM, but the general architecture will be maintained. Things can change only when disturbing factors heavily interfere with the sleep process. Clinical conditions such as severe insomnia and sleep apnea syndrome can determine a drastic curtailment of SWS and an increase of light sleep, but as soon as the disturbing factor is removed or counteracted (hypnotic treatment in insomnia or nasal continuous positive airway pressure in breathing disorders), the sleeping brain tends to recover the original program. Even after sleep deprivation there is an immediate powerful rebound of SWS, the values of which, however, return to normal in the following nights. These findings suggest that the software governing sleep is powerful and resistant. You can influence it with several pressures
700
M.G. TERZANO AND L. PARRINO WAKE REM
STAGE 1 STAGE 2 STAGE 3 STAGE 4
A
0
60 120 180 240 300 360 420 480 540 Mins
0
60 120 180 240 300 360 420 480 540 Mins
WAKE STAGE R STAGE N1 STAGE N2 STAGE N3
B
Fig. 44.1. Comparison between histograms based on the sleep staging rules of Rechtschaffen and Kales (A) and on the new criteria of the American Academy of Sleep Medicine (B). REM, rapid eye movement sleep. R, REM sleep; stage N1, nonREM stage 1; stage N2, nonREM stage 2; stage N3, non-REM stage 3.
but it tends to recover its core trait once the perturbing factor is withdrawn.
Reactivity and arousal during sleep Both robustness and sensitivity are necessary for complex systems to function effectively in the context of changing environments. Sleep is based on a solid program, which is under the influence of interacting regulatory processes: genetic constraints (Dauvilliers and Tafti, 2008; De Gennaro et al., 2008), the circadian sleep–wake alternation (Czeisler et al., 1980), the homeostatic balance between wakefulness and sleep (Borbely, 1982), and the ultradian NREM–REM interaction (McCarley and Massaquoi, 1992). Performing this program, the brain seeks internal stability and at the same time follows the dynamics of the sleep trajectory. This is achieved through control mechanisms, involving the arousal systems, that pace the state progression of the NREM/REM sleep cycle and protect sleep architecture against destabilizing stimulation. A stimulus is an interference that affects the system’s operations and may arise from within or outside
the system. Once the stimulus has registered itself in some way, the system measures its own internal tendency to depart from stability, and uses the responses either by evolving back to its initial condition or by switching to another state (Bar-Yam and Epstein, 2004). Within complex systems, such as the sleeping brain, control can be obtained only if the variety of the controller is at least as great as the variety of the situation to be controlled (Ashby, 1957). This implies that the sleeping brain must be endowed with a number of hierarchically graded arousal responses which guarantee a rapid and flexible adaptation to the interfering stimulus as a buffer system. This task is achieved through a graded activation of the brain expressed by EEG frequency shifts. The EEG responses elicited during sleep are not limited to a single pattern but are part of a continuous spectrum of EEG modifications ranging from high-voltage slow rhythms (K-complexes and delta bursts) to low-amplitude fast rhythms (conventional arousals) (American Sleep Disorders Association, 1992). The EEG responses play a special role in the sleep program, ensuring on the one hand enough stability to the sleeping brain and on the other enough flexibility to provide the necessary arousability from sleep. The sleep-promoting and wake-promoting neurons play a complementary role, both protecting and tailoring the length and depth of sleep according to the individual’s internal and external demands. In other words, the arousal system is the bridge that connects the internal sleep program to the environment and reacts to the signals with a variety of responses. Besides their buffering role against perturbing factors, arousals are natural EEG features of sleep, endowed within the texture of the physiological sleep process. In other words, brief awakenings from sleep are not simply random disruptions of the sleep process but rather are related to the underlying mechanisms of sleep control. Recent studies have also ascertained that brief awakenings exhibit robust scaleinvariant features across different mammalian species (Lo et al., 2004). The term arousal is commonly related to the concept of awakening. In the field of classic neurophysiology, the behavior of wakefulness is associated with the occurrence of EEG desynchronization (low-amplitude fast rhythms). Indeed, according to the conventional criteria, an arousal is identified by a rapid shift towards faster frequencies preceded by at least 10 seconds of continuous sleep (Figure 44.2). Thus, it is not surprising that slow phasic activities such as K-complexes and delta bursts are excluded from the definition of arousal. However, these slow phasic activities, although different in morphology from conventional arousals, are endowed with properties of cerebral, motor, and
NEUROLOGICAL PERSPECTIVES IN INSOMNIA AND HYPERAROUSAL SYNDROMES
701
Fig. 44.2. EEG arousal according to the conventional rules. Only the fast EEG rhythms (right-hand box) are included in the phasic event. The slow waves preceding the shift to the rapid frequencies are excluded (left-hand box).
vegetative activation, i.e., vasoconstriction, increased blood pressure, heart rate acceleration, increased ventilation (Hornyak et al., 1991; Sforza et al., 2000). Consequently, the concept of activation is much more extensive than the term arousal, which is the tip of an iceberg with manifold EEG features including also delta bursts, K-complexes, and K–alpha complexes (De Carli et al., 2004). This does not mean that all the activation complexes exert the same impact upon the vital functions. The activation complexes dominated by EEG synchronization (sequences of K-complexes, delta bursts) are associated with milder variations of motor and autonomic activities, whereas the forms with more rapid rhythms (i.e., conventional arousals) are combined with stronger modifications (Figure 44.3). In a spectrum of continuity, a hierarchy of activation samples can be defined and classified according to the relative amount of EEG synchrony and desynchrony (Halasz et al, 2004).
The cyclic nature of arousal The pattern of long-term EEG activity is generated by a time-averaged and smoothed collection of multiple, discrete frequencies of rhythm generation. Once NREM sleep has been initiated by the combined influence of homeostatic pressure and circadian propensity, there is a progressive inhibition of the arousal–waking system accompanied by alpha-rhythm fragmentation. The progression to the slower activities induces the rising of the slow (<1 Hz) oscillations, which are seminal for the implementation of slow wave activities (1–4 Hz) of deep NREM sleep (Steriade et al., 1993). K-complexes and delta bursts are the most relevant EEG manifestations of the slow (<1 Hz) rhythm regulated by intracortical loops (Amzica and Steriade,
1997). During this slow rhythm, the membrane potential of all cortical neurons oscillates, with a periodicity of about 1 second, between depolarized (up-state) and hyperpolarized (down-state) levels. This pattern of alternating states is associated with the continuous fluctuation of the synaptic release at the cortical level and powerfully entrains thalamic neurons (Massimini et al., 2003). In the state progression of different NREM stages the balance between wake-promoting cortical arousals and sleep-promoting (<1 Hz) slow oscillations is regulated by an infraslow oscillation (0.002–0.02 Hz) expressed in the scalp electrocortical activities by the cyclic alternating pattern (CAP) (Terzano et al, 1985; Ferri et al., 2006). CAP is an EEG periodic activity of NREM sleep organized in sequences of repetitive cycles that recur with a periodicity of 20–40 seconds (Terzano et al., 2001). Each CAP cycle is composed of a phase A (specific, repetitive, and transient EEG pattern) and a phase B (the interval between two consecutive A phases). Phase A of CAP is the EEG marker of cerebral activation, and phase B is an EEG indicator of rebound deactivation (Figure 44.4). CAP is the EEG translation of unstable sleep that accompanies the dynamic evolution of the sleep process, such as falling asleep, stage shifts, NREM/REM transition and intrasleep awakenings. The absence of CAP for more than 60 seconds is scored as nonCAP and reflects a condition of stable consolidated sleep (Terzano et al., 1988d; Smerieri et al., 2007). In the transition from light to deep stages, the <1 Hz oscillations become increasingly more frequent and tend to cluster in transient packages of approximately 10 seconds, similar to the mean duration of a CAP phase A. In consolidated deep sleep, the intermittent clusters of high-voltage slow EEG waves progressively
702
M.G. TERZANO AND L. PARRINO
Fig. 44.3. An example of muscle and autonomic activation linked with a sequence of K-complexes which induces a jerk on the right tibialis muscle and an initial recovery of airflow. The rise in pulse rate starts at the end of the K-complex cluster and accompanies the waxing of chin muscle tone (Milo channel) and breathing restoration. The black box containing EEG features is artificially split into two portions by a dotted vertical line: the slow-wave component of activation (left side) followed by a conventional arousal (right side).
1.45.40
1.45.45
1.45.55
1.45.50
oculo (0,298mV/cm)
1.46.00
1.46.05
1.46.10
1.46.15
1.46.20
52
RM
RM
RM
Spindle
Fp2-F4 (90,3µV/cm)
F4-C4 (90,3µV/cm)
C4-P4 (90,3µV/cm)
F8-T4 (90,3µV/cm)
T4-T6 (90,3µV/cm)
Fp1-F3 (90,3µV/cm)
F3-C3 (90,3µV/cm)
C3-P3 (90,3µV/cm)
F7-T3 (90,3µV/cm)
T3-T5 (90,3µV/cm)
C4-A1 (90,3µV/cm)
Milo (85,5µV/cm)
A tibiale (109µV/cm)
B
A
B
A
B
EKG (0,788mV/cm)
Fig. 44.4. A sequence of cyclic alternating pattern (CAP) in stage 2. Three complete CAP cycles are visible with the A phases coupled with transient heart rate acceleration and the B phases with a pulse deceleration.
NEUROLOGICAL PERSPECTIVES IN INSOMNIA AND HYPERAROUSAL SYNDROMES merge into a continuous nonalternating pattern in which the phases A and B of CAP are no longer distinguishable (nonCAP), being gradually replaced by sustained slowwave activity (Figure 44.5). By contrast, the shift from deep NREM sleep to REM stage is accompanied by the intrusion of cortical arousals, slow-wave fragmentation, and reappearance of the CAP rhythm (Ferrillo et al., 1996; Terzano and Parrino, 2000). Scoring rules, classification of phase A subtypes, and distribution of CAP parameters are detailed in the Appendix.
Homeostatic regulation of the sleeping brain Physiological regulation of the living organism varies according to the different conditions of vigilance. During wakefulness, the homeostatic control is achieved by means of highly dissipative metabolic processes, whereas motor quiescence and decreased sympathetic activity make sleep a condition of low energy expenditure (Parmeggiani, 1990). Although characterized by a low rate of energy transformation, sleep is, nevertheless, an active phenomenon maintained by means of a twofold homeostatic regulation (Moore-Ede, 1986): 1. Predictive homeostasis that warrants, under the control of intrinsic chronobiological systems, an endogenously programmed development of the sleep profile.
703
2. Reactive homeostasis that encompasses the continuous adjustments in response to all changes arising in the organism and in the environment. Therefore, the final architecture of a night of sleep emerges from the dynamic interaction between the internal constraints and the functional adaptability of the sleeping brain to the ongoing events. Owing to the time-related coupling between vigilance and autonomic functions, an adequate and simultaneous regulation of both sleep and neurovegetative systems is assured. Predictive homeostasis controls the tonic development of the NREM/REM cyclic alternation associated with a progressive decline of muscle tone, arterial pressure, body temperature, cardiorespiratory rate, and oxygen consumption. Reactive homeostasis intervenes through corrective responses to the phasic variations of vigilance level and physiological functions induced by the ever-changing environment. In the two-process model proposed by Borbely (1982), the homeostasis of sleep is related to the process-S curve that reflects the damping decline of EEG synchronization from sleep onset to final arousal. The slope of the process-S curve depends on sleep intensity and is linked to the duration of previous wakefulness, whereas its beginning and interruption are related to the process-C curve that undergoes the circadian constraints of internal clocks. This model supplies predictive information on the development and duration of
Fig. 44.5. A 60-second stretch of nonCAP in stage 2, characterized by a sustained homogeneous EEG trace (with intermittent spindles) and stable heart rate and SaO2 values.
M.G. TERZANO AND L. PARRINO
sleep based on the interaction between a single oscillator (process C) and a homeostatic process (process S). However, it neglects the occurrence and role of microstructural phenomena that partake in the accomplishment of process S and permit continuous adjustments of the sleeping brain to the unpredictable conditions of reality (Halasz, 1993, 1998; Terzano and Parrino, 2000). The different phase A subtypes of CAP represent a wide spectrum of short-lived graduated homeostatic reactions, which appear to be superimposed on the background rhythms of the single NREM stages and restrain the variability of biological functions within compatible ranges. From this perspective, sleep dynamics reflect a predefined plot implemented by ceaseless surprises. Every night, sleep onset is followed by a chain of regular and predictable events (the prevalence of SWS in the first part of the night, the 90–120-minute alternation between NREM and REM sleep, the intrinsic structure of sleep cycles, the duration of the single stages). On the other hand, it is a common experience that even in the same individual no two sleep recordings are exactly identical, as a series of random factors (eating, environment, worries, tiredness) vary from night to night. In other words, the sleeping brain can be considered as a kind of computer with certain inherited programs that receive and code input information from the world and guide adaptive action accordingly. This means that the sleeping brain must be able to process information and predict instability in the external milieu. Normative studies (Parrino et al., 1998; Bruni et al., 2002, 2005) have ascertained that normal sleep contains certain amounts of CAP rate, with age-related differences along the natural lifespan (Figure 44.6). Within compatible ranges, the sleeping brain can incorporate a supply of perturbation (increase in CAP rate) in the absence of relevant alterations of sleep stages. However, an excessive enhancement of instability drags sleep into becoming shallower and fragmented, as shown by a curtailment of the deeper stages and an increase of nocturnal awakenings (Terzano et al., 1990). Thus, the oscillating instability of CAP acts both as a protective mechanism for architectural stability and as a preparatory device for macrostructural alterations (Terzano and Parrino, 1993). Through the profile of sleep architecture and the magnitude of CAP-related changes it is possible to reconstruct the brain’s nocturnal experience.
Acoustic perturbation: an experimental model of insomnia The sleeping brain continuously explores the external world, especially by means of the hearing function. Macrostructural changes such as stage shifts and
70 60 CAP Rate (%)
704
50 40 + 30 20 10
0
10
20
30
40 50 60 Age (years)
70
80
90
Fig. 44.6. Distribution of the single CAP rate values across the different ages in normal healthy sleepers. Notice that across the lifespan physiological CAP rate tends to remain above 20% (horizontal black line), the minimum dynamic effort exerted by the brain to maintain a proper sleep structure.
awakenings are generally determined by strong acoustic stimuli (Terzano et al., 1993). However, noise can impinge upon sleep even when macrostructural alterations are lacking. An isolated stimulus (250 milliseconds; 1000 Hz; 60 dB) delivered during nonCAP in stage 2 immediately evokes a CAP sequence that persists in stage 2 (Terzano et al., 1986). In other words, arousal stability can be compromised despite an unmodified macrostructural background. The possibility of converting nonCAP into CAP by means of acoustic perturbation has been exploited in experimental studies based on continuous white noise administered throughout the night. The increases in CAP rate correlate positively with the increases of sound pressure level and with the impairment of subjective appreciation of sleep quality. In healthy young adults, values of CAP rate between 25% and 45% emerge when the subjective report is essentially satisfactory. For values of CAP rate between 45% and 60%, subjects generally refer to a moderate nocturnal discomfort, whereas a CAP rate above 60% corresponds to a severe complaint (Terzano et al., 1990). From the macrostructural viewpoint, no remarkable alterations of the conventional PSG parameters emerge at 45 dB, where CAP rate already shows a significant increase compared with the baseline condition (<30 dB). More relevant macrostructural changes, such as reduced slow-wave sleep and more frequent and longer awakenings, occur only at higher noise intensities (55, 65, and 75 dB respectively). Thus, in the chain of events from normal to pathological sleep, the expansion of CAP rate is a first-aid response for maintaining the physiological organization of sleep. Under the thrust of increasing
NEUROLOGICAL PERSPECTIVES IN INSOMNIA AND HYPERAROUSAL SYNDROMES 67
70 57
(%)
44 35
49
705
of zolpidem against noise reverberated especially upon stages 3 and 4, where the disruptive effects of acoustic perturbation were more prominent (Terzano et al., 1988c).
25
Long-term efficacy of zolpidem 0 BASAL
45 dBA
55 dBA
65 dBA
75 dBA
Fig. 44.7. Escalating values of CAP rate in healthy volunteers undergoing increasing levels of controlled acoustic perturbation during different nights.
sound pressure level, CAP operates as a “buffer” mechanism that counteracts, within compatible ranges, the disruptive effects of noise on the macrostructure of sleep (Figure 44.7). However, when adaptive thresholds are crossed, the destabilizing effects of noise also reverberate on the macrostructural level (Terzano and Parrino, 1993).
PHARMACOLOGICAL MANAGEMENT OF INSOMNIA Effects of zolpidem on CAP rate The sensitivity of CAP rate to noise has enabled the use of an “active” technique for exploring the effects of hypnotic drugs on the organization of sleep under strictly controlled conditions. In a group of healthy young adults with normal habits and no sleep complaints, an experimental trial was carried out on the basis of the aforementioned premises of microstructural manipulation by means of continuous noise (Terzano et al., 1988a, b). After an adaptation night, treatments (either placebo or 10 mg zolpidem) and conditions (presence or absence of continuous 45 dB white noise automatically delivered and controlled during the entire sleep recordings) were administered four times at 48-hour intervals, according to a completely randomized crossover factorial design. Despite the lack of significant macrostructural change when placebo was associated with noise, this condition provided a model of acute situational insomnia as disclosed by the complaint of a poor sleep quality. The subjective judgment was, however, supported by the microstructural data. Compared with baseline values (25%), white noise induced a significant increase of CAP rate during the noisy placebo nights (55%). Under unperturbed conditions, zolpidem preserved the regular organization of sleep at both the macrostructural and the microstructural level (CAP rate 26%), but the drug drastically reduced the increased values of CAP rate induced by acoustic perturbation (CAP rate 38%). The protective effects
In a long-term study (Terzano et al., 1997), zolpidem 10 mg was used for 5 weeks in patients with transient or short-term insomnia. After adaptation to the sleep laboratory, nocturnal PSG recordings were accomplished on: night 1 (baseline), night 2 (first day of drug administration), night 3 (seventh day of drug administration), night 4 (28th day of drug administration), night 5 (third day after the end of drug tapering). At the macrostructural level, significant overall modifications emerged only for SWS. For this parameter, a significant difference was found only between the baseline night (10%) and the first night of drug administration (20%), but the amounts of SWS remained enhanced during the remaining drug period. Highly significant and persistent differences did emerge, instead, at the microstructural level. In particular, CAP rate was significantly reduced throughout the entire drug period, decreasing from 59% (baseline night) to 32–38% (zolpidem nights). The variations in CAP rate correlated with the subjective appreciation of sleep quality. There was no PSG evidence of rebound insomnia when active medication was discontinued. Efficacy of zolpidem was also confirmed when the drug was administered according to an intermittent regimen (Parrino et al., 2008).
Hypnotic drugs in situational insomnia The model of situational insomnia based on continuous noise and CAP analysis has been used to compare the effectiveness of different hypnotic compounds against a common background (Terzano et al., 1995). Comparative multidrug studies have been carried out on a number of benzodiazepine (brotizolam, triazolam, lorazepam) and nonbenzodiazepine (zolpidem, zopiclone) drugs in healthy subjects both under basal (silent baseline night at a sound pressure of 30 dB) and acoustically perturbed conditions (noise-disturbed night at a sound pressure level of 55 dB). This model of situational insomnia allows discrimination between hypnotic drugs and placebo, between nonbenzodiazepine compounds and benzodiazepine agents, and between zolpidem and zopiclone (Parrino et al., 1997).
Antidepressant drugs and insomnia The close relationship between sleep and depression can justify the extensive use of antidepressant drugs in several forms of insomnia. However, the hypnotic
706
M.G. TERZANO AND L. PARRINO impairment in social, occupational, or other important areas of functioning. 3. The sleep disturbance does not occur exclusively during the course of narcolepsy, breathing-related sleep disorder, circadian rhythm sleep disorder, or a parasomnia. 4. The disturbance does not occur exclusively during the course of another mental disorder (e.g., major depressive disorder, generalized anxiety disorder, delirium). 5. The disturbance is not due to the direct physiological effects of a substance (e.g., a drug of abuse, a medication) or a general medical condition.
efficacy of an antidepressant agent does not necessarily imply that the sleep disorder is determined by a mood disturbance. The beneficial action of sedating antidepressant medication in primary insomnia has been reported (Curry et al., 2006). In addition, not all effective antidepressants exert the same hypnotic action. In a study carried out blind for 8 weeks in 125 patients with major depression and insomnia, 61 individuals were treated with fluoxetine and 64 with nefazodone (Gillin et al., 1997). PSG recordings were accomplished in the second, fourth, and eighth weeks of treatment. Both compounds proved effective in improving the symptoms of depression. However, in the fluoxetine group sleep appeared severely altered (decreased sleep efficiency and shallower sleep depth), whereas patients using nefazodone also presented subjective (self-report) and objective (PSG measures) improvement of sleep quality. Thus, the wake-promoting effect of fluoxetine and other selective serotonin reuptake inhibitors with activating properties suggests that the improvement in depressive symptoms may not be associated with a simultaneous improvement of insomnia. In support of this separation between antidepressant and hypnotic action, it is interesting to note that the effects on mood tend to appear after several days of treatment (generally weeks), whereas the effects on sleep commonly occur a few days after introduction of the medication. In a clinical–PSG study conducted on adult dysthymic patients with chronic insomnia, administration of trazodone CR (controlled release) reduced the excessive values of pretreatment CAP rate (65%) and improved subjective sleep quality in 4 days. Significant improvement of the mood-related symptoms occurred only after 3 weeks of medication (Parrino et al., 1994).
PRIMARY INSOMNIA Does primary insomnia exist? Primary insomnia generally refers to a situation where underlying causes of secondary insomnia have been ruled out. In primary insomnia, sleeplessness is not attributable to a medical, psychiatric, or environmental cause. The diagnostic criteria for primary insomnia from the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (American Psychiatric Association, 2000) are as follows: 1. The predominant complaint is difficulty initiating or maintaining sleep or nonrestorative sleep for at least 1 month. 2. The sleep disturbance (or associated daytime fatigue) causes clinically significant distress or
Primary insomnia subsumes a number of insomnia diagnoses in the International Classification of Sleep Disorders (American Academy of Sleep Medicine, 2005) including psychophysiological insomnia, paradoxical insomnia, idiopathic insomnia, and some cases of inadequate sleep hygiene. Primary insomnia is sometimes referred to as “pure” insomnia and in this case difficulty sleeping is at the core of the disorder. In other cases, primary insomnia and other disorders are independent, but cooccurring (Vgontzas, 2005). Computer-aided methods of sleep EEG, such as power spectral analysis, have revealed significantly increased fast activity in primary insomnia compared with that in good sleepers (Merica et al., 1998; Perlis et al., 2001). Studies assessing a wide range of physiological aspects in primary insomnia have also measured vital signs, temperature and metabolic rate, neuroendocrine function (e.g., cortisol and plasma melatonin), immune function (cellular and humoral immune components), cortical/neurological function (using functional neuroimaging and cognitive assessments), and psychological aspects (e.g., depressive tendencies and mood states). Through such investigations, a distinct profile involving endocrine, neurological, cognitive, and behavioral factors has been identified that suggests a pivotal role for psychophysiological hyperarousal in the disease etiology (Roth et al., 2007). Studies have shown significantly increased heart rate and core body temperature, and a raised metabolic rate in patients with insomnia (Bonnet and Arand, 1997). Evening and nocturnal plasma cortisol concentrations have exhibited alterations in the circadian cortisol rhythm (Rodenbeck and Hajak, 2001; Vgontzas et al., 2001a). In both young and elderly individuals with primary insomnia, nocturnal plasma melatonin levels tend to be lower than those in healthy controls (PandiPerumal et al., 2007). Patients with insomnia have also been shown to exhibit lower levels of cellular immunity (CD3þ, CD4þ, CD8þ cells) compared with normal sleepers (Savard et al., 2003).
NEUROLOGICAL PERSPECTIVES IN INSOMNIA AND HYPERAROUSAL SYNDROMES 707 Functional neuroimaging evidence of increased metamount of time they have slept, little is known about abolic and neuronal activity in primary insomnia has the mechanisms that underpin this phenomenon. In a also emerged recently, showing significant increases study carried out on 20 individuals with insomnia and in whole-brain metabolism and greater activity in brain 20 individuals who did not have insomnia, all subjects arousal systems in patients with insomnia compared were asked to perform two time estimation tasks, one with healthy subjects (Nofzinger et al., 2006). If, on in the laboratory during the day and one in the particithe one hand, insomniacs have globally increased brain pant’s own bedroom during the night. The results indimetabolism during both waking and sleep, possibly a cated that the performance of the insomnia group was reflection of hyperarousal (Nofzinger et al., 2004), on no different from that of the no-insomnia group, the other they show relative reductions in glucose regardless of the context in which the time estimates metabolism in the prefrontal cortex, possibly due to were made. Time overestimation correlated positively insufficient sleep restoration. with cognitive and physiological arousal experienced Under normal circumstances, sustained wakefulness during the time estimation tasks. These findings argue should produce an easy transition into sleep, consoliagainst the hypothesis that individuals with insomnia dated sleep, deep sleep, and sustained sleep. Given that misperceive their sleep simply because they are poor the latter phenomena do not occur with insomnia, and estimators of time (Tang and Harvey, 2005). Candidate the duration of wakefulness appears to be normal, it is mechanisms that underpin misperception can be sought plausible that the “sleep homeostat” itself is dysreguin the investigation of sleep microstructure. lated (Tononi and Cirelli, 2006). What happens during At the Parma Sleep Disorders Center, data were colthe night somehow reflects the diurnal neurophysiologlected from all-night PSG recordings of 20 patients ical experiences of the sleeping brain. In particular, with a diagnosis of sleep state misperception or parawakefulness is accompanied by synaptic potentiation in doxical insomnia (International Classification of Sleep a large fraction of cortical circuits, resulting in a net Disorders; American Academy of Sleep Medicine, increase in synaptic weight. In contrast, sleep (in particu2005). Recruitment of misperceptors without coexistlar SWS) is associated with synaptic downscaling. Under ing neurological, medical, or psychiatric disorders was normal conditions, the total synaptic strength increases based on objective total sleep time (TST) of at least during wakefulness and reaches a maximum just before 6.5 hours, objective sleep latency (SL) shorter than going to sleep. At sleep onset, total synaptic strength 30 minutes, underestimated difference between objecstarts to decline, and reaches a baseline level by the time tive and subjective TST of at least 120 minutes, and sleep ends (Tononi and Cirelli, 2007). subjective estimation of sleep latency >20% of objecSleep deprivation and sleep restriction produce two tive sleep latency. PSG data from misperceptors were kinds of symptoms: (1) “sleepiness” and related sympcompared with those from 20 normal sex- and agetoms, due to increased sleep pressure mediated by central matched subjects (controls). Patients and controls prehomeostatic mechanisms; and (2) cognitive impairment, sented nonsignificant differences in the amounts of irritability, difficulty concentrating, and fatigue, due to objective sleep time (464 vs. 447 minutes) and objective synaptic overload of cortical and limbic circuits caused sleep latency (9 vs. 8 minutes). However, compared by local sleep loss. Symptoms resulting from dysregulato controls, misperceptors reported a significantly tion of synaptic homeostasis are prominent in primary shorter time of perceived sleep (285 vs. 461 minutes; insomnia and in syndromes characterized by subjective P < 0.0001), and a significantly longer duration of perfeeling of nonrestorative sleep (Tononi and Cirelli, 2006). ceived sleep latency (51 vs. 22 minutes; P < 0.0001). At Whatever the underlying cause, primary insomnia the microstructural level, arousal index (32 vs. 19 per is the outcome of an internal dysregulation of sleephour; P < 0.0001) and total CAP rate (58% vs. 35%; promoting and arousal-promoting mechanisms. The P < 0.0001) were significantly higher in insomniacs. sleeping brain can articulate a number of graded In the sleep period between objective and subjective arousal responses that guarantee a quick and flexible sleep onset, CAP rate was 64.4% in misperceptors adaptation to the interfering stimulus as a buffer sysand 45.1% in controls (P < 0.002). Insomniacs showed tem. However, when the internal buffer systems are significantly higher amounts of CAP rate in stage 1 unable to control the stability of internal environment, (62.7% vs. 37.5%; P < 0.0001) and in stage 2 (53.3% sleep becomes fragile, fragmented, and nonrestorative. vs. 33.2%; P < 0.0001), but not in SWS. The percentage of subtypes A2, which include both sleep-promoting and Paradoxical insomnia wake-promoting EEG features, was significantly higher (P < 0.001) in misperceptors (31%) compared with conAlthough it is an established finding that people with trols (24%). It is interesting to notice that misperceptors insomnia characteristically overestimate the time they reported a limited amount of subjective awakenings have taken to get to sleep, and underestimate the total
708
M.G. TERZANO AND L. PARRINO
(mean 4) in contrast to objective findings (mean 11). The mismatch could be in part explained by the high amounts of CAP between successive awakenings that were merged together in a single experience. In other words, if sleep between two successive awakenings is disturbed, as reflected by increased amounts of CAP, time separating the two events is perceived as continuous wake. These findings suggest that in misperceptors difficulty to maintain consolidated sleep is interpreted as wakefulness (Mercer et al., 2002). In particular, if sleep between two successive awakenings is excessively fragmented (i.e., increased arousal index and CAP rate), the interval separating the two events is globally combined and perceived as waking time (Ozone et al., 2007; Parrino et al., 2009).
CAP and arousals in primary insomnia In a study of 50 patients with a diagnosis of primary insomnia (Parrino et al., 2004), the PSG findings were compared with those of age- and sex-matched healthy subjects with sleep complaints (controls). After an adaptation night, each patient had two randomized double-blind PSG recordings. Twenty-five patients followed a placebo–drug sequence and 25 a drug–placebo succession. Active medication consisted of widely used hypnotic drugs at therapeutic nighttime doses: zolpidem (17 patients), triazolam (13 patients), zopiclone (10 patients), brotizolam (7 patients), and flurazepam (3 patients). Compared with controls, primary insomnia appeared to be associated with significantly increased amounts of CAP and EEG arousals (Figure 44.8). When sleep quality was improved by active medication, most
CAP variables appeared highly sensitive to hypnotic treatment, whereas EEG arousals were poorly affected by sleep-promoting drugs (Figure 44.8). Hypnotic treatment improved total sleep time, nocturnal awakenings, stage 1 and SWS. However, the most significant correlation between sleep quality and PSG variables was found for CAP rate (Figure 44.9). The PSG variables with the greatest difference in mean value between placebo and medication are shown in Table 44.2 (Terzano et al., 2003). In a placebo-controlled randomized crossover study, 17 Japanese patients with psychophysiological insomnia were evaluated. During the first period, patients were administered the placebo on the first night, followed by either zolpidem or the placebo on the second night (treatment night). The second crossover period was conducted after a minimum 3-day observation. Zolpidem significantly decreased the overnight CAP rate values (57.6% vs. 39.0%; P ¼ 0.009) and improved “sleep depth” (P ¼ 0.044) and “sleep quality” (P ¼ 0.023) subjective questionnaire scores. The amount of time spent in SWS was significantly increased by zolpidem without affecting the amounts of stage 2 and REM sleep. Significant negative correlations (P ¼ 0.022) were found when the sleep quality score was matched to the CAP rate (Ozone et al., 2008).
The autonomic costs of insomnia If insomnia is not only a subjective compliant but also a disorder supported by objective disturbances, a biological price must be paid by patients afflicted by this sleep disorder.
500
placebo drug
100
444 405
253 262
250
222 182
65
83
87 99
209
111
VAS (mm)
(min.)
80 60 40 20
r = −0,51 p < 0,0001
0 TST*
S1+S2
S3+S4*
REM
CAP* AROUSALS
Fig. 44.8. Impact of placebo (white bars) and active hypnotic medication (black bars) on sleep variables in patients with primary insomnia. The sequence of administration (placebo/drug or drug/placebo) was completely randomized. Compared with placebo, active medication significantly increased total sleep time (TST) and slow-wave sleep (stages 3 þ 4) and reduced CAP time (marked by an asterisk (all P<0.0001). Note that the acute action of hypnotic agents had no particular effect on superficial sleep, REM sleep, and the total number of arousals.
0
10
20
30
40 50 CAP rate (%)
60
70
80
Fig. 44.9. CAP rate values plotted against subjective sleep quality, measured by means of a visual analog scale (VAS). The higher the VAS score, the better the restorative properties of the previous night’s sleep. Note the concentration of drug nights (black squares) on the left side of the graph, associated with lower CAP rate values and higher VAS scores. In contrast, placebo nights (white squares) prevail on the right side of the chart.
NEUROLOGICAL PERSPECTIVES IN INSOMNIA AND HYPERAROUSAL SYNDROMES Table 44.2 Polysomnographic variables with the greatest difference in mean values between placebo and hypnotic medication Discriminant analysis* CAP rate A1 subtypes A2 subtypes WASO Total sleep time Slow-wave sleep Arousal index A3 subtypes
0.881 0.524 0.513 0.248 0.233 0.216 0.199 0.154
*Placebo vs. hypnotic drug. CAP, cyclic alternating pattern; WASO, wake-time after sleep onset.
In normal subjects, increases in low-frequency and decreases in high-frequency R–R interval oscillations have been described during CAP, indicating a relative dominance of the sympathetic tone during the states of unstable NREM sleep. Accordingly, reverse autonomic findings are associated with the nonCAP condition (Ferini-Strambi et al., 2000; Ferri et al., 2000). Further studies have ascertained that, during CAP, blood pressure increases significantly in comparison with that for nonCAP, reaching the same levels as those found in REM sleep and wakefulness (Iellamo et al., 2004). The low-frequency component of blood pressure variability and the baroreflex sensitivity are significantly higher during CAP than nonCAP. In particular, baroreflex sensitivity is no different during CAP and REM and is greater during both in comparison with the awake state. A novel ECG-based analysis technique has been developed that combines heart rate variability and respiratory modulation of R-wave amplitude to generate sleep spectrograms of high- and low-frequency coupling states that correlate more closely with CAP scoring but not with conventional NREM stages (Thomas et al., 2005). Spontaneous switches are seen in health and disease and are not dependent on delta power or stage. The low-frequency coupled (unstable) state is characterized by phasic EEG, fluctuating arousal thresholds, cyclic respiratory volume/flow change and autonomic outflow, cyclic variation in heart rate, and blood pressure close to REM/wake levels. Conventional stage is generally superficial NREM sleep. The highfrequency coupled (stable) state usually is associated with nonCAP EEG, stable arousal threshold, stable respiration and autonomic outflow, sinus arrhythmia, and blood pressure dipping. Conventional stage may be deep NREM sleep. This suggests that the stability dimension
709
may be integrated across several measurable sleep-state characteristics. Fragmented REM sleep takes on CAPlike features. Sleep-disrupting stimuli (e.g., sleep apnea, upper airway resistance, depression, pain) increase CAP sleep (Terzano et al., 1996; Farina et al., 2003; Rizzi et al., 2004; Guilleminault et al., 2007; Lopes et al., 2007) and low-frequency coupling, whereas sleep-enhancing conditions (e.g., sleep deprivation rebound, successful positive airway pressure titration, and sedative/ hypnotics) increase nonCAP (Parrino et al., 1993, 2000; Parrino and Terzano, 1996; Thomas, 2002; Lopes et al., 2007) and high-frequency coupling. This pattern of bimodal switching is also seen in rodents, suggesting that sleep (at least NREM sleep) is fundamentally bistable across mammalian species (Depootere et al., 1993). The developmental changes of sleep structure represent further risk factors. Both arousals and CAP rate correlate positively with aging (Boselli et al., 1998; Terzano et al., 2002), which is associated with increased levels of low-frequency unstable states during sleep. Increased total wake time is another sleep feature peculiar to aging. Accordingly, mean 24-hour interleukin-6 and cortisol levels are significantly higher in old than in young adults (Vgontzas et al., 2001b).
INSOMNIA OF INTEREST FOR NEUROLOGISTS Once it is established that insomnia is not only a subjective compliant but reflects an internal dysregulation of the sleep–wake mechanisms, a revision of disturbed sleep in different medical conditions can be carried out. In particular, difficulty initiating and maintaining sleep as well as nonrestorative sleep are common encounters in the neurological clinical practice (Table 44.3).
Hypnotic-dependent insomnia This type of insomnia occurs in association with tolerance to or withdrawal from sedative–hypnotic medications (Kales et al., 1974). Several patterns of hypnotic Table 44.3 Major neurological causes of insomnia Hypnotic-dependent or substance-dependent insomnia Synucleinopathies (Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy) Epilepsy Stroke Headache and migraine Neuromuscular disorders and painful syndromes Agrypnia excitata (fatal familial insomnia, Morvan’s chorea, delirium tremens)
710
M.G. TERZANO AND L. PARRINO
use have been associated with insomnia due to use of sleeping pills. In a first pattern, brief use of a hypnotic, for several consecutive nights, may lead to difficulty in sleeping when the drug is stopped (termed rebound insomnia), which may result in resuming use of the hypnotic. In the second pattern, sustained use of hypnotics frequently causes tolerance associated with a decrease in the drug’s hypnotic effects and return of symptoms. This often leads to an increase in the patient’s dosage. In the third pattern, partial withdrawal may occur in the presence of persistent drug tolerance. Despite dosage increases, partial withdrawal can cause a diminished hypnotic effect or the hypnotic effect to dissipate well before the end of the night. If the hypnotic therapy is stopped abruptly there may be central nervous system (CNS) withdrawal symptoms, which can include nausea, aches, irritability, and restlessness. The experience of withdrawal symptoms can predispose the patient toward resumption of chronic use, in search of more normal sleep and improved daytime functioning.
Synucleinopathies The synucleinopathies comprise a set of neurodegenerative disorders that share a common pathological lesion composed of aggregates of insoluble a-synuclein protein in selectively vulnerable populations of neurons and glial cells (Iwatsubo, 2007). These pathological aggregates appear to be closely linked to the onset and progression of clinical symptoms and the degeneration of affected brain regions in neurodegenerative disorders. The major synucleinopathies include Parkinson’s disease (PD), dementia with Lewy bodies, and multiple system atrophy (Mahowald et al., 2007). Parkinson’s disease. Sleep abnormalities in PD are frequent and partially due to nocturnal recurrence of PD motor symptoms and side-effects of pharmacotherapy. Insomnia can be caused by a primary sleep disorder such as restless legs syndrome, periodic limb movements, sleep-disordered breathing, REM behavior disorder (Wetter et al., 2000; Ondo et al., 2002; Comella, 2003), psychophysiological and sleep hygiene factors, and from the parkinsonism itself, with the resulting inability to turn in bed (Lees et al., 1988). There is also increasing evidence that disease underlying the degenerative process accounts for impairment in the expression of wakefulness and REM sleep, which could be due to the primary degeneration of sleep-regulating centers such as the locus coeruleus and the involvement of nondopaminergic transmitters. It should be also noted that dopamine neurons show state-dependent fluctuations in their activity (Diederich et al., 2005).
Progressive supranuclear palsy (PSP). Patients with PSP show a number of sleep alterations (Petit et al., 2004), including decreased total sleep time, decreased sleep efficiency (approximately 50%), increased wakefulness and increased percentage of stage 1 sleep, decreased percentage and duration of REM sleep. A characteristic feature is the reduction in abundance and amplitude of sleep spindles.
Dementia Dementia is characterized by progressive cognitive decline, which can lead to sleep–wake disturbances. Nocturnal awakenings and uncontrolled wanderings are common features (Paniagua and Paniagua, 2008) and may reflect insomnia secondary to night/day reversal, medication effects, emotional distress, understimulation or overstimulation during the day, nocturia, pain, or restless legs syndrome. Patients with dementia also suffer from severe insomnia or hypersomnia (Boeve et al., 2002). They spend a significant portion of the night in bed awake and a significant portion of their daytime hours asleep (Okawa et al., 1991). However, each sleep or wake period may be as short as several minutes, with frequent transitions between sleep and wake over the course of the 24-hour day (Vitiello et al., 1991). The increase in diurnal sleep interferes with the homeostatic drive and does not compensate for the SWS and REM sleep decrease during the night (Vitiello et al., 1991).
Epilepsy The presence of nocturnal seizures affects the regular profile of the sleep architecture. In most cases, the immediate effect of an epileptic attack corresponds to an upward shift towards either awakening or more superficial sleep stage (Bazil, 2002). Enhanced sleep fragmentation and higher percentages of wakefulness and light sleep with a decrease in stages 3, 4, and REM are common PSG findings (Touchon et al., 1991). In addition, marked sleep instability is often observed in epileptic patients, even in the absence of nocturnal seizures (Terzano et al., 1992). Overall, sleep-related attacks mostly affect the conventional sleep parameters, whereas nocturnal interictal discharges basically have a destabilizing impact on CAP parameters. Patients with nocturnal frontal lobe epilepsy with sleep complaints and excessive daytime sleepiness present an enhanced degree of unstable sleep, as expressed by a high CAP rate (Nobili et al., 2006; Parrino et al., 2006).
Fatal familial insomnia, Morvan’s chorea, delirium tremens Some neurological conditions, characterized by movement disorders that start or persist during sleep, hinder
NEUROLOGICAL PERSPECTIVES IN INSOMNIA AND HYPERAROUSAL SYNDROMES sleep onset and/or sleep continuity, causing a poor sleep complaint. CNS lesions and/or dysfunction in three specific neurological conditions (fatal familial insomnia, Morvan’s chorea, and delirium tremens) impair the basic mechanisms of sleep generation inducing a syndrome in which the inability to sleep is consistently associated with motor and sympathergic overactivation. Agrypnia excitata is the term that aptly defines this generalized overactivation syndrome (Lugaresi and Provini, 2001).
Stroke About 20–40% of stroke patients have sleep–wake disorders, mostly in form of insomnia, excessive daytime sleepiness/fatigue, or increased sleep needs (Bassetti, 2005). Depression, anxiety, sleep-disordered breathing (SDB), stroke complications, and medications may contribute to sleep–wake disorders and should be addressed first therapeutically. Brain damage per se, often at thalamic or brainstem level, can be also a cause of persisting sleep–wake disorders. The latter are frequently reported in patients with cerebral hemorrhage. In a prospective study carried out on patients who survived an episode of subarachnoid hemorrhage, 34% had severe problems with sleep, frequently reporting problems initiating (25%) or maintaining (31%) sleep, difficulty returning to sleep (28%), tiredness (31%), and excessive sleepiness during the day (6%). In sleep-monitoring studies, severe sleep fragmentation, sleep apnea, restless legs syndrome/periodic limb movement disorder, or a combination of these disorders of sleep and wake were common findings (Schuiling et al., 2005). The risk of an ischemic stroke is increased in men whose sleep is frequently disturbed. In the Caerphilly cohort study (Elwood et al., 2006), up to one-third of the men reported at least one symptom suggestive of sleep disturbance, and one-third reported daytime sleepiness. Compared with men who reported no such symptoms, the adjusted relative odds of an ischemic stroke were significantly increased in men with any sleep disturbance, the strongest association being with sleep apnea (relative odds 1.97). More than 65% of stroke patients have SDB, mostly in the form of obstructive sleep apnea (Arzt et al., 2005; Bassetti et al., 2006). SDB represents both a risk factor and a consequence of stroke. The presence of SDB has been linked with poorer long-term outcome and increased long-term mortality from stroke (Yaggi et al., 2005).
711
hemicrania (Kayed et al., 1978) and in cluster headache (Dexter and Riley, 1975; Manzoni et al., 1981). Hypnic headache is mostly related to REM sleep, with attacks occurring during REM sleep (usually the first REM period), and it has been considered a possible REM sleep disturbance even though the association of REM sleep and headache is generally nonspecific (Evers and Goadsby, 2003). However, the specific REM relationship of hypnic headache attacks was not confirmed in a study carried out on six polysomnographically recorded episodes: four arose from NREM and two from REM sleep (Manni et al., 2004). Headaches occurring during the night are often related to a sleep disturbance (Paiva et al., 1997), and episodic morning migraine can be associated with insomnia (Alstadhaug et al., 2007). PSG studies indicate that evaluation of patients with cluster headache should also include consideration that sleep-related breathing disorders may be present (Chervin et al., 2000).
Neuromuscular disorders Most of the sleep disturbances in neuromuscular disorders are secondary to sleep-related respiratory dysfunction. However, other factors such as pain, muscle cramps, muscle immobility, joint pains, contractures, kyphoscoliosis, obesity due to sedentary life, craniofacial abnormalities, anxiety, and depression may further contribute to sleep dysfunction.
FINAL CONSIDERATIONS There is a need for newer, more clinically useful classifications for insomnia. Existing classifications differ, and many terms remain inadequately defined, which leads to diagnostic confusion. Historically, insomnia has been classified according to symptom type, symptom duration, and underlying cause, but these classifications have not been based on evidence of their utility, and newer research suggests the need for change. The subtyping of insomnia in terms of whether there is an identifiable underlying cause such as a psychiatric or medical illness was based on an unproven assumption that in most instances other disorders caused insomnia. Recent studies suggest the need to revisit these classification strategies. (Krystal, 2005)
Headache and migraine
The underlying factors of insomnia
The relationship between sleep and migraine has long been recognized. REM sleep is a well-known precipitating factor in headache attacks in chronic paroxysmal
According to the dynamic model of insomnia of Spielman et al. (1996), a basic threshold for sleeplessness exists and if this threshold is exceeded insomnia
712 M.G. TERZANO AND L. PARRINO will occur. In particular, three dynamic factors contribnot necessarily stable. The orexin neurons in the lateral ute to insomnia. hypothalamus may help to stabilize this system by excitThe first is predisposition or basic sleep drive. ing arousal regions during wakefulness, preventing Some individuals may have a strong sleep drive and unwanted transitions between wakefulness and sleep are always far from the sleeplessness threshold. By (Saper et al., 2005). These mechanisms allow rapid contrast, some people have a weak sleep drive and arousal during times of emergency or behavioral are close to the sleeplessness threshold even under necessity, but activation of these circuits at inapproprithe best circumstances. Any small event can trigger ate times may be a mechanism for insomnia (Nofzintheir insomnia, and sometimes they will be sleepless ger, 2005). In a model of acute stress, male rats for no apparent reason. Usually, this is a lifelong experienced insomnia and presented simultaneous problem arising from a weak homeostatic drive or an activation of both wake and sleep circuitry in the brain overreactive autonomic nervous system. Among the resulting in faster flip-flop transitions (Lu et al., 2006). predisposing factors, the familial component seems to In human EEG sleep, the flip-flop switch could be play a significant role. In a study carried out by reflected by the periodic swings of CAP that rapidly Bastien and Morin (2000) on 285 subjects evaluated oscillate between states of activation (phase A) and for insomnia, 35% of patients had a positive family inhibition (phase B). history of sleep disturbance. Insomnia was the most common type of sleep disturbance identified (76%), Insomnia is not simply a mental problem and the mother was the family member most frequently In the last 15 years, quantification of arousals accordafflicted. A more recent investigation (Dauvilliers et al., ing to the American Academy of Sleep Medicine 2005) conducted on 256 consecutive chronic insom(AASM) rules has been carried out for a number of niacs, including both primary and psychiatric insomnia, sleep disorders as a translation of fragmented sleep, showed that 72.7% of patients with primary insomnia with increased amounts commonly described in sleepreported familial insomnia compared with 24.1% in the related breathing disorders. Surprisingly, the number no-insomnia control group. Among the psychiatric of EEG arousals may not appear to be increased in insomniacs, 43.3% reported familial insomnia. Even in insomniacs (Bonnet and Arand, 1996; Rosa and Bonnet, this case, the mother was the relative most frequently 2000), indicating that simple counting of these events affected. A tendency to a younger age at onset was may not reflect adequately the impaired processes of observed in familial and primary insomnia. disturbed sleep. The concept of arousals as stage marThe next factor is precipitation. Something happens – kers has been introduced in the recently published sleep perhaps stress, an illness, a grief reaction, or somescoring manual (AASM, 2007). thing else. Under normal circumstances, you would In the meantime, a number of experimental and clinexpect only transient or short-term insomnia, but the ical studies (Parrino et al., 1997; Terzano and Parrino, insomnia continues for a month, then another, and 1992; Terzano et al., 1990, 2003) have confirmed the another. The precipitating event has long gone, but topical role of unstable sleep in insomniacs and estabthe insomnia remains. If the insomnia persists long lished a significant correlation in these patients between after the precipitant has gone, there is something perCAP rate and subjective estimates of sleep quality. petuating the insomnia. This perpetuation factor can Regardless of any other change in the conventional be conditioned insomnia, a grief reaction turned to PSG measures, the higher the CAP rate the poorer the depression, dependence on alcohol to fall asleep, or quality of sleep. Accordingly, any sleep-improving counterproductive bedtime habits or routines. Because treatment reduces the amount of CAP and potentiates the brain acquires habits through frequent repetition, sleep stability through the increase of nonCAP (Terzano the sooner the perpetuating factor is eliminated, the and Parrino, 1993; Parrino and Terzano, 1996; Parrino faster the sleep system will bring the sleep–wake pattern et al., 2000; Thomas, 2002, 2007; Terzano et al., back to normal. 2003). PSG remains the “gold standard” for measuring Recent studies have shown that the control of wake sleep (American Sleep Disorders Association, 1995), and sleep emerges from the interaction of cell groups and especially insomnia (Chesson et al., 2000). Unlike that produce arousal with other nuclei that induce sleep, other sleep disorders, such as sleep-related breathing such as the ventrolateral preoptic nucleus (VLPO). The disorders and periodic leg movement, the nature and VLPO inhibits the ascending arousal regions and is in severity of which are quantified by specific respiratory turn inhibited by them, thus forming a mutually inhibiand motor indexes, no apparent organ dysfunction tory system resembling what electrical engineers call a underlies several cases of insomnia (in particular pri“flip-flop switch”. This switch may help produce sharp mary insomnia). Compared to subjectively defined transitions between discrete behavioral states, but it is
NEUROLOGICAL PERSPECTIVES IN INSOMNIA AND HYPERAROUSAL SYNDROMES good sleepers, PSG findings in insomniacs reveal impairment of sleep continuity parameters (i.e., longer sleep latencies, more time awake after sleep onset, lower sleep efficiency) and reduced total sleep time. In addition, insomniacs tend to spend more time in stage 1, less time in stages 3 and 4, and display more frequent stage shifts through the night. There is, however, a significant overlap in the distribution of sleep recordings of subjectively defined insomniacs and good sleepers, such that some individuals with insomnia complaints may show better conventional sleep measures than good sleepers (Carskadon et al., 1976). This overlap might account for some of the discrepancies between conventional PSG data and subjective evaluation of sleep quality. Investigation of the microstructure of sleep has begun to shed some light on these paradoxical findings. The extension of conventional sleep measures to CAP variables may improve our knowledge of the diagnosis and management of insomnia. These premises allow us to attribute a more objective identity to insomnia, which otherwise risks being considered an inscrutable, unexplainable, and immeasurable mental complaint.
REFERENCES Alstadhaug K, Salvesen R, Bekkelund S (2007). Insomnia and circadian variation of attacks in episodic migraine. Headache 47: 1184–1188. American Academy of Sleep Medicine (2005). International Classification of Sleep Disorders. Diagnostic & Coding Manual. 2nd edn. AASM, Westchester, IL. American Academy of Sleep Medicine (2007). AASM Manual for the Scoring of Sleep and Associate Events. Rules, Terminology and Technical Specifications. AASM, Westchester, IL. American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders. 4th edn. text revision. APA, Washington, DC. American Sleep Disorders Association (1992). EEG arousals: scoring rules and examples. A preliminary report from the Sleep Disorders Atlas Task Force of the American Sleep Disorders Association. Sleep 15: 174–184. American Sleep Disorders Association (1995). Practice parameters for the use of polysomnography in the evaluation of insomnia. Sleep 18: 55–57. Amzica F, Steriade M (1997). The K-complex: its slow (< 1 Hz) rhythmicity and relation to delta waves. Neurology 49: 952–959. Arzt M, Young T, Finn L et al. (2005). Association of sleepdisordered breathing and the occurrence of stroke. Am J Respir Crit Care Med 172: 1447–1451. Ashby WR (1957). An Introduction to Cybernetics. Chapman & Hall, London. Bar-Yam Y, Epstein IR (2004). Response of complex networks to stimuli. Proc Natl Acad Sci U S A 101: 4341–4345. Bassetti CL (2005). Sleep and stroke. Semin Neurol 25: 19–32.
713
Bassetti CL, Milanova M, Gugger M (2006). Sleep-disordered breathing and acute ischemic stroke: diagnosis, risk factors, treatment, evolution, and long-term clinical outcome. Stroke 37: 967–972. Bastien CH, Morin CM (2000). Familial incidence of insomnia. J Sleep Res 9: 49–54. Bazil CW (2002). Sleep and epilepsy. Semin Neurol 22: 321–327. Billiard M, Bentley A (2004). Is insomnia best categorized as a symptom or a disease? Sleep Med 5 (Suppl 1): S35–S40. Bixler EO, Vgontzas AN, Lin H-M et al. (2002). Insomnia in central Pennsylvania. J Psychosom Res 53: 589–592. Boeve BF, Silber MH, Ferman TJ (2002). Current management of sleep disturbances in dementia. Curr Neurol Neurosci Rep 2: 169–177. Bonnet MH, Arand DL (1995). 24-hour metabolic rate in insomniacs and matched normal sleepers. Sleep 18: 581–588. Bonnet MH, Arand DL (1996). The consequences of a week of insomnia. Sleep 19: 453–461. Bonnet MH, Arand DL (1997). Hyperarousal and insomnia. Sleep Med Rev 1: 97–108. Borbely AA (1982). A two process model of sleep regulation. Hum Neurobiol 1: 195–204. Boselli M, Parrino L, Smerieri A et al. (1998). Effect of age on EEG arousals in normal sleep. Sleep 21: 351–357. Bruni O, Ferri R, Miano S et al. (2002). Sleep cyclic alternating pattern in normal school-age children. Clin Neurophysiol 113: 1806–1814. Bruni O, Ferri R, Miano S et al. (2005). Sleep cyclic alternating pattern in normal preschool-age children. Sleep 28: 220–230. Carskadon M, Dement WC (2000). Normal human sleep: an overview. In: MH Kryger, T Roth, WC Dement (Eds.), Principles and Practice of Sleep Medicine. 3rd edn. WB Saunders, Philadelphia, pp. 15–25. Carskadon MA, Dement WC, Mitler MM et al. (1976). Selfreports versus sleep laboratory findings in 122 drug-free subjects with complaints of chronic insomnia. Am J Psychiatry 133: 1382–1388. Chervin RD, Zallek SN, Lin X et al. (2000). Sleep disordered breathing in patients with cluster headache. Neurology 54: 2302–2306. Chesson A, Hartse K, Anderson WM et al. (2000). Practice parameters for the evaluation of chronic insomnia. An American Academy of Sleep Medicine report. Standards of Practice Committee of the American Academy of Sleep Medicine. Sleep 23: 237–241. Comella CL (2003). Sleep disturbances in Parkinson’s disease. Curr Neurol Neurosci Rep 3: 173–180. Cortoos A, Verstraeten E, Cluydts R (2006). Neurophysiological aspects of primary insomnia: implications for its treatment. Sleep Med Rev 10: 255–266. Curry DT, Eisenstein RD, Walsh JK (2006). Pharmacologic management of insomnia: past, present, and future. Psychiatr Clin North Am 29: 871–893. Czeisler CA, Weitzman E, Moore-Ede MC et al. (1980). Human sleep: its duration and organization depend on its circadian phase. Science 210: 1264–1267.
714
M.G. TERZANO AND L. PARRINO
Dauvilliers Y, Tafti M (2008). The genetic basis of sleep disorders. Curr Pharm Des 14: 3386–3395. Dauvilliers Y, Morin C, Cervena K et al. (2005). Family studies in insomnia. J Psychosom Res 58: 271–278. De Carli F, Nobili L, Beelke M et al. (2004). Quantitative analysis of sleep EEG microstructure in the time– frequency domain. Brain Res Bull 63: 399–405. De Gennaro L, Marzano C, Fratello F et al. (2008). The electroenphalographic fingerprint of sleep is genetically determined: a twin study. Ann Neurol 64: 455–460. Depoortere H, Francon D, Granger P et al. (1993). Evaluation of the stability and quality of sleep using Hjorth’s descriptors. Physiol Behav 54: 785–793. Dexter JD, Riley TL (1975). Studies in nocturnal migraine. Headache 15: 51–62. Diederich NJ, Vaillant M, Mancuso G et al. (2005). Progressive sleep ’destructuring’ in Parkinson’s disease. A polysomnographic study in 46 patients. Sleep Med 6: 313–318. Elwood P, Hack M, Pickering J et al. (2006). Sleep disturbance, stroke, and heart disease events: evidence from the Caerphilly cohort. J Epidemiol Community Health 60: 69–73. Evers S, Goadsby PJ (2003). Hypnic headache: clinical features, pathophysiology, and treatment. Neurology 60: 905–909. Farina B, Della Marca G, Grochocinski VJ et al. (2003). Microstructure of sleep in depressed patients according to the cyclic alternating pattern. J Affect Disord 77: 227–235. Ferini-Strambi L, Bianchi A, Zucconi M et al. (2000). The impact of cyclic alternating pattern on heart rate variability during sleep in healthy young adults. Clin Neurophysiol 111: 99–101. Ferrillo F, Gabarra M, Nobili L et al. (1996). Comparison between visual scoring of cyclic alternating pattern (CAP) and computerized assessment of slow EEG oscillations in the transition from light to deep non-REM sleep. J Clin Neurophysiol 14: 210–216. Ferri R, Parrino L, Smerieri A et al. (2000). Cyclic alternating pattern and spectral analysis of heart rate variability during normal sleep. J Sleep Res 9: 13–18. Ferri R, Bruni O, Miano S et al. (2005). Topographic mapping of the spectral components of the cyclic alternating pattern (CAP). Sleep Med 6: 29–36. Ferri R, Bruni O, Maino S et al. (2006). The time structure of the cyclic alternating pattern during sleep. Sleep 29: 693–699. Gillin JC, Rapaport M, Erman MK et al. (1997). A comparison of nefazodone and fluoxetine on mood and on objective, subjective and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial. J Clin Psychiatry 58: 185–192. Guilleminault C, Poyares D, Rosa A et al. (2006). Chronic fatigue, unrefreshing sleep and nocturnal polysomnography. Sleep Med 7: 513–520. Guilleminault C, Lopes MC, Hagen CC et al. (2007). The cyclic alternating pattern demonstrates increased sleep instability and correlates with fatigue and sleepiness in adults with upper airway resistance syndrome. Sleep 30: 641–647.
Halasz P (1993). Arousals without awakening – dynamic aspect of sleep. Physiol Behav 54: 795–802. Halasz P (1998). Hierarchy of micro-arousals and the microstructure of sleep. Neurophysiol Clin 28: 461–475. Halasz P, Terzano MG, Parrino L et al. (2004). The nature of arousal in sleep. J Sleep Res 13: 1–23. Hatoum HT, Kong SX, Kania CM et al. (1998). Insomnia, health related quality of life and health-care resource consumption. A study of managed-care organisation enrollees. Pharmacoeconomics 14: 629–637. Hornyak M, Cejnar M, Elam M et al. (1991). Sympathetic muscle nerve activity during sleep in man. Brain 114: 1281–1295. Iellamo F, Placidi F, Marciani MG et al. (2004). Baroreflex buffering of sympathetic activation during sleep: evidence from autonomic assessment of sleep macroarchitecture and microarchitecture. Hypertension 43: 814–819. Iwatsubo T (2007). Pathological biochemistry of alphasynucleinopathy. Neuropathology 27: 474–478. Kales A, Bixler Eo, Tan TL et al. (1974). Chronic hypnoticdrug use: ineffectiveness, drug withdrawal insomnia, and dependence. JAMA 227: 513–517. Kayed K, Godtlibsen OB, Sjaastad O (1978). Chronic paroxysmal hemicrania IV: “REM sleep locked” nocturnal headache attacks. Sleep 1: 91–95. Krystal AD (2005). The effect of insomnia definitions, terminology, and classifications on clinical practice. J Am Geriatr Soc 53 (7 Suppl): S258–S263. Lees AJ, Blackburn NA, Campbell VL (1988). The nighttime problems of Parkinson’s disease. Clin Neuropharmacol 11: 512–519. Lo C-C, Chou T, Penzel T et al. (2004). Common scaleinvariant patterns of sleep–wake transitions across mammalian species. Proc Natl Acad Sci U S A 101: 17545–17548. Lopes MC, Quera-Salva MA, Guilleminault C (2007). NonREM sleep instability with major depressive disorder: subjective improvement and improvement of non-REM sleep instability with treatment (Agomelatine). Sleep Med 9: 33–41. Lu J, Sherman D, Devor M et al. (2006). A putative flip-flop switch for control of REM sleep. Nature 441: 589–594. Lugaresi E, Provini F (2001). Agrypnia excitata: clinical features and pathophysiological implications. Sleep Med Rev 5: 313–322. Mahowald MW, Schenck CH, Bornemann MA (2007). Pathophysiologic mechanisms in REM sleep behavior disorder. Curr Neurol Neurosci Rep 7: 167–172. Manni R, Sances G, Terzaghi M et al. (2004). Hypnic headache: PSG evidence of both REM- and NREM-related attacks. Neurology 62: 1411–1413. Manzoni GC, Terzano MG, Moretti G et al. (1981). Clinical observations on 76 cluster headache cases. Eur Neurol 20: 88–89. Massimini M, Rosanova M, Mariotti M (2003). EEG slow (approximately 1 Hz) waves are associated with nonstationarity of thalamo-cortical sensory processing in the sleeping human. J Neurophysiol 89: 1205–1213.
NEUROLOGICAL PERSPECTIVES IN INSOMNIA AND HYPERAROUSAL SYNDROMES McCarley RW, Massaquoi SG (1992). Neurobiological structure of the revised limit cycle reciprocal interaction model of REM cycle control. Sleep Res 1: 132–137. Mercer JD, Bootzin RR, Lack LC (2002). Insomniacs’ perception of wake instead of sleep. Sleep 25: 564–571. Merica H, Blois R, Gaillard JM (1998). Spectral characteristics of sleep EEG in chronic insomnia. Eur J Neurosci 10: 1826–1834. Moore-Ede MC (1986). Physiology of the circadian timing system: predictive vs. reactive homeostasis. Am J Physiol 250: R735–R752. National Institutes of Health (2005). State of the Science Conference Statement on Manifestations and Management of Chronic Insomnia in Adults. Sleep 28: 1049–1057. Nobili L, Sartori I, Terzaghi M et al. (2006). Relationship of epileptic discharges to arousal instability and periodic leg movements in a case of nocturnal frontal lobe epilepsy: a stereo-EEG study. Sleep 29: 701–704. Nofzinger EA (2005). Neuroimaging and sleep medicine. Sleep Med Rev 9: 157–172. Nofzinger EA, Buysse DJ, Germain A et al. (2004). Functional neuroimaging evidence for hyperarousal in insomnia. Am J Psychiatry 161: 2126–2128. Nofzinger EA, Nissen C, Germain A et al. (2006). Regional cerebral metabolic correlates of WASO during NREM sleep in insomnia. J Clin Sleep Med 2: 316–322. Nowell PD, Buysse DJ, Reynolds DF 3rd et al. (1997). Clinical factors contributing to the differential diagnosis of primary insomnia and insomnia related to mental disorders. Am J Psychiatry 154: 1412–1416. Ohayon MM (2002). Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 6: 97–111. Okawa M, Mishima K, Hishikawa Y et al. (1991). Circadian rhythm disorders in sleep–waking and body temperature in elderly patients with dementia and their treatment. Sleep 14: 478–485. Ondo WG, Vuong K, Jankovic J (2002). Exploring the relationship between Parkinson’s disease and restless legs syndrome. Arch Neurol 59: 421–424. Ozone M, Yagi T, Itoh H et al. (2007). Microstructure of sleep in paradoxical insomnia. Sleep 30 (Suppl): A253. Ozone M, Yagi T, Tamura Y et al. (2008). Effects of zolpidem on cyclic alternating pattern, an objective marker of sleep instability, in Japanese patients with psychophysiological insomnia: a randomized crossover comparative study with placebo. Pharmacopsychiatry 41: 106–114. Paiva T, Farina A, Martin A et al. (1997). Chronic headaches and sleep disorders. Arch Intern Med 157: 1701–1705. Pandi-Perumal SR, Srinivasan V, Spence DW et al. (2007). Role of the melatonin system in the control of sleep: therapeutic implications. CNS Drugs 21: 995–1018. Paniagua MA, Paniagua EW (2008). The demented elder with insomnia. Clin Geriatr Med 24: 69–81. Parmeggiani PL (1990). Homeostatic function of the hypothalamus and control of the wake–sleep cycle. In: M Mancia, G Marini (Eds.), The Diencephalon and Sleep. Raven Press, New York, pp. 133–145.
715
Parrino L, Terzano MG (1996). Polysomnographic effects of hypnotic drug. Psychopharmacology 126: 1–16. Parrino L, Spaggiari MC, Borselli M et al. (1993). Effects of prolonged wakefulness on cyclic alternating pattern (CAP) during sleep recovery at different circadian phases. J Sleep Res 2: 91–95. Parrino L, Spaggiari MC, Boselli M et al. (1994). Clinical and polysomnographic effects of trazodone CR in chronic insomnia associated with dysthymia. Psychopharmacology 116: 389–395. Parrino L, Borselli M, Spaggiari MC et al. (1997). Multi-drug comparison (lorazepam, triazolam, zolpidem, zopiclone) in situational insomnia: polysomnographic analysis by means of the cyclic alternating pattern (CAP). Clin Neuropharmacol 20: 253–263. Parrino L, Borselli M, Spaggiari MC et al. (1998). Cyclic alternating pattern (CAP) in normal sleep: polysomnographic parameters in different age groups. Electroencephalogr Clin Neurophysiol 107: 439–450. Parrino L, Smerieri A, Borselli M et al. (2000). Sleep reactivity during acute nasal CPAP in obstructive sleep apnea syndrome. Neurology 54: 1633–1640. Parrino L, Ferrillo F, Smerieri A et al. (2004). Is insomnia a neurophysiological disorder? The role of sleep EEG microstructure. Brain Res Bull 63: 377–383. Parrino L, Halasz P, Tassinari CA et al. (2006). CAP, epilepsy and motor events during sleep: the unifying role of arousal. Sleep Med Rev 10: 267–285. Parrino L, Smerieri A, Giglia F et al. (2008). Polysomnographic study of intermittent zolpidem treatment in primary sleep maintenance insomnia. Clin Neuropharmacol 31: 40–50. Parrino L, Milioli G, De Paolis F et al. (2009). Paradoxical insomnia: the role of CAP and arousals in sleep misperception. Sleep Med 10: 1139–1145. Perlis ML, Merica H, Smith M et al. (2001). Beta EEG activity and insomnia. Sleep Med Rev 5: 365–376. Petit D, Gagnon JF, Fantini ML et al. (2004). Sleep and quantitative EEG in neurodegenerative disorders. J Psychosom Res 56: 487–496. Rizzi M, Sarzi-Puttini P, Atzeni F et al. (2004). Cyclic alternating pattern: a new marker of sleep alteration in patients with fibromyalgia? fibromyalgia? J Rheumatol 31: 1193–1199. Rodenbeck A, Hajak G (2001). Neuroendocrine dysregulation in primary insomnia. Rev Neurol 157: S57–S61. Rosa RR, Bonnet MH (2000). Reported chronic insomnia is independent of poor sleep as measured by electroencephalography. Psychosom Med 62: 474–482. Roth T, Roehrs T, Pies R (2007). Insomnia: pathophysiology and implications for treatment. Sleep Med Rev 11: 71–79. Saper CB, Cano G, Scammell TE (2005). Homeostatic, circadian, and emotional regulation of sleep. J Comp Neurol 493: 92–98. Savard J, Laroche L, Simard S et al. (2003). Chronic insomnia and immune functioning. Psychosom Med 65: 211–221. Schieber JP, Muzet A, Ferierre PJR (1971). Les phases d’activation transitoire spontanees su cours du sommeil normal chez l’homme. Arch Sci Physiol 25: 443–465.
716
M.G. TERZANO AND L. PARRINO
Schuiling WJ, Rinkel GJ, Walchenbach R et al. (2005). Disorders of sleep and wake in patients after subarachnoid hemorrhage. Stroke 36: 578–582. Sforza E, Jouny C, Ibanez V (2000). Cardiac activation during arousal in humans: further evidence for hierarchy in the arousal response. Clin Neurophysiol 111: 1611–1619. Smerieri A, Parrino L, Agosti M et al. (2007). Cyclic alternating pattern sequences and non-cyclic alternating pattern periods in human sleep. Clin Neurophysiol 118: 2305–2313. Soldatos CR, Allaert FA, Ohta T et al. (2005). How do individuals sleep around the world? Results from a single-day survey in ten countries. Sleep Med 6: 5–13. Spielman AJ, Nunes J, Glovinsky PB (1996). Insomnia. Neurol Clin 14: 513–543. Steriade M, Nunez A, Amzica F (1993). A novel slow (<1 Hz) neocortical oscillation andother sleep rhythms. J Neurosci 13: 3252–3265. Tang NK, Harvey AG (2005). Time estimation ability and distorted perception of sleep in insomnia. Behav Sleep Med 3: 134–150. Terzano MG, Parrino L (1991). Functional relationship between macro- and microstructure. In: MG Terzano, P Halasz, AC Declerck (Eds.), Phasic Events and Dynamic Organization of Sleep. Raven Press, New York, pp. 101–119. Terzano MG, Parrino L (1992). Evaluation of EEG cyclic alternating pattern during sleep in insomniacs and controls under placebo and acute treatment with zolpidem. Sleep 15: 64–70. Terzano MG, Parrino L (1993). Clinical applications of cyclic alternating pattern. Physiol Behav 54: 807–813. Terzano MG, Parrino L (2000). Origin and significance of the cyclic alternating pattern (CAP). Sleep Med Rev 4: 101–123. Terzano MG, Parrino L (2005). The cyclic alternating pattern (CAP) in human sleep. In: C Guilleminault (Ed.), Clinical Neurophysiology of Sleep Disorders, Vol. 6. Elsevier, Amsterdam, pp. 79–93. Terzano MG, Mancia D, Salati MR et al. (1985). The cyclic alternating pattern as a physiological component of normal NREM sleep. Sleep 8: 137–145. Terzano MG, Parrino L, Fioriti G et al. (1986). Morphologic and functional features of cyclic alternatine pattern (CAP) sequences in normal NREM sleep. Funct Neurol 1: 29–41. Terzano MG, Parrino L, Fioriti G et al. (1988a). The cyclic alternating pattern rate: a sleep variable sensitive to environmental modifications. A controlled study utilizing white noise and zolpidem. In: JP Sauvaent, SZ Langer, PL Morselli (Eds.), Imidazopyridines in Sleep Disorders. Raven Press, New York, pp. 219–230. Terzano MG, Parrino L, Fioriti G et al. (1988b). Variations of the cyclic alternating pattern rate: and homeostasis of sleep organization: a controlled study on the effects of white noise and zolpidem. Pharmacol Biochem Behav 29: 827–829. Terzano MG, Parrino L, Fioriti G et al. (1988c). Cyclic alternating pattern. A new approach to the pharmacology of sleep disorders. Neurophsyiol Clin 18: 447–457.
Terzano MG, Parrino L, Spaggiari MC (1988d). The cyclic alternating pattern sequences in the dynamic organization of sleep. Electroencephalogr Clin Neurophysiol 69: 437–447. Terzano MG, Parrino L, Fioriti G et al. (1990). Modifications of sleep structure induced by increasing levels of acoustic perturbation in normal subjects. Electroencephalogr Clin Neurophysiol 76: 29–38. Terzano MG, Parrino L, Anelli S et al. (1992). Effects of generalized interictal EEG discharges on sleep stability: assessment by means of cyclic alternating pattern. Epilepsia 33: 317–326. Terzano MG, Parrino L, Fioriti G et al. (1993). Assessment of noise-induced sleep fragility in two age ranges by means of polysomnographic microstructure. J Sound Vib 162: 339–345. Terzano MG, Parrino L, Boselli M et al. (1995). Changes of cyclic alternating pattern (CAP) parameters in situational insomnia under brotizolam and triazolam. Psychopharmacology 120: 237–243. Terzano MG, Parrino L, Boselli M et al. (1996). Polysomnographic analysis of arousal responses in obstructive sleep apnea syndrome by means of the cyclic alternating pattern. J Clin Neurophysiol 13: 145–155. Terzano MG, Parrino L, Borselli M et al. (1997). Sensitivity of cyclic alternating pattern to prolonged pharmacotherapy: a 5-week study evaluating zolpidem in insomniac patients. Clin Neuropharmacol 20: 447–454. Terzano MG, Parrino L, Smerieri A et al. (2001). Atlas, rules, and recording techniques for the scoring of cyclic alternating pattern (CAP) in human sleep. Sleep Med 2: 537–553. Terzano MG, Parrino L, Rosa A et al. (2002). CAP and arousals in the structural development of sleep: an integrative perspective. Sleep Med 3: 221–229. Terzano MG, Parrino L, Spaggiari MC et al. (2003). CAP variables and arousals as sleep EEG markers for primary insomnia. Clin Neurophysiol 114: 1715–1723. Terzano MG, Parrino L, Cirignotta F et al. (2004). Studio Morfeo: insomnia in primary care, a survey conducted on the Italian population. Sleep Med 5: 67–75. Terzano MG, Parrino L, Smerieri A et al. (2005). CAP and arousals are involved in the homeostatic and ultradian sleep processes. J Sleep Res 14: 359–368. Thomas RJ (2002). Cyclic alternating pattern and positive airway pressure titration. Sleep Med 3: 315–322. Thomas RJ (2007). Cyclic alternating pattern in the electroencephalogram: what is its clinical utility? Sleep 30: 553–555. Thomas RJ, Mietus JE, Peng CK et al. (2005). An electrocardiogram-based technique to assess cardiopulmonary coupling during sleep. Sleep 28: 1151–1161. Tononi G, Cirelli C (2006). Sleep function and synaptic homeostasis. Sleep Med Rev 10: 49–62. Tononi G, Cirelli C (2007). Staying awake puts pressure on brain arousal systems. J Clin Invest 117: 3648–3650. Touchon J, Baldy-Moulinier M, Billiard M et al. (1991). Sleep organization and epilepsy. Epilepsy Res Suppl 2: 73–81.
NEUROLOGICAL PERSPECTIVES IN INSOMNIA AND HYPERAROUSAL SYNDROMES Vgontzas AN (2005). The diagnosis and treatment of chronic insomnia in adults. Sleep 28: 1047–1048. Vgontzas AN, Bixler EO, Lin HM et al. (2001a). Chronic insomnia is associated with nyctohemeral activation of the hypothalamic–pituitary–adrenal axis: clinical implications. J Clin Endocrinol Metab 86: 3787–3794. Vgontzas AN, Bixler EO, Witman AM et al. (2001b). Middleaged men show higher sensitivity of their sleep to the arousing effects of corticotrophin-releasing hormone than young men: clinical implications. J Clin Endocrinol Metab 86: 1489–1495.
717
Vitiello MV, Poceta JS, Prinz PN (1991). Sleep in Alzheimer’s disease and other dementing disorders. Can J Psychol 45: 221–239. Wetter TC, Collado-Seidel V, Pollmacher T et al. (2000). Sleep and periodic leg movement patterns in drug free patients with Parkinson’ disease and multiple system atrophy. Sleep 23: 361–367. Yaggi HK, Concato J, Kernan WN et al. (2005). Obtsructive sleep apnea as a risk factor for stroke and death. N Engl J Med 353: 2034–2041.
APPENDIX Technical and Methodological Requirements For Scoring A CAP Sequence The identification of CAP should be preceded by the definition of sleep stages according to the conventional criteria (AASM, 2007). Onset and termination of a CAP sequence A CAP sequence is composed of a succession of CAP cycles (see Figure 44.4). A CAP cycle is composed of phase A and the subsequent phase B. All CAP sequences begin with a phase A and end with a phase B. Each phase of CAP is 2–60 s in duration. This cutoff relies on the consideration that the great majority (about 90%) of A phases occurring during sleep are separated by an interval of less than 60 s (Terzano and Parrino, 1991).
sleep EEG pattern for >60 s), with the following three exceptions. There is no temporal limitation: (1) before the first CAP sequence arising in nonREM sleep; (2) after a wake to sleep transition; (3) after a REM to nonREM sleep transition (Terzano et al., 2001). Stage shifts Within nonREM sleep, a CAP sequence is not interrupted by a sleep stage shift if CAP scoring requirements are satisfied. Consequently, because CAP sequences can extend across adjacent sleep stages, a CAP sequence can contain a variety of different phase A and phase B activities (Terzano et al., 2001).
NonCAP
CAP in REM sleep
The absence of CAP for >60 s is scored as nonCAP. An isolated phase A (that is, preceded or followed by another phase A but separated by more than 60 s), is classified as nonCAP. The phase A that terminates a CAP sequence is counted as nonCAP (see Figure 44.5). This transitional phase A bridges the CAP sequence to nonCAP (Terzano et al., 2001).
CAP sequences commonly precede the transition from nonREM to REM sleep and end just before REM sleep onset. REM sleep is characterized by the lack of EEG synchronization; thus phase A features in REM sleep consist mainly of desynchronized patterns (fast low-amplitude rhythms), which are separated by a mean interval of 3–4 min (Schieber et al., 1971). Consequently, under normal circumstances, CAP does not occur in REM sleep. However, pathophysiologies characterized by repetitive phase As recurring at intervals <60 s (e.g., periodic REM-related sleep apnea events) can produce CAP sequences in REM sleep (Terzano et al., 1996).
Minimal criteria for the detection of a CAP sequence CAP sequences have no upper limits on overall duration and on the number of CAP cycles. In young adults, 3 min is the approximate mean duration of a CAP sequence, which contains an average of six CAP cycles (Smerieri et al., 2007). At least two consecutive CAP cycles are required to define a CAP sequence. Consequently, three or more consecutive phase As must be identified with each of the first two phase As followed by a phase B (interval <60 s) and the third phase A followed by a greater than 60 s nonCAP interval (Terzano and Parrino, 2005). General rule A phase A is scored within a CAP sequence only if it precedes and/or follows another phase A in the 2–60-s temporal range. CAP sequence onset must be preceded by nonCAP (a continuous nonREM
Movement artifacts Body movements can trigger or interrupt a CAP sequence. Body movements linked to one or more phase As in the temporal range of 2–60 s can be included within the CAP sequence if other scoring criteria are met (Terzano et al., 2001). Recording techniques and montages CAP is a global EEG phenomenon involving extensive cortical areas. Therefore, phase As should be visible on all EEG leads. Bipolar derivations such as Fp1–F3, F3–C3, C3–P3, P3–O1 or Fp2–F4, F4–C4, C4–P4, P4–O2 guarantee a favorable detection of the phenomenon. A calibration of 50 mV/7 mm with
NEUROLOGICAL PERSPECTIVES IN INSOMNIA AND HYPERAROUSAL SYNDROMES a time constant of 0.1 s and a high-frequency filter in the 30-Hz range is recommended for the EEG channels. Monopolar frontal, central, and occipital EEG derivations, eye-movement channels, and submentalis EMG, currently used for the conventional sleep staging and arousal scoring, are also essential for scoring CAP. Airflow and respiratory effort, cardiac rhythm, oxygen saturation, and leg movements should be included for clinical studies. Amplitude limits Changes in EEG amplitude are crucial for scoring CAP. Phasic activities initiating a phase A must be a third higher than the background voltage (calculated during the 2 s before onset and 2 s after offset of a phase A). However, in some cases, a phase A can present ambiguous limits owing to inconsistent voltage changes. Onset and termination of a phase A are established on the basis of an amplitude/frequency concordance in the majority of EEG leads. The monopolar derivation is mostly indicated when scoring is carried out on a single derivation. All EEG events that do not meet clearly the phase A characteristics cannot be scored as part of phase A (Terzano et al., 2001). Temporal limits The minimal duration of a phase A or a phase B is 2 s. If two consecutive phase As are separated by an interval <2 s, they are combined as a single phase A. If they are separated by a 2-s interval, they are scored as independent events (Terzano et al., 2001). The phase A subtypes of CAP In normal sleepers (Parrino et al., 1998), CAP rate (the percentage ratio of CAP time to NREM sleep time) varies according to a complex age-related curve. The lower values are found in young adults
719
(32%), and the highest amounts appear in elderly subjects (55%). A physiological peak of CAP rate is reached also in the peripubertal age range, indicating a vigorous interaction between developmental factors and sleep microstructure (Bruni et al., 2002). Based on the amount and distribution of slow oscillation, the A phases of CAP can be classified in subtypes A1, A2, and A3 (Figure 44.10). In particular, subtypes A1 are composed almost entirely of <1-Hz rhythms, subtypes A2 contain approximately 50% slow oscillations and 50% low-voltage fast activities, whereas subtypes A3 include only a minimal proportion of slow oscillation with a predominance of rapid activities (Terzano et al., 2001). Accordingly, subtypes A1 dominate in the first part of the sleep cycle where they accompany the progressive transition from light sleep (stages 1 and 2) to deep sleep (stages 3 and 4), and therefore appear to be involved in the process of buildup and maintenance of EEG synchronization (Figure 4.11). By contrast, subtypes A2 and A3 prevail physiologically in the final part of the sleep cycle (Figure 44.11), where they disrupt EEG synchronization and prepare the appropriate desynchronized background for the onset of REM sleep (Terzano et al., 2005). With regard to motor and autonomic functions, subtypes A1 are associated with a mild activation, subtypes A2 with a moderate activation, and subtypes A3 with a powerful activation (Terzano and Parrino, 2000). Recent findings using topographic brain mapping show that different phase A subtypes involve separate regions of the cerebral cortex. Subtypes A1 are essentially the expression of transient activation restricted to the frontal lobe which seldom crosses the fronto-occipital midline; in contrast, subtypes A3 are projected into the parieto-occipital regions and subtypes A2, with mixed slow–rapid components, span from frontal to occipital lobes (Ferri et al., 2005).
720
M.G. TERZANO AND L. PARRINO
Fig. 44.10. Specimens of phase A subtypes framed in boxes. The thick black lines above the boxes indicate the portions of A phases characterized by rapid EEG rhythms (limited in subtype A1, approximately 50% in subtype A2, prevalent in subtype A3). Note the progressively stronger activation of muscle and vegetative functions from subtype A1 to subtype A3.
NEUROLOGICAL PERSPECTIVES IN INSOMNIA AND HYPERAROUSAL SYNDROMES
721
20
15
10
0
0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220 230 240 250 260 270 280 290 300 310 320 330 340 350 360 370 380 390 400 410 420 430 440 450 460 470 480 490 500
Phases A2 + A3
Phases A1
5
W R S1 S2 S3 S4
Fig. 44.11. Distribution of CAP phase A subtypes in relation to the structural development of the sleep histogram in a healthy normal sleeper. Note the link between the buildup of slow-wave sleep and subtypes A1 (which also follow the exponential decline of sleep intensity) and the ultradian recurrence of subtypes A2 and A3 in close temporal connection with REM sleep.
Handbook of Clinical Neurology, Vol. 99 (3rd series) Sleep Disorders, Part 2 P. Montagna and S. Chokroverty, Editors # 2011 Elsevier B.V. All rights reserved
Chapter 45
Insomnia: nature, diagnosis, and treatment CHARLES M. MORIN 1 * AND RUTH M. BENCA 2 1 Universit Laval, Quebec, Canada 2
University of Wisconsin, Madison, WI, USA
INTRODUCTION Insomnia is a prevalent complaint both in the general population and in clinical practice. Chronic insomnia can present as the primary problem or as a coexisting condition with another medical or psychiatric disorder. Insomnia diagnosis and therapeutic approaches have evolved over the past two decades (National Institutes of Health, 2005). Whereas it used to be conceptualized exclusively as a symptom of other psychiatric or medical disorders, current diagnostic classifications of sleep disorders make a distinction between the symptom and the syndrome of insomnia (American Psychiatric Association, 2000; American Academy of Sleep Medicine, 2005). In addition, there have been significant advances in the treatment of insomnia, from a predominantly symptomatic approach to more focused interventions on perpetuating factors with cognitive– behavioral therapy (CBT) and on more targeted brain receptors with pharmacotherapy (National Institutes of Health, 2005).
SIGNIFICANCE OF INSOMNIA Population-based estimates indicate that about 30% of adults report insomnia symptoms, 9–12% experience additional daytime symptoms, and 6–10% meet diagnostic criteria for an insomnia syndrome (Ohayon, 2002). In primary care medicine, approximately 20% of patients report significant sleep disturbances (Simon and VonKorff, 1997). Insomnia is more prevalent among women, middle-aged and older adults, shiftworkers, and patients with medical or psychiatric disorders. Difficulties initiating sleep are more common among young adults, and problems maintaining sleep are more frequent among middle-aged and elderly adults. The incidence of insomnia is higher among
first-degree family members (daughter, mother) than in the general population (Dauvilliers et al., 2005), although it is unclear whether this link is inherited through a genetic predisposition, learned by observations of parental models, or simply a byproduct of another psychopathology. Persistent insomnia can produce an important burden for the individual and for society, as evidenced by increased rates of absenteeism, reduced productivity, increased risks of depression, and higher rates of healthcare utilization (Ford and Kamerow, 1989; Breslau et al., 1996; Simon and VonKorff, 1997; Sivertsen et al., 2006b; Ozminkowski et al., 2007; Daley et al., 2009).
NATURE OF INSOMNIA Presenting complaints Insomnia is characterized by a spectrum of complaints reflecting dissatisfaction with the quality, duration, or continuity of sleep. These complaints may involve problems with falling asleep initially at bedtime, waking up in the middle of the night and having difficulty going back to sleep, waking up too early in the morning with an inability to return to sleep, nonrestorative or unrefreshing sleep (American Psychiatric Association, 2000; American Academy of Sleep Medicine, 2005). In addition, daytime fatigue, cognitive impairments, and mood disturbances (e.g., irritability, dysphoria) are extremely frequent and often the primary concerns prompting patients with insomnia to seek treatment. In addition to clinical diagnostic criteria (Table 45.1), several quantitative indicators are useful to evaluate the severity and significance of insomnia. These include the intensity, frequency, and duration of sleep difficulties and their associated daytime consequences. For example, sleep-onset and sleep-maintenance insomnia
*Correspondence to: Charles M. Morin, Ph.D., Universite´ Laval, 2325 Rue des Bibliothe`ques, E´cole de Psychologie, Pavillon F.A.S., Quebec City, Quebec, Canada G1V 0A6. Tel: (418) 656-3275, Fax: (418) 656-5152, E-mail:
[email protected]
724
C.M. MORIN AND R.M. BENCA
Table 45.1 Diagnostic criteria for primary insomnia (adapted from DSM-IV-TR) ● ● ●
●
A subjective complaint of difficulty initiating or maintaining sleep, or of nonrestorative sleep Duration of insomnia longer than 1 month The sleep disturbance (or associated daytime fatigue) causes clinically significant distress or impairment in social, occupational, or other important areas of functioning The sleep disturbance does not occur exclusively in the context of another mental or sleep disorder, and is not the direct physiological effect of a substance or a general medical condition
are often defined by a latency to sleep onset and/or time awake after sleep onset greater than 30 or 45 minutes, with corresponding sleep time of less than 6.5 hours. Such criteria, while arbitrary, are useful to operationalize the definition of insomnia. Total sleep time alone is not a good index to define insomnia because there are individual differences in sleep needs. Some people may function well with as little as 5–6 hours of sleep and would not necessarily complain of insomnia, whereas others needing 9–10 hours may still complain of inadequate sleep. It is also important to distinguish the occasional insomnia that everyone experiences at one time or another in life from the more recurrent insomnia, usually defined by the presence of sleep difficulty for three or more nights per week. A distinction is also made between situational/acute insomnia, a condition lasting a few days and often associated with life events or jet lag, short-term insomnia (lasting between 1 and 4 weeks), and chronic insomnia, lasting more than a month. Finally, it is necessary to consider the impact of insomnia on a person’s psychosocial and occupational functioning to judge its clinical significance. As such, insomnia must be associated with marked distress or significant impairments of daytime functioning to make the diagnosis (American Psychiatric Association, 2000; Edinger et al., 2004; American Academy of Sleep Medicine, 2005).
Polysomnographic (PSG) findings PSG evaluation of self-defined insomniacs reveals more impairments of sleep continuity parameters (i.e., longer sleep latencies, more time awake after sleep onset, lower sleep efficiency) and reduced total sleep time compared with findings in self-defined good sleepers. Although sleep architecture is not always altered, a subset of individuals with chronic insomnia show increased amount of stage 1, reduced stages
3–4, and more frequent stage shifts through the night. Interestingly, sleep disturbances recorded in primary insomniacs are similar to those observed in patients with generalized anxiety disorder or some affective disorders such as dysthymia (Reynolds et al., 1984; Hauri and Fisher, 1986; Benca et al., 1992), perhaps suggesting a common underlying thread to these conditions. Investigations of the microstructure of sleep reveal increased beta activity in primary insomniacs relative to healthy controls, both around the sleep-onset period and during nonrapid eye movement (NREM) sleep (Lamarche and Ogilvie, 1997; Merica et al., 1998; Perlis et al., 2001b; Bastien et al., 2008). These data are consistent with the presumed role of attentional processes and information processing (Perlis et al., 2001a; Devoto et al., 2005; Jones et al., 2005), as well as with psychological findings of hypervigilance and a ruminative, worry-prone cognitive style among insomniacs. In general, there is a significant overlap in the sleep patterns of subjectively defined insomniacs and good sleepers, such that some insomniacs may show better objective sleep than good sleepers, and some good sleepers may show more sleep impairments than insomniacs.
Daytime complaints and findings Most patients with significant insomnia complaints also report impairments of daytime functioning, involving fatigue, mood disturbances, and difficulties with attention and concentration, memory, and completion of tasks (Buysse et al., 2007). Patients may initially report excessive daytime sleepiness, but a closer investigation usually reveals mental and physical fatigue rather than true physiological sleepiness, which is more likely among patients with insomnia comorbid with another medical (e.g., pain) or sleep disorders (e.g., sleep-related breathing disorders). Insomniacs have trouble sleeping at night, in part because of chronic state of hyperarousal, which may also interfere with the ability or propensity for sleep during the day. Despite significant subjective complaints, objective evaluation of daytime performance usually reveals fairly mild and selective deficits (e.g., attention) on various neurobehavioral measures (Riedel and Lichstein, 2000). In general, impairments on these measures are more strongly associated with subjective than with objective sleep disturbances. Individuals with insomnia tend to have lower expectations and to perceive their performance as more impaired relative to how they should perform, and as more impaired than that of normal controls. Discrepancies between subjective and objective performance are similar to those observed between subjective and objective
INSOMNIA: NATURE, DIAGNOSIS, AND TREATMENT measures of sleep, which may reflect a generalized faulty appraisal of sleep and daytime functioning among individuals with insomnia (Vignola et al, 2000).
Subtypes of insomnia DSM-IV recognizes only one form of primary insomnia (American Psychiatric Association, 2000), whereas the International Classification of Sleep Disorders distinguishes different subtypes (Table 45.2), the most common being psychophysiological, paradoxical, and idiopathic insomnia (American Academy of Sleep Medicine, 2005). Psychophysiological insomnia is presumed to result from conditioned arousal, which is more likely to develop among individuals with an increased psychological (worry-prone) and biological predisposition (hyperarousability) to insomnia. The sleep of individuals with psychophysiological insomnia is more sensitive to daily stressors and is characterized by extensive night to night variability (Vallieres et al., 2005a). Table 45.2 Insomnia diagnostic subtypes Type of insomnia Primary insomnia Adjustment (< 3 months)
Psychophysiological (> 6 months) Paradoxical
Idiopathic insomnia
Inadequate sleep hygiene Behavioral insomnia of childhood Comorbid insomnia Associated with a mental disorder Associated with a drug or substance Associated with a medical condition Associated with another sleep disorder
Description
Temporally linked with a stressor and expected to resolve with disappearance of initial precipitating factor Conditioned arousal, heightened anxiety about sleep Marked discrepancy between subjective complaints and PSG findings Insidious onset during childhood, unrelated to psychological trauma or medical disorders; persistent throughout adulthood
725
Paradoxical insomnia involves a genuine complaint of poor sleep that is not corroborated by objective findings. A patient may perceive very little sleep (e.g., 2–3 hours per night), whereas PSG recordings show normal or near-normal sleep duration and quality. This condition is not the result of an underlying psychiatric disorder or of malingering, but is likely to be mediated by psychological and cognitive (information processing) variables influencing the perception of sleep and wakefulness. To some degree, all insomniacs tend to overestimate the time it takes them to fall asleep and to underestimate the time they actually sleep. In paradoxical insomnia, however, the subjective complaint of poor sleep is disproportionate to objective findings. Thus, this condition may represent the far end of a continuum of individual differences in sleep perception. Idiopathic (childhood) insomnia presents an insidious onset during childhood, unrelated to psychological trauma or medical disorders, and is very persistent throughout the adult life. It does not present the variability observed with other forms of primary insomnia. A mild defect of the basic neurological sleep/wake mechanisms may be a predisposing factor, a hypothesis that comes from the observations that patients with this condition often have a history of learning disabilities, attention-deficit/hyperactivity disorder, or similar conditions associated with minimal brain dysfunction. Despite their heuristic value, these insomnia phenotypes and others remain to be validated empirically.
Course and prognosis The onset of Insomnia can occur at any time during life, but the first episode is more common in young adulthood. It is often precipitated by stressful life events, such as marital separation, occupational or family stress, and interpersonal conflicts (Bastien et al., 2004). In a small subset of cases (e.g., idiopathic insomnia), insomnia begins in childhood, in the absence of psychological or medical problems, and persists throughout adulthood (Hauri and Olmstead, 1980). Insomnia is a common problem among women during menopause and often persists even after other symptoms (e.g., hot flashes) have resolved with hormone replacement therapy. Insomnia may also have a latelife onset, which needs to be distinguished from normal (age-related) changes in sleep; such late-life onset is often associated with other health-related problems. Potential risk factors for insomnia include female sex, advancing age, a worry-prone cognitive style, hyperarousal, and a past history of insomnia (Klink et al., 1992; Morin and Espie, 2003). For most individuals, insomnia is transient in nature, lasting a few days, and resolving itself once the initial precipitating
726 C.M. MORIN AND R.M. BENCA event has subsided. For others, perhaps those more and increased cortisol and adrenocorticotropic horvulnerable to sleep disturbances, insomnia may persist mone levels during sleep and throughout the 24-hour long after the initial triggering event has disappeared; period (Vgontzas et al., 2001; Rodenbeck et al., other factors would then perpetuate sleep disturbances 2002). Reduced sleep efficiency was correlated with (Spielman and Glovinsky, 1991). The course of insomnia higher cortisol levels (Vgontzas et al., 2001; Rodenbeck may also be intermittent, with repeated brief episodes et al., 2002). A neuroimaging study revealed that, comof sleep difficulties following a close association with pared to healthy controls, insomniacs had increased the occurrence of stressful events (Vollrath et al., cerebral glucose metabolic rates during wakefulness 1989). Longitudinal studies have shown that chronicity and NREM sleep, and also exhibited smaller declines rates may range from 45% to 75% for follow-ups of in glucose metabolism from wakefulness to sleep in 1–7 years (Buysse et al., 2008; Morin et al., 2009). Even wake-promoting brain areas such as the ascending when insomnia has developed a chronic course, there is reticular activating system (Nofzinger et al., 2004). typically extensive night to night variability in sleep Positron emission tomography in patients with insompatterns, with an occasional restful night’s sleep internia demonstrated that increased wakefulness after twined with several nights of poor sleep (Vallieres sleep onset was correlated with increased activation in et al., 2005a). The subtype of insomnia (i.e., sleep onset the pontine region and in some thalamocortical netor maintenance insomnia) may also change over time. works during sleep (Nofzinger et al., 2006). Finally, a Although there is little information about its natural hisstudy of brain neurochemicals found that levels of tory, the prognosis for insomnia varies across indivigamma-aminobutyric acid (GABA) were nearly 30% duals and is probably mediated by a combination of lower in patients with primary insomnia than in conbiologically related predisposing factors and psychologtrols; GABA levels were negatively correlated with ical and behavioral perpetuating factors. It may also wake after sleep onset (Winkelman et al., 2008). be complicated by the presence of comorbid psychiatric or medical disorders. In fact, there is extensive comorPsychological basis. Psychological and behavioral bidity (40–50%) between insomnia and psychiatric factors also play an important role in the development disorders, most notably with major depression and and maintenance of insomnia, as evidenced by higher generalized anxiety disorder (Ford and Kamerow, levels of presleep cognitive arousal (e.g., intrusive 1989; Benca et al., 1992; Buysse et al., 1994; Breslau thoughts, worries) and general psychological reactivity et al., 1996; Ohayon and Roth, 2003). among individuals with insomnia relative to good sleepers. Although chronic exposure to stress may contribEtiology and pathophysiology ute to insomnia, it may be that sleep disturbance results from a reduced ability to cope with daily stresAlthough insomnia is likely multifactorial and the presors, combined with increased cognitive arousal at bedcise etiologies are not known, hyperarousal is considered time (Morin et al., 2003). to be a central feature of insomnia. A hyperarousal state Learning and conditioning are also involved in the can be conditioned to sleep-related stimuli or a more maintenance or exacerbation of sleep disturbances; enduring feature present throughout the 24-hour period. the discomfort associated with insomnia can lead to a It is likely that both biological and psychological factors negative association between temporal (bedtime) and contribute to increased arousal and interference with environmental (bed/bedroom) stimuli previously assonormal initiation and maintenance of sleep. ciated with sleep. Over time, the combination of Biological basis. In studies comparing patients with maladaptive sleep habits (e.g., napping, excessive insomnia to normal sleepers, a number of physiological amounts of time spent in bed) and sleep-related cognidifferences suggestive of increased arousal have been tions (e.g., unrealistic sleep expectations, worry about reported, including increases in body temperature, the consequences of insomnia, sleep-related monitorgalvanic skin response, heart rate, and metabolic rate, ing) may exacerbate or perpetuate what might otherboth near sleep onset and during sleep (Bonnet and wise have been a transient sleep problem (Espie, Arand, 1997). Patients with insomnia have also shown 2002; Morin and Espie, 2003; Morin et al., 2003). increased high-frequency (beta) EEG activity during Although it remains unclear whether hyperarousal is NREM sleep, and changes in patterns of event-related a direct cause, a byproduct, or even a consequence of potentials suggestive of increased arousal (Merica insomnia, it is a central feature in the pathophysiology et al., 1998; Perlis et al., 2001a, b; Devoto et al., 2005; of insomnia. Along with a reduced homeostatic sleep Bastien et al., 2008). Neuroendocrine studies have drive (Besset et al., 1998), it is likely to arise from the demonstrated increased levels of circulating catecholainteraction of biologically based predisposing factors mines and urinary free cortisol (Vgontzas et al., 1998), and psychologically based exacerbating factors.
INSOMNIA: NATURE, DIAGNOSIS, AND TREATMENT
EVALUATION AND DIFFERENTIAL DIAGNOSIS Clinical and laboratory evaluations The diagnosis of insomnia is derived primarily from a detailed clinical evaluation of the patient’s subjective complaint (Table 45.3). The sleep history should cover the type of complaint (initial, middle, late insomnia), its duration (acute vs. chronic), and course (recurrent, persistent); typical sleep schedule; functional analysis of precipitating, perpetuating, and alleviating factors; perceived consequences and functional impairments, and the presence of medical, psychiatric, or environmental contributing factors. A complete history of alcohol and drug use, and of prescribed and over-the-counter medications is also essential (Morin and Espie, 2003; Buysse et al., 2006; Schutte-Rodin et al., 2008). The use of a sleep diary is essential in the evaluation of insomnia (Table 45.4). The patient should keep a daily diary to document the nature and initial severity of insomnia, identify behavioral and scheduling factors that may perpetuate insomnia, and monitor treatment compliance and progress. The Insomnia Severity Index (Bastien et al., 2001) is a brief questionnaire that can also be helpful to measure the patient’s perception of insomnia severity and its impact on daytime functioning (Table 45.5). Several additional measures of insomnia symptoms, fatigue,
727
anxiety, and depressive symptomatology may also provide useful complementary information in the evaluation of insomnia (Buysse et al., 2006). A more comprehensive psychological evaluation may be necessary for patients with suspected psychiatric disorders. Although PSG is not indicated for the routine evaluation of insomnia, it is often necessary to rule out other sleep disorders that might contribute to the insomnia complaint (e.g., periodic movements during sleep, sleep apnea) (Littner et al., 2003). PSG can also be particularly useful in suspected case of paradoxical insomnia or when a patient is unresponsive to treatment. The role of actigraphy in insomnia evaluation and treatment monitoring is not well established. Although it may represent a useful adjunct, actigraphy is not clinically indicated for routine assessment, diagnosis, or management of insomnia (Ancoli-Israel et al., 2003; Buysse et al., 2006). In the research environment, actigraphy is useful for examining night to night variability and for identifying individuals with circadian rhythm disorders. It has also been used to document treatment adherence and outcome in clinical trials of behavioral therapy for insomnia (Morin et al., 2006). Although a potentially useful complement to selfreport and PSG measures, actigraphy devices and algorithms are not all equivalent and there may be significant variability in the reliability and validity of sleep–wake data derived from different devices.
Table 45.3 Evaluation of insomnia Nature of the complaint – difficulties falling or staying asleep, early morning awakening Daytime symptoms – fatigue, mood disturbances, attention/ concentration problems Clinical significance – frequency, severity, duration of sleep difficulties Onset and course of insomnia Typical sleep–wake schedule (weekdays, weekends) Sleeping environment (noise, light, temperature) Functional analysis – evening activities, pre-bedtime rituals, triggers of nocturnal and morning awakenings (pain, noise); behavioral responses to insomnia Perpetuating/exacerbating (worries about sleep loss, daytime napping, excessive amounts of time in bed) Beliefs about sleep requirement expectations and consequences of poor sleep Use of sleeping aids/substances (caffeine, alcohol, drugs) Other medical problems Recent life events contributing to insomnia Symptoms of other psychiatric disorders (anxiety, depression) Symptoms of other sleep disorders (restless legs syndrome, sleep apnea) Previous treatment for insomnia and outcome
Differential diagnosis The differential diagnosis of insomnia requires a distinction between primary insomnia and insomnia associated with a (comorbid) medical, psychiatric, or other sleep disorder. Although the essential clinical features of insomnia are similar for primary and comorbid insomnia, in primary insomnia the sleep disturbance does not occur exclusively during the course of another mental or sleep disorder and is not due to the direct physiological effects of a substance or general medical condition. Primary insomnia is a diagnosis essentially made by exclusion, after ruling out several other conditions such as psychiatric (depression and anxiety), medical (pain), circadian (phase-delay syndrome), or other sleep disorders (restless legs syndrome/periodic limb movements, sleep-breathing disorders) as the main contributing factor to sleep disturbances. A diagnosis of comorbid insomnia is made when the sleep disturbance is judged to be related temporally and causally to another psychiatric, medical, or sleep disorder (American Psychiatric Association, 2000; American Academy of Sleep Medicine, 2005). Such distinction is not always easily made, given the bidirectional relationship between insomnia and psychological symptoms
728
C.M. MORIN AND R.M. BENCA
Table 45.4 Sleep diary Week: __________ to ___________ Example 1.
Yesterday, I napped from ___ to ___ (Note the times of all naps)
2.
Yesterday, I took ___ mg of medication and/or ___ oz ___ of alcohol as sleep aid
3.
Last night, I went to bed and turned the lights off at ___ o’clock
11:15 pm
4.
After turning the lights off, I fell asleep in ___ minutes
40 min
5.
My sleep was interrupted ___ times (Specify number of nighttime awakenings)
2
6.
My sleep was interrupted for ___ minutes (Specify duration of each awakening)
10 min (45 min)
7.
This morning, I woke up at ___ o’clock (Note time of last awakening)
6:15 am
8.
This morning, I got out of bed at ___ o’clock (Specify the time)
6:40 am
9.
When I got up this morning I felt ___ (1 ¼ Exhausted, 2 ¼ Fair, 3 ¼ Refreshed)
2
10.
Overall, my sleep last night was ___ (1 ¼ Restless, 2 ¼ Fair, 3 ¼ Very Sound)
3
Mon
Tue
Wed
Thu
Fri
Sat
Sun
1:50 to 2:30 pm
Reproduced by permission of Guilford Press from Morin (1993).
and the difficulty in determining the relative onset and course of these different coexisting conditions. In clinical practice, the main differential diagnosis is usually between primary insomnia and insomnia comorbid with anxiety (generalized anxiety disorder; GAD) or depression (dysthymia or major depression). This distinction is not always clear as several symptoms (e.g., sleep disturbance, fatigue, mood and cognitive problems) overlap among those conditions. Excessive worrying is the predominant feature of GAD; this characteristic is also present in primary insomnia, but its main focus is limited to insomnia and its potential consequences, whereas in GAD worrying is about multiple sources (e.g., health, family, work). In depression, the predominant clinical feature is sadness and a significant loss of interest. In primary insomnia, the interest is present but there is a lack of energy or fatigue, presumably resulting from sleep disturbances, preventing the individual from
engaging in potentially pleasurable activities or social interactions. In addition to the nature of the symptoms, the history should also identify the relative onset and course of each condition in order to determine whether insomnia is primary or secondary in nature.
TREATMENT The first step in treating symptomatic insomnia is to identify and remove the contributing factors. General sleep hygiene recommendations are also useful as preventive strategies. Specific insomnia therapies include psychological and behavioral interventions, medications, and a variety of complementary and alternative therapies (e.g., acupuncture, yoga, herbal therapies). The rest of this chapter focuses on psychological/behavioral and pharmacological therapies; most of the alternative therapies have not been evaluated adequately with regard to their efficacy and safety in the management of insomnia.
INSOMNIA: NATURE, DIAGNOSIS, AND TREATMENT
729
Table 45.5 Insomnia Severity Index (ISI) For each question below, please circle the number corresponding most accurately to your sleep patterns in the LAST MONTH. For the first three questions, please rate the SEVERITY of your sleep difficulties. 1.
Difficulty falling asleep: None 0
2.
Moderate 2
Severe 3
Very Severe 4
Mild 1
Moderate 2
Severe 3
Very Severe 4
Satisfied 1
Neutral 2
Dissatisfied 3
Very Dissatisfied 4
A Little Interfering 1
Somewhat Interfering 2
Much Interfering 3
Very Much Interfering 4
How NOTICEABLE to others do you think your sleeping problem is in terms of impairing the quality of your life? Not at all Noticeable 0
7.
Mild 1
To what extent do you consider your sleep problem to INTERFERE with your daily functioning (e.g., daytime fatigue, ability to function at work/daily chores, concentration, memory, mood). Not at all Interfering 0
6.
Very Severe 4
How SATISFIED/dissatisfied are you with your current sleep pattern? Very Satisfied 0
5.
Severe 3
Problem waking up too early in the morning: None 0
4.
Moderate 2
Difficulty staying asleep: None 0
3.
Mild 1
A Little Noticeable 1
Somewhat Noticeable 2
Much Noticeable 3
Very Much Noticeable 4
How WORRIED/distressed are you about your current sleep problem? Not at all 0
A Little 1
Somewhat 2
Much 3
Very Much 4
Guidelines for Scoring/Interpretation: Add scores for all seven items ¼ _____ Total score ranges from 0–28 0–7 ¼ No clinically significant insomnia 8–14 ¼ Subthreshold insomnia 15–21 ¼ Clinical insomnia (moderate severity) 22–28 ¼ Clinical insomnia (severe) # Morin, C.M. (1993, 2006).
Psychological and behavioral therapies TREATMENT
RATIONALE AND INDICATIONS
Psychological and behavioral therapies for insomnia include sleep restriction, stimulus control therapy, relaxation-based interventions, cognitive strategies, sleep hygiene education, and combined cognitive and behavioral therapy. A summary of these interventions is provided below and in Table 45.6; more extensive descriptions are available in other sources (Morin and Espie, 2003). The main objectives of psychological and behavioral approaches are to alter the factors that
perpetuate or exacerbate sleep disturbances. Such features may include hyperarousal, sleep-scheduling factors, poor sleep habits, and misconceptions about sleep and the consequences of insomnia. Although numerous factors can precipitate insomnia, when it becomes a persistent problem, psychological and behavioral factors are almost always involved in perpetuating it over time, hence the need to target those factors directly in treatment (Spielman and Glovinsky, 1991). The primary indication for behavioral treatment is in the management of persistent insomnia, with evidence available for both primary and comorbid insomnia.
730
C.M. MORIN AND R.M. BENCA
Table 45.6 Psychological and behavioral treatments for primary insomnias Therapy
Description
Stimulus control therapy
A set of instructions designed to strengthen the association between the bed/bedroom with sleep and to re-establish a consistent sleep–wake schedule: (1) Go to bed only when sleepy; (2) get out of bed when unable to sleep; (3) use the bed/bedroom for sleep only (no reading, watching TV, etc.); (4) arise at the same time every morning; (5) no napping A method designed to restrict time spent in bed as close as possible to the actual sleep time, thereby producing mild sleep deprivation. Time in bed is then gradually increased over a period of few days/weeks until optimal sleep duration is achieved Clinical procedures aimed at reducing somatic tension (e.g., progressive muscle relaxation, autogenic training) or intrusive thoughts (e.g., imagery training, meditation) interfering with sleep. Most relaxation requires some professional guidance initially and daily practice over a period of a few weeks Psychotherapeutic method aimed at reducing worry and changing faulty beliefs and misconceptions about sleep, insomnia, and daytime consequences. Other cognitive strategies can also be used to control intrusive thoughts at bedtime and reduce excessive monitoring of the daytime consequences of insomnia General guidelines about health practices (e.g., diet, exercise, substance use) and environmental factors (e.g., light, noise, temperature) that may promote or interfere with sleep. This may also include some basic information about normal sleep and changes in sleep patterns with aging A combination of any of the above behavioral (e.g., stimulus control, sleep restriction, relaxation) and cognitive procedures
Sleep restriction therapy Relaxation training
Cognitive therapy
Sleep hygiene education Cognitive–behavioral therapy (CBT)
SLEEP
RESTRICTION
Poor sleepers often increase their time in bed in a misguided effort to provide more opportunity for sleep, a strategy that is more likely to result in fragmented and poor-quality sleep. Sleep restriction consists of curtailing the amount of time spent in bed to the actual amount of sleep (Spielman et al., 1987). For example, if a person reports sleeping an average of 6 hours per night out of 8 hours spent in bed, the initial sleep window (i.e., from initial bedtime to final arising time) would be set at 6 hours. Subsequent adjustments to this “sleep window” are based on sleep efficiency (SE) for a given period of time (usually the preceding week); time in bed is increased by about 20 minutes for a given week when SE exceeds 85%, decreased by the same amount of time when SE is lower than 80%, and kept stable when SE falls between 80% and 85%. Periodic (weekly) adjustments are made until optimal sleep duration is achieved. Changes to the prescribed sleep window can be made at the beginning of the night (i.e., postponing bedtime), at the end of the sleep period (i.e., advancing arising time), or at both ends. To prevent excessive daytime sleepiness, time in bed should not be reduced to fewer than 5 hours per night in bed. This procedure leads to improvements in sleep continuity through a mild sleep deprivation and reduction of sleep anticipatory anxiety. Caution is needed when using sleep restriction with patients operating heavy equipments or who are required to drive
long distances (e.g., truck drivers). Sleep restriction is contraindicated in patients with bipolar disorder, seizures, or with some parasomnias (sleep-walking, night terrors) (Smith and Perlis, 2006).
STIMULUS
CONTROL THERAPY
Individuals with insomnia may develop apprehension around bedtime and come to associate the bedroom with frustration and arousal rather than with sleep. Stimulus control therapy (Bootzin et al., 1991) consists of a set of instructions designed to strengthen the association between temporal (bedtime) and environmental (bed and bedroom) stimuli and rapid sleep onset, and to establish a regular circadian sleep–wake rhythm. These instructions are: ● ●
● ● ●
Go to bed only when sleepy. Get out of bed when unable to sleep (e.g., after 20 min), going to another room and returning to bed only when sleep is imminent. Curtail all sleep-incompatible activities (i.e., no TV watching, problem-solving in bed). Arise at a regular time every morning regardless of the amount of sleep the night before. Avoid daytime napping.
Despite the straightforward nature of these recommendations, the main challenge for most patients is to comply with all of them, which is essential to reverse
INSOMNIA: NATURE, DIAGNOSIS, AND TREATMENT the conditioning processes perpetuating insomnia. Caution is advised in using some of these procedures (e.g., getting out of bed when unable to sleep) with the frail elderly, who may be at risk for falls.
RELAXATION-BASED
INTERVENTIONS
Relaxation is probably the most commonly used nondrug therapy for insomnia. Some relaxation methods (e.g., progressive muscle relaxation) focus primarily on reducing somatic arousal (e.g., muscle tension), whereas attention-focusing procedures (e.g., imagery training, meditation) target mental arousal in the forms of worries or intrusive thoughts. Most of these methods are equally effective for treating insomnia. The most critical issue is to practice diligently and daily the selected method for at least 2–4 weeks. Professional guidance is often necessary in the initial phase of training.
COGNITIVE
THERAPY
This psychotherapeutic method seeks to alter dysfunctional sleep cognitions (e.g., beliefs, expectations, attributions) and maladaptive cognitive processes (e.g., excessive self-monitoring) through Socratic questioning and behavioral experiments. The basic premise of this approach is that appraisal of a given situation (sleeplessness) and excessive monitoring of sleeprelated cues (e.g., fatigue, time left for sleep) can trigger an emotional response (fear, anxiety) that is incompatible with sleep. For example, when a person is unable to sleep at night and worries about the possible consequences of sleep loss on the next day’s performance, this can set off a spiral reaction and feed into the vicious cycle of insomnia, emotional distress, and more sleep disturbances. Cognitive therapy is designed to identify dysfunctional cognitions and reframe them into more adaptive substitutes in order to short-circuit the self-fulfilling nature of this vicious cycle. Treatment targets may include unrealistic expectations (“I must get my 8 hours of sleep every night”) and amplification of the consequences of insomnia (“Insomnia may have serious consequences on my health”) (Morin and Espie, 2003). Cognitive therapy is particularly useful to modify these maladaptive cognitions and to teach patients more adaptive skills to cope with insomnia (Harvey et al., 2007).
SLEEP
HYGIENE EDUCATION
Sleep hygiene education is intended to provide information about lifestyle (diet, exercise, substance use) and environmental factors (light, noise, temperature) that may either interfere with or promote better sleep. Sleep
731
hygiene guidelines include: (a) avoiding stimulants (e.g., caffeine) for several hours before bedtime; (b) avoiding alcohol around bedtime as it fragments sleep; (c) exercising regularly (especially in late afternoon or early evening) as it may deepen sleep; (d) allowing at least a 1-hour period to unwind before bedtime; (e) keeping the bedroom environment quiet, dark, and comfortable. In addition to these guidelines, it is useful to provide basic information about normal sleep, individual differences in sleep needs, and changes in sleep physiology over the course of the lifespan. This information is particularly useful to help some patients distinguish clinical insomnia from short sleep or from normal (age-related) sleep disturbances. Although inadequate sleep hygiene is rarely the primary cause of insomnia, it may potentiate sleep difficulties caused by other factors or interfere with treatment progress. Addressing these factors should be an integral part of insomnia management, even though it is rarely sufficient for more severe insomnia, which often requires more directive and potent behavioral interventions.
MULTICOMPONENT
THERAPIES
Despite some unique features, the interventions described above can be combined together effectively. There is a general preference among investigators and clinicians for combining multiple interventions, with CBT becoming the standard approach in the field (Morin et al., 2006). The most common combination involves a behavioral (stimulus control, sleep restriction, and, sometimes, relaxation), a cognitive, and an educational (sleep hygiene) component, usually referred to as CBT. Such a combination is often preferred to address the different components presumed to perpetuate insomnia.
Evidence for efficacy, durability, and generalizability EVIDENCE
FOR EFFICACY
Several meta-analyses (Morin et al., 1994a; Murtagh and Greenwood, 1995; Smith et al., 2002) and systematic reviews commissioned by the American Academy of Sleep Medicine (Morin et al., 1999b, 2006) have summarized the findings from clinical trials evaluating the efficacy of psychological and behavioral therapies for persistent insomnia. Evidence from these sources shows that treatment produces reliable changes in several sleep parameters, including sleep-onset latency (effect sizes ranging from 0.41 to 1.05), number of awakenings (0.25–0.83), duration of awakenings (0.61–1.03), total sleep time (0.15–0.49), and sleep quality ratings (0.94–1.14). Based on Cohen’s criteria, the
732 C.M. MORIN AND R.M. BENCA magnitude of those therapeutic effects is large (i.e., over time, with data available up to 24 and even 36 d > 0.8) for sleep latency and sleep quality, and modmonths after treatment completion. Although intervenerate (i.e., d > 0.5) for other sleep parameters. When tions that restrict the amount of time spent in bed may transformed into a percentile rank, these data indicate yield only modest increases (and even a reduction) of that approximately 70–80% of patients with insomnia sleep time during the initial treatment period, this achieve